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Abstract
The self-controlled case series method (SCCSM) is a novel study design to investigate 
associations between acute responses with transient point exposures (for example 
vaccination). The method provides an attractive alternative to cohort and case-control 
designs. The method is unusual in that it requires data only on individuals who 
experience a response (the ‘cases’). The method works as follows. Prior to the study a 
post-exposure risk period is defined, which corresponds to the period in which 
responses causally related to exposure are likely to occur. An observation period is 
also defined, and individuals with responses arising within this observation period are 
sampled. The data are then analysed using a Poisson model, conditional on the total 
number of events occurring for each individual. This conditioning ensures that 
including only cases does not bias the relative risk estimator.
The self-controlled case series method has been used to good effect in many settings, 
particularly in investigating putative associations between adverse events and 
paediatric vaccines. However, so far only limited research has been undertaken on the 
statistical properties of the method in finite samples, and virtually no work has been 
undertaken on design issues. The method also needs to be extended in various 
directions, for example application in surveillance methods.
This thesis provides detailed investigations of these topics. To this end, expressions 
for the asymptotic bias, variance and mean square error of the log-relative incidence 
are derived. Simulation studies taking account of age are carried out to study small 
and medium sample performance. Sample size formulae are obtained and validated
1
via simulations, thus improving the design of self-controlled case series studies. The 
method is extended to applications in surveillance and simulation studies are 
conducted to evaluate this use of the method. The methods are illustrated using data 
on intussusception and oral polio vaccine.
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Chapter 1
Introduction, background and literature review
1.1 Introduction
Research has traditionally been classified into two types: pure and applied. Philips et 
al [1] have considered a threefold classification of research: exploratory, testing-out 
and problem-solving, which applies to both quantitative and qualitative research.
Exploratory research is said to be the type of research that involves tackling a new 
problem/issue/topic about which little is known, so the research idea cannot at the 
beginning be formulated very well. The problem may come from any part of the 
discipline; it may be a theoretical research puzzle or have an empirical basis. In this 
type of research, a researcher will need to examine what theories and concepts are 
appropriate, developing new ones if necessary, and whether existing methodologies 
can be used. Exploratory research involves pushing out the frontiers of knowledge in 
the hope that something useful will be discovered.
Philips et al describe testing-out research as the type of research in which a researcher 
is trying to find the limits of previously proposed generalisations. In this type of 
research, one might ask questions such as: Does the theory of previously proposed 
generalisation apply in different situations? Can the theory apply in new technology? 
Under what circumstances does the theory fail? What bits of the theory might need 
extending? In this type of research, all sorts of questions can be tested, the amount of
19
testing out to be done is endless and continuous. By doing this, in the process the 
researcher will be able to improve previously proposed theories or generalisations by 
specifying, modifying, extending and clarifying.
As for problem-solving research, the research starts from a particular problem in the 
real world, and bring together all the intellectual resources that can be brought to bear 
on its solution. The problem has to be defined and the method of solution has to be 
discovered. The person working in this research may have to create and identify 
original problem solutions every step of the way. This will usually involve a variety of 
theories and methods, often ranging across more than one discipline since real-world 
problems are likely to be ‘messy’ and not soluble within the narrow confines of an 
academic discipline.
With respect to the Philips et al research classification, this thesis can be described as 
one of testing-out research, with some elements of problem-solving, as applied to a 
statistical method in epidemiology called the self-controlled case series method. We 
will begin by first describing what this method is, its advantages and limitations, its 
application, and the aims of the thesis.
1.2 Background
The self-controlled case series method (SCCSM), or case series method for short is a 
modified cohort method for estimating the relative incidence of specified events in a 
defined period after a point exposure. While the method was originally developed to 
investigate associations between vaccination and acute adverse events [2, 3], it has
20
subsequently been applied in other settings for example in pharmacoepidemiology 
(Hubbard et al [4] and Hocine et al[5]). Becker et al [6] have independently derived 
and applied the case series method in other areas of epidemiology. A step-by-step 
account of the theory, applications, modelling issues are given by Whitaker et al [7]. 
The same paper by Whitaker et al describes how the method can be implemented in 
various statistical software packages. The case series method in its semiparametric 
form [8] can be applied to continuous exposures but in the thesis we shall consider 
point exposures only.
1.3 Motivation
The self-controlled case series model was developed in order to analyse vaccine 
safety record linkage data relating to measles, mumps and rubella (MMR) vaccination 
and aseptic meningitis [9, 10]. For this study, episodes of aseptic meningitis arising 
in children aged 1-2 years over a defined calendar time period were obtained from 
laboratory and hospital records. The age and calendar time window determined by the 
period of event ascertainment defines an observation period for each child. From now 
onwards, the term ‘case’ refers to an individual who has experienced one or more 
events of interest over his or her observation period. Vaccination records were linked 
to cases resulting in a combined data set that consisted of cases and their exposures. 
The difficulty with such data sets is that usually they do not comprise accurate 
denominators. Furthermore, it may not be wholly clear from what population the 
cases arise and most likely the catchment areas of the hospitals from which the cases 
were obtained may not be clearly defined. Thus using methods such as cohort and 
case-control studies which are population based methods would require ingenuity,
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especially since vaccine coverage in the population is unlikely to be uniform. If 
answers are required quickly about a possible association between an event of interest 
with the vaccine exposure, employing a cohort study may not be a good idea as it may 
take a long time, it would be very expensive to undertake and would require a large 
sample size. The self-controlled case series method was developed to deal with such 
difficulties. In the MMR and convulsions data set, a positive association between 
vaccination with the Urabe mumps strain and aseptic meningitis in the period 15-35 
days post-vaccination was confirmed, and the composition of MMR vaccines used in 
the UK was changed [9, 10].
The self-controlled case series method will be described in technical terms in chapter 
2. Briefly, a retrospective Poisson cohort model is specified, and the case series model 
is derived from this by conditioning on the total number of events experienced by 
each individual in the observation period.
1.4 Advantages and limitations
The following are the main advantages of the self-controlled case series method. The 
method uses cases only and provides consistent estimates (as the number of cases 
becomes large) of the relative incidence. It controls implicitly for all fixed 
multiplicative confounders, that is, confounders that act multiplicatively on the 
baseline rates and do not vary (or not vary much) with time over the observation 
period, such as variables relating to genetics, location, socio-economic status, gender, 
individual frailty, severity of underlying disease, etc. Age or temporal variation in the 
baseline incidence is controlled for in the model. Further under certain circumstances,
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the method has high efficiency relative to the retrospective cohort method from which 
it is derived by conditioning [2]. Assembling the required data is much more likely to 
be easier in self-controlled case series method than cohort or case-control studies.
Like any other method, the self-controlled case series method has limitations which 
we now give. The most restrictive limitation is that the method requires that the 
probability of exposure is not affected by the prior occurrence of an outcome; 
sometimes this condition may not be fulfilled. For non-recurrent events, the method 
works only when the event risk is small over the observation period. The method does 
not produce estimates of absolute incidence, only estimates of relative incidence. A 
further assumption is that the observation period is independent of the timing of 
events. A less severe limitation of the method is that it requires variability in the time 
or age of the event: if all events were to happen at exactly the same age, which is very 
unlikely but not impossible, then the method would fail.
1.5 Why use the self-controlled case series method
Investigations of suspected or hypothesised associations of adverse outcomes with 
transient exposures, such as vaccination, usually require epidemiological studies such 
as cohort studies and case control studies. A disadvantage of a cohort study is that for 
rare events it has to be very large to achieve sufficient power. This may not be 
practical and can be very expensive. Sometimes researchers have got round this 
problem by reconstructing large retrospective cohorts (Ray et al [11]) using data sets 
assembled for other purposes. Case control studies require smaller sample sizes. The 
main disadvantages with case control studies is that they are more prone to selection
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bias, recall bias, and ascertainment bias (Altman [12]). Confounding by variables 
related both to avoidance of vaccination and to the outcome of interest is a major 
problem for both cohort and case-control studies as noted by Farrington et al [3]. For 
example Fine et al [13] found that parental education, ethnic group, age of the mother, 
maternal smoking, birth weight, evolving neurological disorders, and conditions 
predisposing to seizures are related to both vaccination and to sudden infant death 
syndrome or encephalopathy and hence may be confounding factors. Both the cohort 
method and case-control method are data-intensive, involving large cohorts or careful 
selection and matching of controls [14]. The self-controlled case series method aspires 
to control for fixed confounders by using cases only. This helps to reduce the data 
collection effort, and concentrates it on the cases.
Observations of clustering or troughs of events shortly after exposure leads to 
speculation about associations with exposure. There are several methodological 
difficulties involved in carrying out epidemiological studies to monitor such 
associations. Such studies are prone to many biases, for example, Fine et al [13] found 
that there is often differential ascertainment of cases in recently vaccinated and 
unvaccinated individuals and differential vaccination rates in individuals at higher or 
lower risk. Both would lead to bias in cohort and case control studies, whereas case 
series studies may escape bias from the latter. The cohort method is based on 
comparisons of incidence rates for person-time aggregated both across and within 
individuals. But the self-controlled case series method removes the contribution of 
comparisons between individuals, focussing attention on event rates in different 
periods within each individual’s observation time (Farrington et al [3]). For this 
reason, individuals who experience no events contribute no information about the
24
association between vaccination and outcome. Such individuals can be ignored 
without introducing any bias. On the other hand individuals who experience one or 
more events do contribute information on the risk period and age group in which the 
events occurred. The self-controlled case series method thus combines aspects of the 
case control and cohort methods, using retrospectively ascertained vaccination 
histories in cases to estimate the relative incidence in different intervals after 
vaccination relative to a control period.
1.6 Other case-only methods
Looking at cases only to detect risk factors for diseases is not new. Various studies 
have been conducted in which cases only are used, for example, a Markov chain 
method using cases only was used by Aalen et al [15] and a similar method modified 
as survival analysis was used by Prentice, et al [16]. However, it has been argued [2, 
8] that the methods of Aalen et al and Prentice et al give a valid test for no association 
but do not yield readily interpretable effect estimates. Another use of cases only can 
be seen in the case-crossover model developed by Maclure [17]. Maclure’s method 
resembles a case-control method with referents selected from the case’s own history. 
It has been argued [18] that although the case-crossover method is self-matched, it 
only yields consistent estimates when the distribution of exposure in case and control 
time intervals is exchangeable, in particular implying stationarity of exposures. There 
are several variants of this method, reviewed by Greenland [19], and the case- 
crossover approach has been used in many settings [20]. Another method in which 
cases only are used is that of Feldmann [21]. In this method, a constant base-line 
incidence is assumed. Feldmann’s method does give consistent estimates, though it is
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only approximately self-matched for rare events. The earlier approaches of using 
cases only have characteristics which the self-controlled case series method 
incorporates, in particular, it coincides with Feldmann’s method when the disease is 
rare and the base-line incidence is constant. The self-controlled case series method is 
similar to Prentice’s in that it also controls for age, it is similar to Maclure’s in that it 
also controls for fixed confounders. The main difference between the case series 
method and the method of Maclure is that it is derived from the same statistical model 
as a cohort study design, and hence can handle non-exchangeable exposures and in 
particular controls for age effects. Furthermore in this method one does not need to 
specify the prior probabilities for exposure as required in some other case-crossover 
designs (Marshall et al [22]). Smeeth et al [14] describe the advantages and 
disadvantages of case-control and case-only study designs.
1.7 Where the self-controlled case series method has been used.
This method has been used in various situations, but the main area it has been used is 
in modelling adverse events in vaccine studies. Table 1.1 below is adapted from 
Whitaker et al [7] which documents published applications of the case series method. 
A review of applications to vaccine safety is given by Andrews [23] and also by 
Farrington [24]. Independently, Navidi [25] proposed what is essentially a case series 
method, with time-varying exposures, for application in studies of air pollution. This 
method is described as a bi-directional or ambidirectional case-crossover method. The 
case series version of this method is that in which the entire observation period is used 
as controls. A similar approach has also been discussed by Lumley and Levy [26].
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Farrington and Whitaker [8] describe a generalisation of this approach, in which 
residual seasonality is controlled.
Table 1.1 Studies using the case series method
Exposure Outcome Reference
DTP vaccine Febrile convulsion [9]
MMR vaccine Febrile convulsion [9]
MMR vaccine Idiopathic thrombo-cytopenic purpura [9,27]
MMR vaccine Aseptic meningitis [9,28]
MMR vaccine Autism [29,30]
MMR vaccine Invasive bacterial infection [31]
MMR vaccine Gait disturbance [32]
Influenza vaccine Asthma [33, 34]
Influenza vaccine Bell’s palsy [35]
Oral polio vaccine Intussusception [36,37]
Oral rotavirus vaccine Intussusception [38]
DTP, MMR, HBV, HIB, 
OPV vaccine Wheezing [39]
Antidepressants Hip fracture [4]
Antidepressants Myocardial infarction [40]
Long-haul air travel Venous thromboembolism [6]
Influenza vaccine Any medical visits [41]
Common vaccines and infections Myocardial infarction and stroke [42]
DTP=diphtheria, tetanus, pertusis 
MMR=measles, mumps, rubella
HBV=hepatitis B vaccine, HIB=haemophilias influenza type B 
OPV=oral polio vaccine
A comparative evaluation of the self-controlled case series method has been 
undertaken by Farrington et al [3] and also by Glanz et al [43]. In Farrington et al’s 
comparisons, estimates of the relative incidence of febrile convulsions associated with 
Measles Mumps and Rubella (MMR) vaccine were obtained using the case series 
method, the case-control method and the cohort method. Theoretical arguments about 
the efficiency of the self-control case series method were presented. Overall the 
findings were that the self-controlled case series method produced results similar to 
the cohort method, whereas the 1-1 matched case-control estimates had wider 
confidence intervals reflecting the lower power of the method for a given number of 
cases. In conclusion Farrington et al [3] noted that the cohort study remains the
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“ideal” design for the study of adverse reaction to vaccines, and should be used 
whenever feasible. However, for studies of rare adverse events or for routine 
surveillance purposes, large-scale cohort studies may be costly, impractical, or prone 
to confounding. In such circumstances, the case series method provides a powerful 
and practical alternative to cohort and case-control studies.
1.8 Issues to explore and outline of the thesis
The self-controlled case series method is relatively new, and some statisticians and 
epidemiologists are naturally sceptical. This scepticism is a barrier to its use, in spite 
of its benefits such as good power, reduced confounding and practicability. Testing- 
out and extension of the method will hopefully contribute to a better understanding of 
the method amongst the epidemiological community as a whole, including the 
pharmaceutical industry. In this thesis the following issues will be explored:
• Further statistical properties of the method
• Evaluation of its small sample performance
• Improvement in the design of self-controlled case series studies by obtaining 
and validating sample size formulae
• Extending the method’s application to prospective surveillance
We now give the outline of the thesis. In chapter two, we present the case series 
method, and derive some expressions of its theoretical properties. The case series 
method involves fitting a particular log-linear model using maximum likelihood.
Thus, the asymptotic performance of the method is guaranteed by statistical theory. 
Expressions for the asymptotic bias, variance, and the asymptotic mean square error
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of the estimate of relative incidence are derived. A graphical study of the bias, 
variance and asymptotic mean square error are given. In chapter three we present 
extensive simulations to study the validity of asymptotic results in finite samples 
under different situations. We describe how the simulations were carried out. Results 
from the simulations are given starting with what we call the standard scenario with 
varying number of cases and a range of true relative incidences. We then explore 
different risk periods, the effect of age, and different distributions of age at exposure. 
We also investigate indefinite risk periods and the presence of unexposed cases. We 
explore the effects of age using several contrasting scenarios.
Chapters 4 and 5 concern the estimation of sample sizes for case series studies. So far 
little work has been done on the design of self-controlled case series studies. Sample 
size formulae are developed and validated using simulations. The impact of age 
effects on power and sample size are studied. In Chapter 4, we study an earlier 
published sample-size formula [3]. We find that this formula is not accurate, and 
investigate several alternative approaches. In Chapter 5, we extend one successful 
approach to take account of the effect of age ( Musonda et al [44]).
Chapters 6 and 7 relate to applying the self-controlled case series method in a 
prospective surveillance context. The issue of interest is how to apply the self- 
controlled case series method, which is a retrospective method, in a prospective way 
so that possible adverse outcomes with a new vaccine (or several vaccines in routine 
use) can be detected early so that remedial action can be taken. This constitutes a new 
application of the case series method. Following Wald [45] and Page [46] we use the 
sequential probability ratio test (SPRT) and cumulative sum (CUSUM) based on the
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self-controlled case series method so as to apply the self-controlled case series method 
in a prospective situation. These approaches along with extensive simulations to 
demonstrate their performance under different situations are presented.
In chapter 8 we analyse a data set on oral polio vaccine and intussusception, provided 
to us by GlaxoSmithKline Biologicals (Belgium). This study was undertaken in 
preparation for field trials of a new oral rotavirus vaccine. These data require some 
ingenuity in how one applies the self-controlled case series method owing to 
censoring of exposure histories. We describe how to analyse such data. We go on to 
discuss how the findings of the thesis throw light on the results, and how they may 
inform the design of future studies and surveillance programmes based on the case 
series method.
The conclusions of the thesis and its contribution to knowledge about the self­
controlled case series method are presented in chapter 9.
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Chapter 2
The self-controlled case series model
2.1 Introduction
In this chapter we introduce some notation, present the self-controlled case series 
model and derive some of its large sample properties in a simple setting. We present 
the likelihood in section 2.2. In section 2.3 we study the asymptotic bias of the 
relative incidence estimator. In section 2.4 we present a graphical study of the 
asymptotic bias. The asymptotic variance of the estimator is derived in section 2.5. In 
section 2.6 we present a graphical study of the variance. We derive the asymptotic 
mean square error (AMSE) of the relative incidence estimator in section 2.7 and 
present a graphical study of AMSE in section 2.8. We conclude the chapter with a 
brief discussion in section 2.9.
2.2 The self-controlled case series model
The self-controlled case series method is a conditional cohort method for estimating 
the relative incidence of specified events in a defined period after a point exposure. In 
this method, first an observation period is defined. Time within the observation period 
is classified as at risk or as control time in relation to point exposures that are 
regarded as fixed. We then condition on the number of events experienced by each 
individual over the observation period. As mentioned in chapter one, the method
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allows valid inference about the relative incidence of events in risk periods relative to 
the control period, using data on cases only.
We now derive the general form of the likelihood of the self-controlled case series 
model. The pictorial configuration (Figure 2.1) below will help to understand the 
general form of the likelihood described.
Risk
Perioc
k=l
Control
Period
k=0
Control period k=0
Age group 1 (j=0) Age group 2 (j=l)
Vaccinated at this point Event diagnosed at
within observation period this point within
observation period
Figure 2.1 Possible case series configuration
In Figure 2.1 we see a possible configuration in which an observation period (ai9b.] is
defined within which an individual i was exposed (vaccinated) and a risk period (red 
line) is defined shortly after the exposure. It is possible to have several risk periods 
depending on prior knowledge of what time intervals are important. For example 
Griffin et al [47] assumed that the effect of DTP on febrile convulsions or 
encephalopathy had risk periods of 0-3, 4-7, 8-14, and 15-29 days after any dose of 
DTP. The observation period is further divided in age groups; in Figure 2.1 there are
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two age groups. As with risk periods, it is possible to define several age groups. The 
period outside the risk period is known as the control period. In Figure 2.1 it 
comprises of the period before vaccination, a period shortly after vaccination, and a 
period after the risk period. The event in this case was diagnosed some time after the 
risk period in age group 2, but could have occurred anywhere within the observation 
period. The observation period and the location of the risk period within it will 
generally vary between individuals.
In general, we assume that events arise within individuals as a non-homogeneous, 
age-dependent Poisson process. In what follows, a proportional incidence model is 
used to describe the relation between vaccination and the outcome of interest 
(Farrington et al [3]).
Let individuals be indexed byz = 1,2,...,N , age groups be indexed by j  = 0,1,...,/ - I  
(0 denoting the reference age group) and the risk periods be indexed by 
k = 0,1,...,K  -1  (0 denoting the control period).
Further suppose we let the symbols l ijk, eijk, nijk respectively denote incidence, length 
of time at risk, and number of events experienced by an individual z, in age group j  
and risk period k during the observation period (a,-,#,-]. The log-linear model [3]
n^ i ^ i j k ) = ( !)i +  a j  + f ik
is used to parameterise the incidence of an event for an individual effect </>., age effect 
ccj, and exposure effect f3k (with a0 = J30 = 0 ) . Thus the incidence function during 
the baseline period is simply Ai00 = exp($). The Poisson probability model is given
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e  x /Tby: Pr[r] =  where r = 0,1,2,... and for the underlying cohort model,
rl
niJt~Y  o is s o n ^ x e ^ ) .
For the cohort model, <f>l = xf  y for fixed covariates x-, and the Poisson log-likelihood 
kernel (which is equal to the log-likelihood up to an additive constant) is
(«> A  r) = X  £ n<)ttfy+'ai + Pt) -  £  £  r + a ,  + A  H *  •
i jk  i jk
The self-controlled case series model is derived from the cohort model with the
unrestricted by conditioning on the nL , (the total number of events experienced), thus
giving a product multinomial distribution as described by McCullagh and Nelder [48]. 
So the log-likelihood kernel for the self-controlled case series model is
f  \
exp {aj+PMjk 
£ e x p ( ar +/3s)elrs
V rs J
We can see from above that the individual effects = xf  /  cancel out. This is because
incidence rates are contrasted within the same individual’s person-time, so that, in this 
sense, the method is self-controlled. Thus, provided the model is correct, inferences 
from a case series analysis cannot be confounded by fixed multiplicative individual 
effects, which might include genetic factors, location, socio-economic status, sex, 
underlying health status, individual frailty, and so on [7]. Individual effects can 
nonetheless modify the exposure effect but this can be modelled by including suitable 
interaction terms. Note that self-control applies to fixed covariates only and not age or 
time-dependent covariates.
In much of what follows we shall only need the log likelihood in the following
simplified situation. We suppose that there are no age effects, and that all individuals
£(a >fi) = X X nykl°g
i jk
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are observed over the same observation period, comprising two adjacent periods of 
duration ex (the risk period) and e0 (the control period). Suppose that all individuals
are vaccinated at the start of period ex and subsequently at increased risk during this
period. Suppose that in a sample of n events, nQ occur in period e0 and nx in
period ex withw = nQ+nx. Let the ratio of the risk period to the observation period
be r , that is, r = — 1— . Usually the risk period and the observation period will be
e0 + ex
specified in advance. However, only their ratio r is required. Let p  be the relative 
incidence ep ( so that p  = log(p) ).
In this simple situation the log-likelihood kernel is equal to:
I (P) = nxP -  n \og{exep + e0)
Note that this is the same log-likelihood kernel as for the binomial model
nx~B(n ,p)
with
eHe,
P = eHex +e0
d£The maximum likelihood estimator p  of p  is obtained by setting —  = 0, that is
The likelihood ratio statistic for the test of H0 : p  = 0 for this simplified situation is 
then D = (0) =2 nxP -  n^[og{exe^ +e0j - lo g ^ j  + e0)J
where p  is the maximum likelihood estimator.
2.3 Derivation of the bias of the estimator p
In this section we derive an expression of the asymptotic bias up to the second order 
of the estimator of the relative incidence in the simple situation described in the 
previous section when there are no age effects and all individuals have the same 
observation period. The maximum likelihood estimator may be written as
P = log
\ n ~ nu
+ log
r \e,
\ e\ j
x
n - x
Let the function / (x) = log
This is equivalent to:
f ( x )  = log (x) -  log (n -  x) + log
+ log (e  ^
\ e \ J
1 - r where r =—
The random variable X  is the number of events occurring in the risk period. This 
follows a binomial distribution 
X  ~ Binomial («, p)
where p  = exp pr
eo+Pei ( ! - r )  + pr
It follows that the expectation of X  is E (X ) = p  = np and / ( / / )  = log(p) = p. 
By Taylor expansion of p  = f ( X }  about p , we get:
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p  = f i n )  + ( X -  ft) f'(ju) + h *  -  /i)2 r ( M ) + k *  - M f  f m(M)L o
+ J ^ ( X  -  ft)* f  (ft) + residue (2.1)
Taking expectations of the above expression, we have:
E[p)  = P + ^  vax(X)f"(ft)+^-E{X -  f i f  f m( f i ) + ^ - E ( X - f i f  f ’ (ft) + residue.
Now we have:
n 1 -, sof'(ju) =----- with q = l - p ;
x n - x  x (n -x )  npq
sn, -1  1 x2- ( n - x ) 2 1/(*) = — +7------=  + ’ s° f  (a) = —x (n -x )  x (n -x )  n
p - q  
2 2 
p  q
f ' " ( x) = L + — 2_ ^  = 2 ^3 + (» *)3t soy»(/i) = ^ .
x (n -x )  x (n -x )  n
3 3p +q
3 3
p  q
-3
x (« -  x)
=  6
x4 -  (« -  x)' 
xA( n - x )4
, s o r  ( //)= —
4 4p  - q
4 4
p q
6 { p - q ) { p 2+ ? 2)
4 4/? <7
We know that for a binomial, (Johnson et al [49]), the variance, the third and fourth 
moment about the mean are: npq, npq(q -  p), and npq [1 + 3pq(n -  2)] respectively.
Moments of higher order contribute terms that are 0 (« _3) at most. Replacing these
values in (2 .1) above and only considering terms of order up to 0(n 2) we have:
E {p ) = p +
npq 1 p - q
2 2 
p  q
+ npq(q — p) 2
3 3
p +q
3 3
p  q
+
3n2p 2q2 6 ( , P - ? ) ( / + 9 2) + 0(r f i )
24 n 4 4p  q
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Simplifying, we get the asymptotic bias of ft up to second order in terms of p  and q
as given below:
E 1 (p ~ q) .+ 1 ( p ~ g)
2n pq n2 p 2q2
3 l  2 2\ (^3+‘?3)
- ( p  +* ) - K— ^ + 0(n"3) (2.2)
For interpretation purposes, we substitute
1 — r
P =
pr epr
(l - r )  +pr (l - r )  + e^ r’ ^ ( l - r )  + e^r
and note thatp 3 + q 3 = ( p  + q)(p2 ~pq  + q2) = (.P2 ~ pq + q2)
thus
£(/!)
(rep +1 —r)
12 n*
[rep — (1 —r)) 5 +Arep ( l - r )  + 5 ( l - r )2 + 0(n 3) (2.3)
Note that in (2.3) above, the expression —  (rep -  (1 -  r ))( H— | is the
In v ' \  1 -  r rep J
asymptotic bias up to the first order. We can further factorise (2.3) above to get the 
following expression:
+ 0 ( n z)
1 + 6n ( l - r ) re
5 {rep ) + 4rep (l -  r) + 5 (l -  r f
(2.4)
We can see in (2.4) above that the expression
1 +
sgn
6« ( l - r ) re^
5(re13'} + 4rep ( l - r )  + 5 ( l - r )2 is always greater than 1. So the
= sgn {^re13 -  (1 -  r) J j and |2nd order bias| > |lst order bias|. Both
the first and second order asymptotic bias are zero when rep = 1 -  r . This occurs when
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the risk period is chosen such that the same (expected) number of cases occurs in the 
risk period as outside it. Further we note that the asymptotic bias is negative when
2.4 Graphical study of the asymptotic bias
In this subsection, we explore the behaviour of the asymptotic bias (2.4) graphically. 
Note that an estimate with small bias and small variance is generally preferable to one 
with zero bias and large variance [50]. In addition to exploring the behaviour of the
self-controlled case series method has small bias and small variance. Figure 2.2 (a),
(b), ... (f) below shows the asymptotic bias of the first and second order varying with 
the ratio of the risk period to the observation period at fixed relative incidence of 0.5, 
1, 2, 5 and 10. We present the asymptotic bias for n=10, 20, 50, 100 cases; 
asymptotically as n -» oo the bias is zero (explored but results not shown) when there 
are a lot (n > 100) of cases.
r
|  j*
and positive when ef > —
r
bias of p , we shall later explore under what circumstances the estimator from the
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Figure 2.2 First and second order asymptotic bias varying with the ratio of the risk 
period to the observation period.
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Similarly Figure 2.3 (a), (b), (c) and (d) below shows the bias varying with relative 
incidence at fixed ratios of the risk period to the observation r -  0.1,0.2,0.5 and 0.9. 
We can see that the bias decreases as one would expect with increasing sample size. 
There is little difference between the first order bias and the second order bias except 
for small sample sizes (e.g, n=10). The asymptotic bias is greatest for small ratio of 
risk period to the observation period (ratio less than 0.1 Figure 2.2 (a), and (b)) and 
long ratio of risk period to observation period (ratio greater than 0.9, Figure 2.2 (d), 
(e), (f) ). Varying the relative incidence with fixed ratio of risk period to observation 
period (ratios 0.1, 0.2, 0.5, and 0.9) and fixed number of cases (n=10, 20, 50 and 100) 
there is an appreciable bias when the relative incidence is less than 1 and r < 0.5 
(Figure 2.3. (a), (b), (c)) and for large relative incidences when r = 0.9 (Figure 2.3 d).
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2nd order bias
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Figure 2.3 First and second order asymptotic bias varying with relative incidence
2.5 The asymptotic variance of /3
Farrington et al [3] found the variance of an estimator /3 up to the first order in the 
simplified situation described in section 2.3. In this section, we extend the calculation 
up to the second order. The variance of p  up to the second order is derived as 
follows.
Squaring both sides of (2.1) and simplifying, keeping powers up to order 4, we get: 
p 1 = f ( M)2 + 2 f(ju){X - ju) f \M )  + (AT ■- mf / W  V )  ++
+ residue
, imt i
12
45
From above, we know / (jli) = (3 . Substituting this value in the expression above we
get:
p 2= p 2+2 P ( X - M) f \ M) + [/?/"(//) + ( f x p j ) 2' +
^ P f ( p ) + f X p ) f X p ) p r ( M ) , / w o o , ( / V ))312
+ residue 
Taking expectations of both sides:
E [p 2) = p 2 + var(2Q [ f i r  Of) + ( / '( /0 )3 
1
+
E (X - ju )  
+ E ( X - f i )
P f m( . p ) + f X p ) f \ p )
f i f M  + / W O O  (/"(A))3
12
+ residue
Substituting for the other values we have:
E [ p 2) = p 2+npq 
+ 3n2p 2q2
P ( p - q ) +m i
n2 p 2q2 ( w ) "
+ npq(q-p) /? (^ 3+ g3) , i i■>,.3 3 3  2 „ :p iqi npq n2p 2q2 O’-? )
p „  6 _ { p - q ) { p 2+q2) , 2  1 p 2+q2 . 1 O’-? )
 X  — 7" X " " .------------------1 “— "— "— I    — ~—- X
12 n4 4 4p  q 3 npq n3p 3q3 4n4 p*qA
+ 0 (r f3)
Simplifying the above expression we get:
E {p 2) = p +
1 + P ( p - q )  ( p ~ q f  , 2P ( p - q )+ •
+
npq An2 p 2 q2 n2 p 2 q2
2 ( p 2+ q2)
- \ { P *  + q2)+ -A p 2 +q2)
2 2 2 n p q
+ 0(0
The asymptotic variance of ft is given by:
var = .We know from above (2.2) that
i  ( / > - ? ) ,  i  ( p - q )
E ( p )~  P + l ^ —----—+ • 2 2 2' 7 2 n pq n p q
2,  2 2\ (p , + ^ )
7 (p  +? ) - K— r ^ + 0(n 3). Squaring both
sides:
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E [ p ) t = p  + P ( p - q ) , ( p - q f  , i p ( p - q )• + +  ■
A  2 2 2 2 2 2« pq An p  q n p  q
3 / 2 2-i {pi+(f )
~ ( p  +1 ) - K— ^ + 0 (« '3)
The asymptotic variance up to the second order is given by:
i f  i ( p - q f  , 2 ( p 3+ q3)var {p ) = e [p 2] - [ e {p )
npq 2 n2p 2q2 n2p 2q2
i ( p - q )2 2 ( p2~ p q + q 2)
npq l n 2p 2q2
+  ■ 2 2 2 n p q
+ 0 (n-3)
+ 0 (n"3)
Substituting the full expressions for p  and <7 in the above we get:
var
( l - r )
+ '
^e^r + l - r ^  ^(e^r + l - r )  +
l - r ( ! - r ) epr
+ 0(n~3) (2.5)
Note from (2.5) above, the expression —(e^r+ 1 —r ) [ —-— I—i— | is the first order
n v ’ ^  1 -  r epr )
variance as was found by Farrington et al [3]. Note further that (2.5) can be factorised 
to give (2 .6) below:
var
I (epr + l - r )
n eHr ( l - r )
1 +
2>(epr) - 2 e ^ r ( l - r )  + 3 ( l - r y  
2nepr(l — r)
+ 0(n3)
We see that the expression
1 +
3 (epr) - 2 e ^ r ( l - r )  + 3 (l-r)"  
2nepr ( \ - r )
is greater than 1, hence the second order
variance is always greater than the first order variance. The asymptotic variance is 
minimised whene^r - l - r . This will be illustrated in the next section graphically.
(2.6)
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2.6 Graphical study of the asymptotic variance of P
Figure 2.4 and Figure 2.5 below show how the asymptotic variance up to the first 
order and second order varies with the ratio of the risk period to the observation 
period and with the relative incidence at fixed sample sizes. Just as in the graphical 
study of the bias, we explored the behaviour of the asymptotic variance for 
n = 10,20,50, and 100. We fixed the relative incidences at 0.2, 0.5, 1, 2, 5 and 10 and 
then varied the ratio of the risk period to the observation period (Figure 2.4 (a), (b),
(c), (d), (e) and (f)). We also fixed the ratio of the risk period to the observation period 
at 0.1, 0.2, 0.5, and 0.9 and varied the relative incidence (Figures 2.5 (a), (b), (c) and
(d)).
Relative incidence=0.2 Relative incidence=0.2
1 st order variance 2nd order variance
LD _
O _
tjW-
o _ «?-
o  in -
i -------- 1-----1-------1------ 1-------1-------1-------1------ 1-------1------ r
0  .1 .2  .3  .4  .5  .6 .7  .8  .9  1 0 .1 .2  .3  .4 .5 .6  .7  .8  .9  1
R atio o f risk period to ob serva tion  tim e R atio o f risk period to ob serv a tio n  tim e
-------------- n = 10    n = 2 0  -------------- n = 10  --------------  n = 20
..................  n = 50   n = 1 0 0  ................... n = 5 0    n = 1 0 0
(a)
48
Relative incidence=0.5
1st order variance
o _
o .
O 10 -
0  .1 .2  .3  .4  .5  .6 .7  .8  .9  1
R atio o f risk period to o b serva tion  tim e
n = 100
Relative incidence=0.5
2nd order variance
o _
O Lfi -
0  .1 .2  .3  .4  .5  .6  .7  .8  .9  1
R atio o f risk period to ob serv a tio n  tim e
n = 1 0 0
(b)
Relative incidences 
1st order variance
o _
-p LO _
o  in -
0  .1 .2 .3  .4  .5  .6 .7  .8  .9  1
R atio o f risk period to ob serva tion  tim e
n = 100
Relative incidences 
2nd order variance
> O _
o  m -
0 .1 .2  .3  .4  .5  .6 .7  .8  .9  1
R atio o f risk period to ob serv a tio n  tim e
n = 100
(c)
49
V
ar
ia
nc
e 
of 
log
 
re
la
tiv
e 
in
ci
de
nc
e 
V
ar
ia
nc
e 
of 
log
 
re
la
tiv
e 
in
ci
d
en
ce
Relative incidence=2
1st order variance
LO _
O _
LO _
0 .1 .2  .3  .4  .5  .6  .7  .8  .9  1
R atio o f risk period to ob serva tion  tim e
n = 1 00
Relative incidence=2
2nd order variance
o _
TJ LO _
O _
_o l o  -
0 .1 .2  .3  .4  .5  .6  .7  .8  .9  1
R atio o f risk period to ob serv a tio n  tim e
n = 1 0 0
Relative incidence=5 
1st order variance
o _
o _
0 .1 .2  .3  .4  .5  .6 .7  .8  .9  1
R atio o f risk period to ob serva tion  tim e
n = 100
Relative incidence=5 
2nd order variance
o _
o  _
o  in -
0 .1 .2  .3  .4  .5  .6  .7  .8  .9  1
R atio o f risk period to o b serv a tio n  tim e
n = 1 0 0
(e)
50
n = 1 0
n = 5 0
n = 20
n = 100
n = 10
n = 50
n = 20
n = 1 0 0
Relative incidence=10
1st order variance
Relative incidence=10
2nd order variance
-O ^
> O
~i-------1---- 1------1------1----- 1------1----- 1----- 1------1----- r
0 .1 .2  .3  .4 .5  .6 .7  .8  .9  1
R atio o f risk period to o b serva tion  tim e
"i------- 1---- 1----- 1------1----- 1------1----- 1----- 1------1----- r
0  .1 .2  .3  .4  .5  .6 .7  .8  .9  1
R atio o f risk period to o b serv a tio n  tim e
Figure 2.4 Asymptotic variance to first and second order varying with the ratio of the 
risk period to the observation period.
We note that in all graphs shown the first order variance was less than the second 
order variance as expected. However, there was little difference between the first 
order variance and the second order variance. As for the bias, the variance decreases 
with increasing sample sizes. The variance is largest for ratios of risk period to 
observation period that are less than 0.1 and greater than 0.9 (Figures 2.4 (a), (b), (c),
(d), (e), and (f)). Varying the relative incidence and fixing the ratio of risk period to 
observation period, we obtain large variances for relative incidences less than 1 (see 
Figure 2.5 (a), (b), (c)). The asymptotic variance is also large when the ratio of the 
risk period to the observation period is high and the number of cases is small (n=10 
and 20 see Figure 2.5 (d)) but this effect disappears as the number of cases increase 
(n=50 and 100). The parameter values that give large asymptotic bias tend to be the 
same that give large asymptotic variance, and conversely the parameter values that
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give small bias tend to give small variance (see Figure 2.2 compared to Figure 2.4, 
and Figure 2.3 compared to Figure 2.5).
Ratio=0.1 
1st order variance
o _
.5 0 .
o  in -
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 100
Ratio=0.1 
2nd order variance
LO _
o _
0  CM
0 1  2 3 4 5 6 7 8 9  10
R ela tiv e  in c id e n c e
n = 100
(a)
Ratio=0.2 
1st order variance
.5 o  _
o  lo -
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 1 0 0
Ratio=0.2 
2nd order variance
o _
<13 CM
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 100
(b )
52
Ratio=0.5
1st order variance
o _
> O _
o  in -
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 100
Ratio=0.5
2nd order variance
o _
> O _
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 1 0 0
(c)
Ratio=0.9 
1st order variance
o _
■ ^  o _
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 100
Ratio=0.9 
2nd order variance
o _
'•£ o
0 1 2 3 4 5 6 7 8 9  10
R ela tive  in c id e n c e
n = 1 0 0
(d )
Figure 2.5 First and second order variance varying with relative incidence
2.7 Asymptotic mean square error (AMSE)
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The asymptotic mean square error up to the second order is derived as shown below. 
Suppose p  is an estimator of p  with some bias, that is, E^P^J = P + b where b is the
bias. The variance of p  is var{^ P^  = e \^P~e {^ P^  . The quantity E ^ p - p J is
called the mean square error and can be written as
e [p  -  = e [p  -03  +b) + b ^  = E ^p  -  E{ft) + b ^  = e [p  -  E ( p ) ^  + b2 (2.7)
e [p - e {P )]  is simply the variance. Hence if we use the asymptotic variance up to
the second order and the asymptotic bias up to the first order in (2.7) above for the 
simple situation described earlier we obtain the asymptotic mean square error 
(AMSE) as given in the formula below.
AMSE = (asymptotic bias)2 + asymptotic variance + 0 (« “3)
_Lx(re/>_a _ r))x|^_I_+J _ j
+
I (e^r + l - r )
n eHr ( l - r )
-2e^r(l-r) + 3(l-ry  
2« e ^ r( l- r )
+ 0(n~3)
Simplifying the above, the AMSE up to the second order is:
+ o(n~3).
i {e^r + \ - r \  
A M S E  = — v 7
n epr{ 1 -  r)
l [ e pr ) - 6 e /?r ( l - r )  + 7 ( l - r ) 2 
Anepr{\ -  r)
I (e^r + 1 —r)
We can see that the expression —-— -------- —is the variance up to the first order. We
n epr( 1 -  r)
expect the graphical illustration of AMSE to be similar to that of the asymptotic 
variance, especially for those values where the bias is close to zero.
(2.7)
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2.8 Graphical study of AMSE
The AMSE varying with the ratio of the risk period to the observation at fixed relative 
incidences of 0.2, 0.5, 1, 2, 5 and 10 is represented in Figure 2.6 (a), (b) and (c). 
Similarly, Figure 2.7 (a) and (b) shows the AMSE varying with the relative incidence 
at fixed ratio of the risk period to the observation period with r = 0.1,0.2,0.5,0.9.
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Figure 2.6 Asymptotic mean square error as a function of the ratio of risk period to 
the observation period.
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Figure 2.7 Asymptotic mean square error as a function of the relative incidence
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As for the bias and variance the values of the AMSE were obtained for the sample 
sizes n=10,20, 50, and 100. Just as for the asymptotic bias and variance, the AMSE 
decreases with increasing sample size. Comparing Figures 2.6 and 2.7 with those 
obtained for the asymptotic variance, we can see that the contribution of the bias is 
negligible in most situations.
2.9 Conclusion
In this chapter, we have described the self-controlled case series model and introduced 
the notation we will be working with from here onwards. The likelihood of the model 
was derived. The maximum likelihood estimator was obtained explicitly in a simple 
situation, for which the likelihood ratio statistic was also obtained. The asymptotic 
bias, variance and the AMSE of the estimator in the simplified scenario were 
calculated. We studied graphically how the asymptotic bias, variance, and the AMSE 
vary with the ratio of the risk period to the observation period and the relative 
incidence at fixed sample sizes.
The main finding in this chapter is to characterise how the asymptotic bias, variance 
and AMSE vary. It is important to know under what situations the self-controlled case 
series method is going to yield biased and/or imprecise estimates. As illustrated, the 
bias is zero when there is same number of cases expected in the risk period as out of 
it. The asymptotic bias and the variance are large when the ratio or the risk period to 
observation period is less than 0.1 and when it is greater than 0.9. They are also large 
for relative incidences less than 1 and when the relative incidence is greater than 8. 
However outside these extremes, the asymptotic bias is close to zero and the
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asymptotic variance is close to its minimum. In other words, the bias and variance do 
not depend sensitively on the parameters r and /? within their central range.
Nevertheless, in many applications to vaccines, short risk periods are required and 
substantial bias can arise in such circumstances unless the relative incidence is high. 
Further investigation, based on simulation rather than asymptotic theory, is therefore 
required. A further limitation of our asymptotic results is that we have explored the 
model without taking age into account. Age is a well known confounder in adverse 
outcomes with respect to vaccines in which the self-controlled case series model is 
widely used. We did not take age into account because the calculation for the 
asymptotic bias, variance and the AMSE become unwieldy. We shall explore the 
effects of age at event, age at exposure, risk periods (fixed or indefinite) and small 
samples by simulation in the next chapter.
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Chapter 3
Performance of the self-controlled case series method: Simulation
study
3.1 Introduction.
In previous chapters the theory behind the self-controlled case series method has been 
described and its properties outlined. In chapter 2, the asymptotic variance and bias 
and asymptotic mean square error up to the second order were derived in a simplified 
scenario.
The estimates obtained by the method are valid asymptotically by virtue of likelihood 
theory. What we now need is to explore the performance of the method in small 
samples and under different conditions. This chapter explores various simulations in 
which we generated data where the true population value of the relative incidence is 
known. We use the self-controlled case series model to analyse the simulated data and 
compare the estimate with the true value. The simulations were set up to mimic those 
scenarios that typically occur in studies of paediatric vaccines.
In section 3.2 we describe how the simulations were carried out. The results from the 
simulations are given in section 3.3. We first present the results from what we call the 
standard scenario with varying number of cases and a range of true relative 
incidences. In subsequent subsections we vary the risk periods, the effect of age at 
event, and the distribution of age at exposure. We also investigate indefinite risk 
periods and the presence of unexposed cases. Results exploring the effects of age in
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form of age groups labelled as strong symmetric, weak monotone increasing age 
effect and strong monotone increasing age effect are given. In all the simulations we 
obtain central estimates and the coverage probabilities for 90%, 95%, and 99% 
confidence intervals. Also given are the percentage of simulations for which the true 
value of /?was below the lower 90%, 95%, 99% confidence limits, and the 
percentage for which the true value of P  was above the upper 90%, 95%, and 99% 
confidence limits. The conclusions of the chapter are given in section 3.4. To reduce 
clutter, most of the detailed results are given in an Appendix.
3.2 The structure of the simulation study
Figure 3.1 shows the structure and stages of the simulation that were carried out. For 
a given set of parameters (described below), sample size n and random seed, a set of n 
exposure times were generated, together with n marginal total numbers of events. 
These marginal totals are generated using a truncated Poisson distribution (excluding 
zero), conditionally on the exposure history.
The exposures and marginal totals vary randomly between runs. However, in each run 
of 10,000 simulations, the exposures and marginal totals remain fixed. This is to 
mimic the fact that the case series method is conditional on exposures and marginal 
totals.
Within a run of 10,000, the events for each individual are randomly reallocated 
10,000 times to the age/exposure categories within each individual’s person time. This 
is done according to the case series model, using a multinomial distribution.
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The output from each run includes the median of the relative incidence estimates. We 
also quote the median of their logarithms. The median is chosen rather than the mean, 
since in finite samples there is a non-zero probability that the estimated log relative 
incidence is ±co and hence its expectation does not exist. The median, compared to the 
true value, provides an appropriate measure of central tendency of the finite sample 
bias. Note that all runs are based on 10,000 independent samples. With this run size, 
the Monte Carlo standard error for the coverage probability of a 95% confidence 
interval is about 0.002 (or 0.2 %, see chapter 4 page 101 for how it is calculated).
3.2.1 The parameters
Each simulation requires the following parameters to be specified.
• Observation period, always taken to be 500 days
• Risk period following exposure (described in section 3.2.4)
• Relative incidence: the true relative incidence took values 0.5, 1, 1.5, 2, 5, 10
• Exposure distribution (section 3.2.3)
• Age groups and age-specific relative incidences (section 3.2.2, Figure 3.2 
below)
• Baseline rate always taken to be (j) = 2 x 10"7 per day, or one per hundred 
thousand over 500-day observation period. Thus the event is assumed to be 
rare, and with high probability, a case has only a single event.
• Sample size: we did simulations with 10, 20, 50, 100, 200, 500, 1000 cases
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3.2.2 Age at the event
In most case series analyses, one needs to control for age. We varied the effect of age 
on the event incidence according to practically realistic scenarios. Thus we explored 
the self-controlled case series model’s performance in the presence of what we call 
weak symmetric, strong symmetric, weak monotone increasing, and strong monotone 
increasing age effects. These are defined as follows.
• Weak symmetric age effect. Age groups (in days, with age associated relative 
incidence in brackets) are: 1-100 (1), 101-200 (1.2), 201-300 (1.5), 301-400 
(1.2), and 401-500 (1).
• Strong symmetric age effect. Age groups (in days, with age associated 
relative incidence in brackets) are: 1-50 (1), 51-100 (2), 101-150 (3), 151-200 
(4), 201-250 (5), 251-300 (5), 301-350 (4), 351-400 (3), and 401-500 (1).
• Weak monotone increasing age effect. Age groups (in days, with age 
associated relative incidence in brackets) are: 1-100 (1), 101-200 (1.1), 201- 
300 (1.2), 301-400 (1.3), 401-500 (1.4)
• Strong monotone increasing age effect. Age groups (in days, with age 
associated relative incidence in brackets) are: 1-50 (1), 51-100 (1.5), 101-150 
(2), 151-200 (2.5), 201-250 (3), 251-300 (3.5), 301-350 (4), 351-400 (5), 451- 
500 (5.5).
Figure 3.2 below shows bar charts representing each of these four choices.
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Figure 3.1 Overview structure of the simulation study.
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Figure 3.2 The four types of age effect.
3.2.3 Exposure distribution
The precision of the relative incidence estimator depends on the extent of between 
individual variation in exposure. We used a beta distribution on [0,500] to generate
age at exposure. The following distributions of age at exposure were investigated.
• Mean age of 250 days and standard deviation of 100 days
• Mean age of 250 days and standard deviation of 50 days
• Mean age of 125 days and standard deviation of 100 days
• Mean age of 125 days and standard deviation of 50 days 
These distributions are shown in Figure 3.3.
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For some simulations, much more highly peaked distributions of age at exposure were 
considered, with mean age of 125 days and standard deviation of 10, 20, 30, and 40 
days. Figure 3.4 below shows graphs of these more extreme distributions of age at 
exposure.
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Figure 3.3 Distribution of age at exposure
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Figure 3.4 Unusually peaked distributions of age at exposure
3.2.4 Risk periods
In the self-controlled case series method, a major issue one has to consider before 
doing any analysis is to define the risk period. Generally speaking the risk period is 
elicited from experts. Different studies need different risk periods. These range from 
very short (one or a few days) to very long (and occasionally indefinite). Typically, in 
vaccine studies, risk periods of a few days/weeks are used, for example Farrington et 
al [9] defined risk periods in three groups (0-3, 4-7, and 8-14 days) when they 
investigated whether there was any association of diphtheria tetanus pertussis (DTP) 
vaccine with febrile convulsion, whereas to study a putative association of measles 
mumps rubella (MMR) vaccine with febrile convulsion they defined two risk periods 
of 6-11 and 15-35 days after vaccination. In each case these choices were based on 
prior knowledge of the biology of the relevant bacteria and viruses.
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We used different risk periods in order to investigate the effect of risk periods on the 
performance of the model. We looked at risk periods of 1, 5, 10, 25, 50, 100 and 200 
days. We also investigated indefinite risk periods. Owing to potentially strong 
confounding between age and exposure effects with indefinite risk periods, we 
considered this scenario separately, and also varied the proportion of cases exposed 
(in other simulations all cases are exposed).
3.3 Results from the simulation study
3.3.1 The standard scenario
We shall now define what we are considering as the reference point, or the standard 
(default) values that are typical in studies of childhood vaccination. The standard 
scenario is one in which the risk period is 25 days, all cases have experienced the 
exposure (vaccination), and the age effect is weak symmetric (see Figure 3.2). The 
standard distribution of age at exposure has mean 250 days and standard deviation 
100 days (see Figure 3.3 above).
For each run, ten thousand samples of 10 cases, 20 cases, 50 cases, 100 cases, 200 
cases, 500 cases, 1000 cases with relative incidences 0.5,1,1.5, 2, 5, and 10 were 
simulated (a total of 7 x 6 = 42 runs). Tables 3.1 and 3.2 below show the results of the 
data simulated under the standard scenario.
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The first column of Tables 3.1 and 3.2 shows the value of the true relative incidence 
followed by the logarithm of the true relative incidence. The next columns shows 
median estimate (values in bold) for 10 000 samples of the simulated data for 
different number of cases, followed by the logarithm of the median estimate. Below 
the median estimates (values in italics), we have three rows of values corresponding 
to the percentages of 90%, 95%, and 99% confidence intervals were the true value 
was below (%low), within (% covered) and above (%hi) the 90%, 95%, and 99% 
confidence intervals respectively. Figure 3.5 below shows the relative bias, defined as 
the ratio
(median relative incidence) -  (true relative incidence)
(true relative incidence)
as a function of sample size for relative incidences of 0.5, 1, 1.5, 2, 5, 10. The 
numbers of cases considered were: 10, 20, 50, 100, 200, 500 and 1000.
1.5
10
1 0  2 0  5 0  1 0 0  2 0 0  5 0 0 1 0 0 0  1 0  2 0  5 0  1 0 0  2 0 0  5 0 0 1 0 0 0  1 0  2 0  5 0  1 0 0  2 0 0  5 0 0 1 0 0 0
Number of cases
T h e  n u m b e r  a b o v e  e a c h  g r a p h  r e p r e s e n t s  th e  tru e re la t iv e  in c id e n c e
Figure 3.5 Relative (median) bias against median estimates for samples of 10, 20, 50, 
100, 200, 500, and 1000 cases for true relative incidences of 0.5, 1, 1.5, 2, 5, 10.
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The relative bias is used here for comparison purposes between different true relative 
incidences. Note that we would expect the relative bias to be equal to zero if the 
estimates were not biased.
We can see in Figure 3.5 above that the median estimates obtained using the self­
controlled case series model with 10 and 20 cases were biased when estimating true 
relative incidences of 0.5 and 1. This bias largely disappears as the number of cases 
increases say for numbers of cases greater or equal to 20. The bias was small when 
estimating the true relative incidences of 1.5, 2, 5 and 10. In chapter two, we showed
|  Y
that the bias (when there are no age effects) is negative when e^< —  -  and positive
r
|  Y
when e»> —  —. A similar phenomenon is demonstrated in Figure 3.5 above: the bias 
r
tends to be negative for small values of the relative incidence, and positive for large 
values of the relative incidence (here r = j ^  = 0.05).
The other pattern we can see in Tables 3.1 and 3.2 is that the coverage probabilities 
for the confidence intervals were reasonably close to the nominal values even with 
small numbers of cases. Figure 3.6 below illustrates the percentages of 90%, 95%, and 
99% confidence intervals that contained the true relative incidence. The figures 
indicate that overall, for the standard scenario described above, the coverage 
probabilities tend to be slightly conservative (that is, higher than nominal values) for 
small sample sizes. As one would expect, the larger the number of cases, the more 
accurate the coverage probabilities are. Note finally that the confidence intervals tend 
to be non-central, and are systematically shifted upwards so that the percentage of 
simulations in which the lower confidence limit falls above the true parameter value is
72
greater than the percentage of simulations in which the upper confidence limit falls 
below the true value.
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Figure 3.6 Percentages of 90% (in blue/dash), 95% (in red/solid) and 99% (in 
green/dots) confidence intervals that contained the true relative incidence of 0.5,1,
1.5, 2, 5, 10 for samples of 10, 20, 50, 100, 200, 500, and 1000 cases.
3.3.2 Varying the risk period
In this section we present results from simulations for the standard scenario defined 
above, except that instead of keeping the risk period fixed at 25 days, we varied it.
The risk periods we looked at were: 1 day, 5 days, 10 days, 50 days, 100 days, and 
200 days. We shall classify the risk periods as; ‘short risk period’ for 1 day and 5 days 
risk periods, ‘typical risk period’ for 10 days and 50 days, and ‘long risk period’ for 
100 and 200 days risk periods. The interest is in observing the effect of the risk period 
on the estimates obtained by the model. Further, to reduce the output, we have
73
restricted our simulations to 20, 100, and 500 cases. Tables 3.3 to 3.8 shows the 
results. In order to reduce clutter, we only present Table 3.3 and 3.4 here; Tables 3.5 
to 3.8 are presented in APPENDIX 1. Table 3.3 shows results for a 1 day risk period, 
Table 3.4 for a 5 days risk period and so on in increasing order up to Table 3.8 which 
shows results for a 200 days risk period. We summarise the results given in Tables 3.3 
to 3.8 via the relative bias graph (see Figures 3.7 (a), (b), (c)) for true relative 
incidence of 0.5, 1, 1.5, 2, 5, 10. We can see from Tables 3.3 to 3.8 that the coverage 
probabilities for the 90%, 95%, and 99% confidence intervals are generally 
conservative, and become closer to their nominal values as the risk period increases in 
the range considered.
74
l o
r -
5-1
< 2
w
CD
U
£
O
3
aa °
a -g
m  P h
*■> w
3  *c  
* 9  > »
r”  <3
H  T 3
ccj
•4-»
CD
V-i
< 2
cn
CD
I
H
CD
CDW5
"Si
^ 3
£
CD
0 .
0 >
r2?  r2?
1/5
<4-1o
t/5
«  ^ N
&  £  
S S3 J
«  «  \ S
«  ' - 5  « v
©  CD
§ s ^
©  O s
^ 3  ^ 3  
<D <D 
ik  J*.
CD CD
<3 0> 
0 > o
£  ^
£  £  
<3 o
G G
< o  O n 
O n O n
o n  n o  vrs-
O  ON (SnOn op On On On
NS?
O  S t "  o N
^  C lC
T fI—  O N
©  O
©  N r f '
I O N  
§
s  ^© }  <©> 
©  r - i
o  <o»
£
<N
03 03
O o  O n 
O n O n
£  ^  S? ^
© v° Cl Cl
0 3  <©> <^>
5 3  ^  ®N 
O n O n o n
t \  r r j
T f  \ p "  \ 0 ^  \ p "  
1 / 5  O N  O N  O NV) CN| O O
1 -H  NO-1 N O ? n o "  
O N  O N  O N  
c o  ' O  O n  
O n O n  O n
s SrO N
s  ^  
£  >
03
©  © n 
©  .,
ON No
'--I 0 3
NO O n 
O n O n
Co r-i
e t
CD
©©
i H
<4-< a© Sm ©  05 ©  
7 3  <D
I Ses
©
o
- s :  - s :  - s ;
N O  N O  S O  
O N  O N  O N
- ©  - ©  
g 2i
CD <D
O  ©  
o  o
N O  N O  
O N  O N
£ " <  C 1
o  o
03 <n
O n O n
o \  « " •  
0 3  ^
N O " N O " 
0 \  <$N 
° 0  O o  
O n O n
C l  C *
o  o  o
0 o  O o  O o  
O n O n  O n
N O " n o "  n o "  
O N  O N  O NJN <N JN
03 OO 03
NS ?  ' " ? 'O N  O N  O N
©  ' O  ° 0  
O n O n O n
03
rf no' no' no'(fi O N  O N  O N
1/5 03 03 03
N O " \ S  
O N  g V  
0-5 l O  O n  
0  O n O n O n
5S? ^  ^O K CO N
03 03 03
N  K  O O  
ON O n  ON
P \  m  <n
I - 0 *
$
ON >0 >
VD On 
O n  O n
0 5ma
CD©
c q
<4-1o
i
^ 3
8!
CD
O
CD
3 ?  r 2?
& a
s 3cs ©vx CD
3^ ^
2* S
CD CD
0> 0) 
.  C 5 C j
N O  N O  N O  
O N  O N  O N
0) o
N O  N O  N O  
O N  O N  O N
 ^ o  o  o
3? ^  ^
O o  C50 ° o
©  O n O n O n
®  ^  ^  £  © CNJ C\J <N^
03 03 03
no" no" no­
o n  o n  o n  
N o  V© O o  
O n O n O n
no" no" no­
o n  o n  o n  ^  ^  fN
y 03 03 03
n o "  n o "  n o ­
o n  o n  o N  
^  'Sj- O n  
©  O n O n  O n
% ^  ^  ^  © vo vo r-i
N O "  N O "  N O  
o n  o N  o N  
03 <©> 03
N O " N O " NO­
O N  O N  O N  
<N v o  O n 
O n O n O n
o ' .  -  . 
° o O n
8 ^  ^  ^| 03 <0. 03
N O " N O " N O " 
0 \  C ^ s  lo Oo 00 
Os 0 \  Oso
O  ^  ^  ^  
©  i n  [ N
03 <N) CO)
^  ^  ^  - - n  o n  
O n ° v  O n
K .  C N
E3
§
r ' ' 1 r ^ 1
o  u
* 0  O n 
O n  O n
&JD
O
i n
u
< 2
§
2
a
0
"cS
. §  - g
f*5 w  
CD ' £
1 £
H  3
cd-(->
CD
T 3
?x
<2
CO
CD
I
H
CD
CD
1/3
VO
o
cc
CD
o
o
1/5
<tx
O a  a
5W «■
CD T J
■ a cd
i s
C3
t®
O
O
o
o
-s; -s; -s;
*C3 "ta " o
CD CD ©
!© 5s. ik2 S> 9?>• >■ >ra © © ©
2  ©  ©  CD
© © © 
b b b
©  O  0 \  
Os 0 \  Os
T f  n o "  \ o "  " P  
(T ) ON ON © 03 03 ^
?  C^f ^  NO"
s | |
rH
8  ^  S ?  s ?
O  ^  >  N
00 
U5 © <N 
© .
o \
03 ^
<"o Os
0\  0\ro
\ c T  N O  \ o  
OV ON £ >  ON es 50
NO" NO" NO­
ON ON ON 
03 V© Os 
Os Cs 0 \
vb 0-3 -N
03
-N, VO Os 
Os Os Os
t" -  NO' NO" 
©  ON ON
©  cr> <N
*N ^ 5  0 \
Os Cs Os
©  P ^ V o
$ b
aOV >  fN  ©
^  £  £  ©N D-s OS 
W  On Os 
VO ,
®V Ntf1 NSS1 • ON ^ n  ON
^ s b
<txo
-so -s; *s;
NO NO NO ON ON ON
"53 "C3 3^ 
CD ©  ©
k. k, k.© © ©
^  3> >© © ©© © ‘
| S
o©
NO NO NO ON ON ON
£  £  £  -2 - 2  -S  
£  ^  £
G G G
©  > n  O n
O n Os Os
NO" .— 
ON N o
n  © >  o n  ® 5  
i d ®
®V Oo on  
©  °v  Os
©  ( S n  N O  o  © °>N 
w  N  (SCN)
©3 ©3 ©3
NO" NO" NO* 
ON ON ON 
C\| C \  Go
Os Os Os
^  ^  ^  
P o  j n  fN
©3 ©3 ©3
i n
SO 03 
©
©3
l >  NO" NO" NO" 
t» . ON ON ON
1/5 <N ©3 ©3
00
0-3 tN Os 
Os Os Os
NT '  '  Os
CS °V ©S
ON « n  Vo 5^5
CS| t \  Os 
Os Os Os
Vo CT) X
M- '- i ©3
NO" NO" NO­ON ON ON 
©3 Vo Os 
Os c s  c s
cs n© r*5 r-<
cc 
CD
o
<N
*** -  o a
4 1 *
I s !
►s;
■v?ON
Si
©©
- s ;  - s ;
NO NO 
ON ON
"cs "CS
Si Si
© © © ©
©©
o §
s  a  ©> ©
kx  ^ k ^G  G
• n  ©s 
Os Os
^  ©3 ©3
I '  ^  ^  
§  !>  ?>©S O s
0-3
NO" NO" NO 
ON ON ON 
©3 ©3 ©3
NO" no" no"
ON ON ON
D-s OO ° 0  CS ©s Os
O
V ©3 ©3 ©3
y~3 CN
vo vo On 
OS CS Os
"o- "ct-
©3 ©© O
NO" no" NO­
ON o n  o n  
^  >  Os
c s  ©S Os
Vo J o  N
t "  SO" NO" NO" 
1/5 ON ON ON1/5 ©3 ©3 ©>
^  ^  ^  ^  
0-3 VC3 ©S 
Os Os Os
NO" NO NO 
ON ON ON 
^
”  ^  ^  s ?^  Os 
-  ON Os Os
^  ^  ^  = vov 5fv nCL vi
&£o
rq
The graphs in Figures 3.7 (a), (b) and (c) show that, for each sample size, the relative 
bias was greatest for 1 day risk period, particularly for low relative incidences. For a 
given relative incidence, the bias is negative for short risk periods and positive for 
long risk periods. The sign of the bias essentially depends on the number of cases in 
the risk and control periods. As the number of cases increases, the relative bias 
decreases and is close to zero even with 1 day risk period.
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Figure 3.7 Relative median bias for 10 000 samples of 20, 100, and 500 cases at true 
relative incidences of 0.5, 1, 1.5, 2, 5, 10
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3.3.3 Varying the age effect
In this section, we explore the effects of age for the strong symmetric, weak 
monotone, and strong monotone increasing age effects (see Figure 3.2 for the 
different age groups and their corresponding age specific relative incidences). We use 
sample sizes 20, 100 and 500 cases as in section 3.3.2, and use risk periods of 10 
days, 25 days, and 50 days with relative incidences of 1, 2 and 5. The distribution of 
age at exposure is the standard one with mean 250 days and standard deviation 100 
days.
Tables 3.9 to 3.11 in APPENDIX 1 shows the results. Tables 3.9 corresponds to the 
strong symmetric age effect, Table 3.10 to the weak monotone increasing age effect, 
and Table 3.11 to the strong monotone increasing age effect. The results in these 
tables are summarised in Figures 3.8 to 3.10. We can see that the relative bias is 
largest for 20 cases, being the smallest number of cases considered. As for the 
findings in section 3.3.2, we note that it is for the shorter risk period (10 days risk 
period in blue/dash) that the relative bias is most prominent. In contrast, the age 
structure, (strong monotone, strong symmetric, or weak monotone) has little influence 
on the relative bias. It appears that the performance of the model is mainly influenced 
by the number of cases and the length of the risk period. Likewise, Tables 3.9 to 3.11 
show that the coverage probabilities of the 90%, 95%, and 99% confidence intervals 
are not substantially affected by the age structure.
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Figure 3.8 Relative median bias for 10 000 samples of 20 cases at true relative 
incidences of 1, 2, 5 with age effects for strong monotone, strong symmetric and weak 
monotone. The risk periods are 10 days, 25 days and 50 days.
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Figure 3.9 Relative median bias for 10 000 samples of 100 cases at true relative 
incidences of 1, 2, 5 with age effects for strong monotone, strong symmetric and weak 
monotone. The risk periods are 10 days, 25 days and 50 days.
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Figure 3.10 Relative median bias for 10 000 samples of 500 cases at true relative 
incidences of 1, 2, 5 with age effects for strong monotone, strong symmetric and weak 
monotone. The risk periods are 10 days, 25 days and 50 days.
3.3.4 Varying the age at exposure.
In the last few sections, we varied the relative incidence, risk periods and the age 
dependence but in all scenarios, the distribution of age at exposure was kept fixed to a 
symmetrical beta distribution with mean 250 days and standard deviation 100 days 
(see Figure 3.3). Here we explore the performance of the model when we vary the 
distribution of age at exposure. We present results for the simulations of 100 cases 
only, and restrict attention to relative incidences of 1, 2, and 5 and risk periods of 10 
days, 25 days and 50 days as in section 3.3.3. We present results for weak symmetric
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age effects (the standard scenario) and strong monotone increasing age effects. We 
investigate distributions of age at exposure with mean 250 days and standard 
deviation of 50 days, mean age of 125 days and standard deviation of 100 days, and 
mean age 125 and standard deviation 50 days, as shown in Figure 3.3. The results are 
given in Tables 3.12 and 3.13 (APPENDIX 1). The graphs in Figures 3.11, (a), (b) 
and (c) below show the relative bias for different age distribution at exposure and 
different age effects.
Figure 3.11 (a) shows that a symmetric distribution of age at exposure that is more 
peaked than that of standard scenario (standard deviation 50 days and mean 250 days) 
has little effect on the results. However Figures 3.11 (b) and (c) reveal some 
differences when the distribution of age at exposure is skewed. In this situation, the 
bias is greater when the age effect is strong monotone than when it is weak 
symmetric. When the age effect is strong monotone, events are most likely to occur at 
older ages, whereas most risk periods span younger ages. Thus the imbalance between 
expected numbers of events in risk period and control periods is greater and this leads 
to greater bias. This effect is most pronounced for short risk periods. A further reason 
for the bias may be confounding between age and exposure effects.
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Figure 3.11 Relative bias against relative incidence, for risk periods 10, 25, 50 days 
and two age effects, when the mean age at exposure is 250 days, standard deviation 50 
days (a), mean age at exposure is 125 days, standard deviation 100 days (b), and mean 
age at exposure is 125 days and standard deviation 50 days (c).
3.3.5 Indefinite risk periods
In all the scenarios explored so far, the risk periods were of pre-determined length. 
The self-controlled case series method can be used even when the risk period 
following an exposure is indefinite. However, the effects of exposure and age may 
then be substantially confounded. The confounding can be controlled by including 
unexposed cases, which contribute exclusively to the estimates of the age effect. This 
was explored in the simulations described below.
In this section, we present results using indefinite post-exposure risk periods when 
100% of cases are exposed, five sixth of the cases are exposed, two thirds of the cases 
are exposed and half of the cases are exposed. We first used two exposure
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distributions (for those exposed): mean 250 days with 100 days standard deviation 
and with mean 125 days with 50 days standard deviation. We used weak symmetric 
and strong monotone increasing age effect with true relative incidences of 1, 2, and 5. 
All runs include 100 cases exposed. The results from the simulations are presented in 
Tables 3.14 to 3.17 (APPENDIX 1). The coverage probabilities are very close to the 
nominal values. Figure 3.12 summarises the relative bias for all the simulations 
presented in Tables 3.14 to 3.17.
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Figure 3.12 Relative median bias for 10 000 samples of different exposed proportions 
such that 100 cases were exposed for the true relative incidences of 1, 2, 5 with age 
effects for strong monotone and weak symmetric age groups.
Figure 3.12 shows that the relative bias is small for relative incidences of 1 and 2, 
whatever the age at exposure and age at event distributions. Note that there was one 
exception to this for the relative incidence of 2 with the weak symmetric age effect. 
The outlier could be due to random variation.
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However, for relative incidence of 5 the relative bias is greater for strong monotone 
increasing age effects than for weak symmetric age effects and greater when the age 
at exposure distribution is skewed than when it is symmetric. This may be explained 
by confounding of age and exposure effects when the risk period is indefinite.
The presence of unexposed cases reduces the bias to some degree, though perhaps less 
than anticipated. To explore these effects further, more peaked and asymmetric 
distributions of age at exposure were investigated. In these additional simulations, the 
relative incidences were 1, 2, and 5 as before, and we used the strong monotone 
increasing age effect. The distributions of age at exposure had mean 125 days and 
standard deviations of 10, 20, 30, and 40 days respectively (see Figure 3.4). All 
simulations were done with indefinite risk periods, and the same proportions exposed 
as those used earlier.
The results are in Tables 3.18 to 3.20 of APPENDIX 1 and are summarised in Figure 
3.13 below. As expected, the bias tends to increase as the standard deviation of the 
age at exposure decreases. The presence of a small proportion of unvaccinated cases 
greatly reduces the bias: the bias with •§ cases vaccinated is much the same as with
j- cases vaccinated.
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Figure 3.13 Relative bias for strong monotone increasing age effect.
3.4 Conclusion
In this last section of the chapter, we bring together the main findings. We have 
investigated a very broad range of scenarios, based on variations of a ‘standard 
scenario’ which is a representative of many studies of paediatric vaccines. In the 
standard scenario we found that the estimates were substantially biased for sample 
sizes of 20 or less, when the true relative incidence was < 1. However for relative 
incidence >1.5 the biases were moderate even with sample sizes of 10 cases, and 
very small when the number of cases was > 50 .
In section 3.3.2, risk periods as short as 1 day and up to a maximum of 200 days were 
investigated. In these situations, the estimates were biased for short risk periods. For
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example when the risk period was 1 day, the bias was large when the relative 
incidence was 0.5 even with 500 cases. Similarly the bias was large for relative 
incidence of 2 and 100 cases. Generally speaking, the longer the risk period in the 
range considered (up to 200 days), the less biased the estimates were.
Different age effects classified as weak symmetric, strong symmetric, weak monotone 
increasing, strong monotone increasing were explored in section 3.3.3. There was 
little evidence that these age effects affected the performance of the self-controlled 
case series model with fixed risk periods. The effect of different distributions of age at 
exposure was explored in section 3.3.4. As with the age at event, the distribution of 
age at exposure did not have much bearing on the results for fixed risk periods.
In section 3.3.5 we looked at the effect of indefinite risk periods. Some researchers 
[51, 52] have argued that the self-controlled case series model may not be effective if 
one is looking at a situation were adverse events may manifest themselves a long time 
after exposure. We explored this issue by extending the risk periods to indefinite 
length. Results showed that overall there was little bias except for large relative 
incidences and distributions of age at event and age at exposure that induce 
confounding between exposure and age effects. This confounding and the bias it 
generates can be controlled by including unvaccinated cases. Some bias remains, but 
it is not large. Including 20% unexposed cases appears sufficient to reduce the bias to 
acceptable levels.
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In all situations explored, the coverage probabilities from ten thousand samples of 
different number of cases were in excess of their nominal values, even in the presence 
of substantial bias.
In chapter 2 we found that when there are no age effects, the magnitude of the 
asymptotic bias depends largely on the balance of expected numbers of events in the 
risk and control periods: when the expected number of events in the risk period is less 
than that in the control period, the bias is negative, and vice versa. When the two 
expectations are equal, the bias is zero.
In this chapter we have explored more complex situations and finite samples by 
simulation. Qualitatively similar results emerge: for a given sample size, the bias is 
greatest in magnitude when the expected number of events in the risk period is much 
smaller than the expected number in the control period. In practice, bias is only a real 
problem when the risk period is very short or relative incidence is low. In other 
circumstances, sample sizes in excess of 20 appear to give reliable results.
Another point to mention is the coverage probabilities. These are generally reasonably 
accurate even in the presence of extreme bias: this is not surprising, since when the
expected number of event in the risk period is very small, the variance of j3 = log(p)
(where p  = ep is the relative incidence) is very large, as may be seen from the 
asymptotic calculations of chapter 2. Hence the confidence intervals will themselves 
be very wide. Confidence intervals based on profile likelihood methods may perhaps 
be better in such circumstances.
89
The overall conclusion is that estimates and confidence intervals based on asymptotic 
theory are reliable except in extreme scenarios (namely very small sample size, very 
short risk period, low relative incidence).
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Chapter 4
Sample size formulae for the self-controlled case series method; first 
attempts
4.1 Introduction
When designing a study, one of the most important questions to address is the 
required sample size. In this chapter we propose various sample size formulae for 
designing a study that will use the self-controlled case series method. In [3] a sample 
size formula for use in case series studies was derived based on a normal 
approximation to the distribution of the estimated relative incidence. However, the 
performance of this sample size formula has not been evaluated. Furthermore it is 
only valid when there are no age effects. In this chapter the accuracy of this sample 
size formula is assessed by simulation. Other sample size formulae are explored and 
results from simulation studies to evaluate their performance are given. All these 
formulae assume a simplified situation without age effect. In chapter 5, a formula 
incorporating age effects will be presented.
In section 4.2, we briefly present some background and the notation to be used in this 
chapter. In section 4.3, we derive four sample size formulae based on different 
asymptotic arguments. These formulae are derived under the assumption that there are 
no age effects, and are evaluated in section 4.4. We conclude with a brief discussion 
in section 4.5.
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4.2 Background and notation
In this chapter we will be concerned only with situations where the underlying (or 
baseline) incidence of an event is constant, that is, does not vary with age (or time, if 
time is the relevant time line). At each time point, an individual is categorized as 
exposed or unexposed. Typically, the times at which an individual is considered to be 
exposed occur within a defined time interval following a point exposure, for example 
receipt of a vaccine. The period of exposure is called the risk period.
We further assume that all individuals are followed up for an observation period of 
the same length, and that a proportion v of individuals in the population experience 
the exposure during this observation period. We will assume, also for simplicity, that 
all exposed individuals spend the same time exposed. As mentioned before in chapter 
2 , in practice, the observation and exposure periods vary between individuals, but this 
variation can reasonably be ignored for the purposes of sample size calculations. If ex
is the length of the risk period and e0 is the duration of the control period, 
thenr = ex /(e0 + et) is the proportion of observation time for which an individual is 
exposed. Usually, ex and e0 + ex will be specified in the design. However, only their 
ratio r is required.
During the risk period, the baseline incidence of an adverse event is increased by a 
multiplicative factor p  = ep, where p  is the relative incidence. The value of 
parameter p  (or/?) which may be considered clinically important is the focus of
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inference. Under the null hypothesis, p  = 1 whereas under the alternative hypothesis 
we specify some value for p  ^ 1, the value we wish the study to detect.
A case is an individual who experiences at least one event during the observation 
period. Suppose that a sample of cases is available, and that a total of n events arise in 
these cases. Note that n refers to events, not individuals: the case series method 
allows multiple events per individual, provided these events are independent. Our 
sample size formulae will generally relate to numbers of events, though in the next 
chapter we briefly touch upon estimating the number of cases required. If the event of 
interest is non-recurrent, then the case series method still applies provided the event is 
rare. Of these n events, suppose that ne arise in exposed individuals, that is, 
individuals who were exposed at some time during the observation period. Suppose 
also that nu events arise in unexposed individuals, that is, individuals who were not
exposed during the observation period. Of the ne events in exposed individuals,
suppose that x arise in a risk period. Then the case series log likelihood for the 
parameter p  can be shown (see chapter 2) to be
t  (p) = x log f— —— 1 + (ne- x )  log f 1 V 1. (4.1)
\ p r + \ - r )  \ p r + \ - r )
Note that (4.1) is equivalent to a binomial likelihood with binomial proportion 
n  = pr  / (p r +1 -  r) and index ne, and that it does not involve nu: only exposed
individuals contribute to the log likelihood when there are no age effects. The 
likelihood ratio statistic for the test of H0:p = l (or equivalently j3 -  0 ) is thus
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D = 2 {£ (p) -  £ (l)} = 2 {x log (p) -  ne log (pr + 1 - r )}. (4.2)
where p  is the maximum likelihood estimator of p . Finally, note that, in large 
samples, we have
\ + v r (p - \)n - n e —— - .  (4.3)
v(pr +1 -  r)
In particular, if p  = 1 then n -  ne / v in large samples, and if  v = 1, then n = ne.
We present four sample size formulae based on different asymptotic approximations, 
assuming there is no age effect. In what follows, the significance level is denoted a , 
and to avoid confusion with the parameter ft (the log relative incidence) we shall
denote power to be 1 -  y . Thus Zx_an is the (1 -  (a  / 2)) -  quantile of the standard
normal distribution, and Zyis its /-q u an tile . For simplicity, the formulae quoted in
this chapter are for ne, the total number of events required in exposed individuals.
4.3 Sample size formulae without age effects
4.3.1 Sample size formula based on the asymptotic sampling distribution of p
In this subsection, we describe the sample size formula which was first published by 
Farrington et al [3]. The idea behind the derivation of the formula is to use p  as the 
test statistic, and base the sample size formula on its asymptotic normal distribution. 
The asymptotic variance of p  maybe obtained by twice differentiating (-1) times 
expression (4.1) with respect to p , taking expectations, and inverting the result. This 
gives the expression for the variance as
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var (A)=
1 p(pr+\-ry 
ne r ( l - r )
A general sample size formula for a normally distributed test statistic where one 
assumes that the variance under the null hypothesis is different from that under the 
alternative hypothesis is given by Armitage et al [53] as
n =
\2
Mi-Mo )
(4.4)
where the test statistic under Hn is distributed
N
f  -i\ 
0Mo»—  
v n j
and under Hl is distributed
N r ^  Mi’
V n  J
Note that //, -  p0 is the clinically important difference to be detected in the population. 
Thus under the null hypothesis,
N (l,l/ner (l-r ))  
and under the alternative,
p  » N ^p ,p (p r  +1 - r f  / ner(l -  r)j .
Replacing the parameters from the two approximate distributions of p  under the null 
and alternative hypothesis in the general expression (4.4) leads to the following 
sample size formula:
1 \ - al2+Zr (pr + l - r ) ^ ]  . (4.5)
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The above is a special case of the formula given by Farrington et al [3] with everyone 
exposed. Note that in all sample size formulae given here we round ne up to the next 
integer that is greater or equal to the number of events needed.
4.3.2 Sample size formula based on the asymptotic sampling distribution of p
A concern about (4.5) is that the sampling distribution of p  may not be symmetric in 
small samples. Thus we derived a sample size formula based on the sampling 
distribution of p  = log (p)  in the hope that this might be less skewed. In chapter two
we showed that the asymptotic variance of p  up to the first order in ne (see formula
(2.6)) is
Under the null hypothesis, 0,1 / ner (l -  r)) whereas under the alternative,
P & N ^P ,(pr + l - r f  Inep r ( l - r)j . Using (4.4) leads to the following expression for 
the sample size formula:
(4.6)
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4.3.3 Sample size formula using second order variance of {$
As has been mentioned above, sample size formula (4.6) was obtained in an effort to 
try and improve on the possible non-symmetric distribution of p  in small samples. 
Evaluation of formulae (4.5) and (4.6) under simulation showed that the two formulae 
were not accurate (results shown in section 4.4): the observed power was not as 
expected in some cases. The results from the simulation were particularly poor when 
the risk period was short and the clinically important relative incidence to be detected 
was in the extremes, for example relative incidences of 0.1, or 10. Having identified
this problem, we extended the asymptotic variance of the estimate p  up to the second
order in ne, in the hope that the sample size formula derived would better take
account of the variation in the estimate of the relative incidence. Below is how the 
sample size formula using second order asymptotic variance was derived. 
prLet p  = — - ----- be the risk of an event m the risk period
p r + l- r
1 — Yand q = 1 -  p =----------- the risk of the event occurring in the control period. As
p r + l - r
before r is the ratio of the risk period to the observation period. The second order 
asymptotic variance was found in chapter 2 as:
var(jg) = — ) 
nepq 2nep  q nep  q
0 AUnder H0 : pQ= p  = 0, crQ - n e var(/?), and p  = 1. Substituting p, p, and q in 
v a r ^ j  above and simplifying, we have:
1 (2 r - l)2 2 ( r ‘+ ( l - r ) 3)
0 r ( l - r )  2n r2( l - r ) 2 ner2( l - r ) 2
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2 1 ( p - q )  2( p + q )Under Hl \px= p, cr, =ncvar(^), /. <r, = ------^ r r  + —
pq 2nep  q nep  q
Substituting cr0 and ox in (4.4) and simplifying in terms of r, and p , we get the
following sample size formula:
n„ =
( r O - r ^ f lo g ^ ) ) '
where
^=r(1_r)_ l ^ +20l±(izrn
2ne ne
2. >, , x2 (p r - \  + r ) \p r  + \ - r f  2 { (p r f + ( l - r f ) ( p r  + l - r )B = p r(l-r )(p r  + l - r )   --------- -------------- —+ —--------------------------------
2w w
Note that the above formula is implicit since ne occurs both on the left and right hand 
sides of (4.7). We obtained ne by an iterative search from a particular starting point. 
We used the lowest value ofne obtained from sample size formulae (4.5) and (4.6) as 
the starting values.
4.3.4 Sample size formula based on the binomial proportion
In the simplified setting as described earlier, events in exposed individuals occur 
either in the risk period or in the control period. Hence the events can be considered to 
follow a binomial distribution with proportion n  = pr  / (p r +1 -  r ); therefore, we can
use binomial proportions to derive a sample size formula for the self-controlled case 
series method. The binomial probabilities under H0 and Hx are:
7U0 = P(event in risk period |iT0) = r
(4.7)
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n, = P(event in risk period IH,) = ---- ——  = p
1 1 i r p + l - r
Let x denote the number of events in the risk period,
thusx~B in(ne,a0) underH0 andx ~Bin(«e,^ 1) underHl.
By the normal approximation to the binomial (Fleiss et al [54]), under
x ne7ro== & and under H,, n'e7rl== « 7^(0,1) . The sample size
V »^0o -a -0) v M -.a -* .)
formula based on the normal approximation to the binomial distribution (Fleiss et al 
[54]) is given by:
Z,-an -  *o) + Zr4 n+  ~ ”i)
7 t x - 7 Tq
Substituting the values of ;r0 and nx we get:
n„ =
z i-a,2 ^ 0 .- r )  + Z r p ( l - r ) 
]] (rp + l - r ) '
-]2
r ( p - l ) ( l - r )  
rp + l - r
(rp  + 1 -  r)Z ,.g;2 *Jr(l - r )  + Zyj r p (  1 -  r) 
r ( p - l ) ( l - r )
(4.8)
In the next section we present a comparative evaluation by simulation of sample size 
formulae (4.5), (4.6), (4.7) and (4.8).
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4.4 Comparative evaluation of sample size formulae (4.5), (4.6), (4.7) and (4.8)
So far, we have derived four sample size formulae for the self-controlled case series 
method. We now present results from a simulation study to evaluate them.
4.4.1 Simulation study
The simulation study was carried out as follows. First we specified the observation 
period (500 days), the relative incidence { p ), the value r , that is the ratio of the risk 
period to the observation period, the power (set at either 80% or 90%), the 
significance level (set at 5%) and we assumed everybody was exposed. The values of 
r , the ratio of the risk period to the observation period were 0.01, 0.05, 0.1, and 0.5 
(corresponding to 5, 25, 50, and 250 days, respectively). The relative incidences { p ) 
to be detected at the two sided 5% significance level with 80% or 90% power were 
0.1, 0.5, 1.2, 1.5, 2, 3, 5, 8 and 10.
After calculating the number of cases required using the specified parameters, we 
rounded the sample size ne up to the next integer. We then generated 2000 random
samples of ne cases with a single event per case. Each of the ne cases was obtained
using a 500-day observation period, including a risk period of duration 500 x r days. 
Thus all cases were assumed to be exposed. The single event for each case was 
randomly allocated to the risk and control period based on the true value of p .
Then p  was estimated using the self-controlled case series method for each sample 
of ne events. The observed power was found by calculating the overall proportion of
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the 2000 samples for which the likelihood ratio test rejected the null hypothesis at the 
5% significance level. The Monte Carlo standard error (MCSE) for the empirical 
power is found by
MCSE / Powerx(1_Power)
V number of simulations
It is about 0.89 per cent at 80% power and 0.67 per cent at 90% power.
4.4.2 Results
Tables 4.1 and 4.2 below show the results obtained using the four sample size 
formulae. The combination of four values of r , nine values of p  , two powers, and 
four sample size formulae thus required 288 different simulations of 2000 samples. 
The different sample sizes calculated using the different formulae are given in 
columns headed N5,N6,N1,N8  corresponding to sample size formulae numbered 
(4.5), (4.6), (4.7), (4.8) respectively. The corresponding observed power (in %) under 
simulation for each sample size is given in columns headed P5 , P 6 , P I , PS .
The sample sizes produced by the four formulae are generally of a similar order of 
magnitude, with some very noticeable exceptions, particularly 
withr = 0.01 and p  > 5 . Forr = 0.01,p  = 10 and power 0.8, the sample sizes ranged 
from 29 (7V8) to 170 (7V7 ), a greater than 5-fold difference. This variation indicates 
that some of these formulae, at least, must be inaccurate over this range.
It is clear that all the four formulae N5,N6,N7  and NS are inaccurate for many 
parameter combinations, especially for extreme values of p . This could be most likely
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due to skewness of the sampling distribution of p  and f3 especially for sample size 
formulae N5 and N6. Formulae N5 and NS tends to overestimate the sample size 
required (as seen by the empirical power) for relative incidence less than one and 
underestimate the sample size required for relative incidence greater than eight but the 
underestimation is not present for relative incidence greater than eight when the ratio 
of the risk period to the observation period was 0.5 for 80% power and when 
r = 0.1 and 0.5 for 90% power (see P5 and PS in Tables 4.1 and 4.2). On the other 
hand, the power observed from formulae N6 and N7 does not seem to show a clear 
pattern; for some values of the relative incidence, the observed power is greater than 
the nominal value (see P6 and P7) and for others it is lower. The power observed 
from all four sample size formulae derived so far seem to be accurate when trying to 
detect relative incidences ofRI = 1.2 and 1.5.
102
Table 4.1 Empirical power for 80 per cent nominal value
r RI N5 N6 N1 NS P5 P6 P I PS
% % % %
0.01 0.10 617 403 819 609 96 67 98 88
0.50 2632 2079 2265 2618 81* 80 81* 83
1.20 21000 22644 22874 21031 80 80 80 79
1.50 3627 4327 4448 3638 78 84 84 80
2.00 1010 1379 1499 1015 76 87 88 78
3.00 301 505 610 302 78 88 95 79
5.00 97 216 306 98 80 95 97 80
8.00 42 122 199 42 62 98 99 62
10.0 30 97 170 29 79 98 99 79
0.05 0.10 128 81 161 119 96 67 99 89
0.50 544 A ll 462 529 84 80 78 86
1.20 4400 4741 4767 4431 80 80 80 80
1.50 767 910 891 779 77 84 82 80
2.00 217 293 274 223 76* 85 83 72*
3.00 67 109 86 69 70 88 84 74
5.00 24 48 56 24 80 95 96 80
8.00 12 28 43 11 75 95 99 69
10.0 9 22 36 8 63 98 99 56
0.1 0.10 67 41 79 58 96 62 98 85
0.50 284 221 210 269 86 73* 80* 83
1.20 2337 2517 2508 2371 78 81 80 80
1.50 412 486 479 425 75 82 81 76
2.00 119 159 153 125 75 85 81 75
3.00 39 60 58 41 64 84 81 75
5.00 15 27 15 15 69 89 69 69
8.00 9 16 11 8 69* 92 80 81*
10.0 7 13 9 6 79 96 79 69
0.5 0.10 22 9 14 9 99 80 97 80
0.50 93 68 69 69 92 77 81 81
1.20 886 947 948 948 77 80 80 80
1.50 169 194 194 194 73 80 80 80
2.00 57 68 69 69 77* 76* 81 81
3.00 24 29 29 29 77 81 81 81
5.00 15 16 14 16 76* 88 82* 88
8.00 14 11 9 11 93 87 75 87
10.0 14 9 11 9 97 81 93 81
r = ratio o f the risk period to the observation period, v = 1 ,the proportion vaccinated, 
RI = relative incidence to be detected, N5 = sample size (using formula (4.5)),
N6 = sample size ( using formula (4.6)), N1 = sample size(using formula (4.7)),
NS = sample size (using formula (4.8) ), P5 = observed power for N  5, P6 = observed 
power for N 6, P I  = observed power for N 1 , PS = observed power for N S . *Saw­
tooth phenomenon (see text).
103
Table 4.2 Empirical power for 90 per cent nominal value
r RI N5 N6 N7 NS P5 P6 P I P8
% % % %
0.01 0.10 696 681 762 688 97 97* 99 95*
0.50 3309 2978 3082 3297 91 87 90 90
1.20 28622 2981 29950 28641 90 90 90 90
1.50 5056 5573 5700 5062 90 91 90 87
2.00 1452 1739 1855 1453 88 92 93 89
3.00 451 617 720 450 86 94 97 84
5.00 155 255 343 152 87 96 99 86
8.00 71 140 217 68 91 97 99 89
10.0 51 110 183 48 85 99* 98* 82
0.05 0.10 144 135 241 135 95* 97* 99 97
0.50 681 609 648 669 92 90 93* 90*
1.20 6006 6251 6277 6026 90 90 90 90
1.50 1073 1178 1203 1079 88 90 92 89
2.00 315 372 394 316 89 92 94 91
3.00 102 135 154 101 84* 94 96 90*
5.00 39 57 74 36 86* 93 99 90*
8.00 21 33 47 17 90 98 99 81
10.0 16 26 40 13 86* 99 99 87*
0.1 0.10 74 67 117 66 94 96* 99 97*
0.50 354 314 332 341 92 90 92* 90*
1.20 3196 3324 3336 3217 90 90 90 90
1.50 579 633 644 585 89 91 93 88
2.00 174 203 213 175 89 90 93 89
3.00 60 75 84 59 85* 91 95 90*
5.00 25 33 41 22 93 95 98 84
8.00 15 20 27 11 91 96 99 84
10.0 13 16 23 9 97 97 100 79
0.5 0.10 24 14 19 11 100 97 99 93
0.50 112 92 94 91 95 91* 90* 91
1.20 1228 1269 1271 1268 89 90 90 90
1.50 247 260 262 259 90 89 90 89
2.00 88 92 94 91 87 90 90 90
3.00 41 40 42 38 95 90* 92 92*
5.00 28 21 25 20 96 95* 95* 89
8.00 28 15 20 13 100 91* 98 95*
10.0 30 14 19 11 100 97 99 92
r = ratio o f the risk period to the observation period, v = I,the proportion vaccinated, 
RI = relative incidence to be detected, N5 = sample size (using formula (4.5)),
N6= sample size (using formula (4.6) N1 -  sample size(usingformula (4.7)
NS -sample size (using formula (4.8)), P5 = observed power for N5, P6= observed 
power for N 6, P I = observed power for N 1 , PS = observed power for N S . * Saw­
tooth phenomenon (see text).
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4.4.3 Saw-tooth phenomenon
The discreteness of the data induces a phenomenon known as saw-toothing. For 
example we can see from Table 4.1 that to detect a relative incidence of 2, at 80% 
power, when the ratio of the risk period to the observation period is 0.05, with all 
cases exposed (vaccinated), sample size formula N5 gives approximately 217 as the 
number of cases needed. The observed power by simulation was 76%, which is 
slightly less than the nominal 80% power. For the same parameters, using sample size 
formula NS gives 223 as the approximate number of cases needed and the observed 
power was 72%. Thus the power is not a monotone increasing function of sample 
size. This was observed in several situations (marked by * in Tables 4.1 and 4.2) and 
with all the other formulae derived. This phenomenon has been observed by other 
researchers for example Chemic et al [55], Cesana et al [56], Brown et al [57] and 
Hoehler [58].
The saw-tooth phenomenon means that the power function has the characteristic that 
it decreases slowly and then jumps up and then cyclically repeats the decreasing trend 
followed by an upward jump. The jump always occurs at a higher level of power than 
in the previous cycle. One consequence of this is that there may be no unique sample 
size.
Chemic et al [55] demonstrated that for continuous random variables, for a given 
significance level and alternative hypothesis, the power function increases 
monotonically as sample size increases, but that this is not the case for discrete 
random variables. Figure 4.1 below is adapted from Chemic et al [55] showing a saw-
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toothed power function. Hoehler [58] argues that because the power function is non­
monotonic with discrete data, calculation of a single required sample size is usually 
impossible. We can, however, specify a range of sample sizes over which a study will 
have a given power to reject the null hypothesis. To get round this problem similar 
methods have recently been used to determine exact sample sizes for comparative 
studies using Fisher’s exact test (Thomas and Conlon [59]).
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Figure 4.1 Saw-toothed behaviour
4.5 Discussion
The sample size formulae derived in this chapter are not accurate. In particular, the 
published sample size formula of Farrington et al [3] is inaccurate for p  < 1 or p  » 1 .  
The least inaccurate of the four sample size formulae is perhaps that based on the 
binomial proportion. In chapter 5 we investigate further variants of the binomial- 
based sample size formula. We also explore other sample size formulae which can 
allow us to include the effect of age. Age is an important confounder in studies of
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vaccine safety, so it is essential that we can have a sample size formula for the self­
controlled case series that can take account of the effect of age.
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Chapter 5
Improved sample size formulae for the self-controlled case series 
method
5.1 Introduction
The sample size formulae derived in the previous chapter are not accurate. Hence we 
sought other sample size formulae that we hoped would be more accurate. In this 
chapter, we present these other formulae.
In section 5.2, we derive a sample size formula based on binomial proportions but 
with continuity correction. In section 5.3 we derive a sample size formula also based 
on binomial proportions but based on the arcsine variance stabilizing transformation. 
In section 5.4 we derive a sample size formula based on the signed root likelihood 
ratio statistic. A comparative evaluation of the three formulae is given in section 5.5. 
The likelihood ratio statistic based sample size formula is then generalised to include 
allowance for age effects in section 5.6. This formula with age effects is evaluated in 
section 5.7. We discuss our findings in section 5.8.
5.2 Sample size formula based on the binomial proportion with continuity 
correction.
Fleiss et al [54] argue that the Type /  error of sample size formula (4.8) is 
conservative, and this can be improved by a continuity correction. We thought this 
could be one of the reasons why formula (4.8) was not very accurate. With continuity
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correction, according to Fleiss et al [54], sample size formula (4.8) can be written as 
shown below:
r( /7 - l) ( l- r )  
rp  + l - r
where ne is the value obtained from sample size formula (4.8) and ne is the sample
size with continuity correction. As before r is the ratio of the risk period to the 
observation period. Note that (5.1) is derived under the same assumptions as those 
used to derive sample size formula (4.8).
5.3 Sample size formula based on the binomial proportion with arcsine 
transformation.
As described in chapter 4, in the simplified setting we are considering, the log 
likelihood is equivalent to that of a binomial with proportion 7r = pr /(p r  + l - r )  and
index ne. A popular approach to improve the normal approximation to the binomial is
to use the arcsine variance-stabilizing transformation [60]. In this situation the test 
statistic is
T = arcsin(V^);
under the null hypothesis
T » TV^arcsin(4r j , 1 / 4ne j ,
while under the alternative,
72 = 1+  1 +  - _  n e 1 + 1+ -
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T » N^arcsm^yjpr / (pr + l - r )  j,l/4 « e j . Thus we obtain the following 
expression for the sample size formula:
(^l-a/2 + )
arcsin ^ Jp r/^p r  + l - r ) ^  -  arcsin (
(5.2)
5.4 Sample size formula based on the signed root likelihood ratio
A limitation of all sample sizes based on the binomial log likelihood is that they are 
not readily extended to handle age effects, since the likelihood is then multinomial. 
Furthermore, the most convenient test to use to decide whether the exposure is 
associated with the outcome is the likelihood ratio test. Thus it makes sense to base 
the sample size on the likelihood ratio statistic (4.2) given in chapter 4. Under the null 
hypothesis, the likelihood ratio statistic has the j 2 (l) distribution, asymptotically. To
obtain an asymptotically normal test statistic, we use the signed root likelihood ratio 
derived as follows.
The log likelihood kernel for the parameter p  given in (4.1) of chapter 4 can be 
written as,
£(P) = x p ~ n e log(epr + l - r ) .  The score function is
. . yi ePr / a. \ «
—  = U (p) = x — t-*------- , and solvingt/(^) = Owe have/? = log
dp epr +1 -  r v '
Hence the likelihood ratio statistic for the null hypothesis H0'.p = 0 is 
Z) =2 jf  (0)J = 2 1x p - ne lo%[ePr +1 - r )J
 ^ x  1 - r ^
y ne- x  r
n o
D = 2 j x log (x) + (ne -  x) log (ne - x )  + x log ~ ne log(ne(1 -  r))
Under HQiD ~ so sgn(/?)Vl) ~ A(0,1) where
sgn(>§) =
+1 if/? > 0 
0 if/?=0
-1 if/?<0
Assume that under Hx,fi >0, and that asymptotically sgn(j3)yJ15 ~ W(£,r2) for some 
£,t to be determined later.
Write
f ( x )  = sgn (j?)>fD =  sgn(y§)7 2 P(x)
P(x) = x log (x) + (ne -  x) log (ne -  x) + x l o g --------- ne log (ne (1 -  r))
Recall that E(X)  may be written
H = E(X) = n p
where p  = pr
rp + l - r
and p - e-nP
Then, using the delta rule (Matthews[60]), to first order
f ( X )  = f(M) + ( X - n ) f \ n  )
hence
(5.3)
£ ( / W )  = / ( / / ) .
Now
P(//) = nep  lo g(p) -  ne lo g(pr +1 -  r)
and asymptotically, under Hv sgn(^) = sgn(/?). So
I l l
Also, from (5.3),
[ f { x ) - f ( n ) X { x - X  f ( X
hence
var[ / ( x )] = var( ^ ) / 'C “ )2 = riepqf'{+j2.
N o w / V ) >= I W = M / ^ ,
2 P(ji) 2P(ji)
hence v a r[ /W ] = ^ ^ ^  = -^  P jM X i--------
2P(m) 2 [/> log(p) -  \og( pr  +1 -  ?■)]
Thus the test statistic sgn(/?-/D) is distributed approximately N ^ , t2  ^ under/ /,, 
with
f  = sgn(fi)^2ne[/riogO)-Iog(/u- + ] -/•)], r 2 = . — -----
2 [/> log(/9) -  log(pr +1 -  r)J
Let /I = i f / j l o g ^ - l o g ^ r  + l - r ) ] ^  = S A — and as before p  = — ——
ri yOr + l - r
Also let Cbe the critical point of s g n , and for simplicity assume /? > 0.
It follows that 1 -  y  = P (sgn(/?)VZ> > C |f/0) = P(Z > C) as the statistic is
approximately A(0,1) under H0 .So C - Z  a . Also, for power > 1 -  y, the critical
1 2
point C must satisfy 1 -y<P(sgn(j3)yfl) > C\Hx j = P ^Z > ——— .
  p  r—
S o  — < -Z  . It follows that C = - Z  \[b  + JneA.
T
Equating the two values of C and solving for«e gives the following sample size 
formula based on the signed root likelihood ratio:
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n
(z,_a;2+z ry g ) 2
(5.4)' e A
If we include the proportion of the population vaccinated v , the above formula can be 
generalised to the formula shown below:
Note that n and ne from expressions (5.4) and (5.5) are in the ratio determined by (4.3) 
from chapter 4. We can see from (4.3) that ifv = 1, that is everyone is vaccinated, 
then n = ne.
5.5 Comparative evaluation of sample size formulae (5.1), (5.2), and (5.4)
In this section, we evaluate the performance of the sample size formulae (5.1), (5.2) 
and (5.4). We tested the performance of the sample size formulae using simulations in 
exactly the same way as described in section 4.4.1 of chapter 4. In all simulations we 
assumed all individuals were exposed, hence v = 1.
5.5.1 Results from the simulation study.
The results for 80% power are shown in Table 5.1, and those for 90% power are 
shown in Table 5.2. As in chapter 4, the numbers of cases calculated from sample size 
formulae (5.1), (5.2), (5.4) for a particular relative incidence to be detected are given 
in columns labelled N1,N2, and N 4 . The corresponding observed powers (in %) from 
simulations are given in columns labelled PI, P2, and PA . We can see a marked 
improvement in terms of the observed power for each sample size formula derived
n = (5.5)
v(rp + \ — r) A
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here. Almost all parameter values gave accurate power (one exception is the 
combination of r -  0.01 and RI = 0.1). This shows that the sample size formula based 
on the binomial with continuity correction, or that using the arcsine variance 
stabilizing transformation, or that based on the signed root likelihood ratio statistic 
would give an accurate sample size. Note that the saw-toothed phenomenon 
mentioned in chapter 4 is still present for sample size formulae (5.1), (5.2) and (5.4). 
In the next section, we extend the sample size formula based on the signed root 
likelihood ratio statistic so as to take account of age.
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Table 5.1 Empirical power for 80 per cent nominal value
r RI Nl N2 NA PI P2 PA
% % %
0.01 0.10 609 420 462 88* 67 92*
0.50 2618 2299 2394 81 80 81
1.20 21031 21801 21537 80 80 80
1.50 3638 3944 3835 80 80 79
2.00 1015 1167 1111 78 81 80
3.00 302 377 348 78 79 80
5.00 98 135 119 80* 77* 82
8.00 42 63 54 82* 80* 81
10.0 29 46 38 79 80 79
0.05 0.10 119 84 92 82 78 79
0.50 529 469 487 84 80 82
1.20 4431 4580 4529 79 81 80
1.50 779 838 817 79 81 79
2.00 223 253 242 81* 80* 79
3.00 69 85 79 80 84 80
5.00 24 32 29 80 82 80
8.00 12 17 14 75 80* 81*
10.0 9 13 11 78 79 78
0.1 0.10 58 42 46 85 82 83
0.50 269 241 250 81* 82* 84
1.20 2371 2441 2417 79 80 80
1.50 425 453 443 76 80 79
2.00 125 140 134 75 81 80
3.00 41 49 46 80 81 80
5.00 16 20 18 78 79* 84*
8.00 8 11 10 81* 81 78*
10.0 7 9 8 79 79 80
0.5 0.10 10 9 9 81 80 80
0.50 69 68 69 81 79 81
1.20 948 947 948 80 80 80
1.50 194 194 194 80 80 80
2.00 69 68 69 81 76 81
3.00 30 29 29 77* 81* 81
5.00 16 15 15 76 79 79
8.00 11 10 10 80 80 80
10.0 10 9 9 78* 81 81*
r -  ratio o f the risk period to the observation period, v = 1, the proportion vaccinated, 
RI = relative incidence to be detected, Nl = sample size using formula (5.1),
N2= sample size using formula (5.2), N  A = sample size usingformula (5.4),
PI = observed power for N l, P 2 -  observed power for N 2 , PA = observed power 
forNA. * Saw-tooth phenomenon.
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Table 5.2 Empirical power for 90 per cent nominal value
r RI Nl N2 NA PI P2 PA
% % %
0.01 0.10 688 562 571 95 90* 89*
0.50 1001 861 882 91 91* 90*
1.20 28641 29185 28993 90 90 90
1.50 5062 5279 5197 90 91 90
2.00 1453 1562 1517 88 89 90
3.00 450 505 480 86 89* 90*
5.00 152 180 166 87 91 91
8.00 68 85 76 91* 90* 90
10.0 48 61 54 88 90 89
0.05 0.10 135 113 114 92 87 87
0.50 669 628 639 92 90* 89*
1.20 6026 6131 6094 90 90 90
1.50 1079 1122 1106 88 90* 91*
2.00 316 338 329 89* 90 89*
3.00 101 113 108 84 91 91
5.00 36 43 40 86 91 90
8.00 18 22 20 90 93 90
10.0 13 17 15 86 89* 93*
0.1 0.10 66 56 57 94 87 89
0.50 341 323 328 92 90 92
1.20 3217 3268 3250 90 90 90
1.50 585 606 599 89 90 90
2.00 176 187 182 89 89* 90*
3.00 59 65 62 85 91 89
5.00 23 26 25 93* 89* 91
8.00 12 14 13 91* 94 90*
10.0 9 11 10 93* 91* 89
0.5 0.10 12 12 11 92 92* 93*
0.50 91 91 91 91 91 91
1.20 1268 1268 1268 89 90 90
1.50 259 260 259 90 90 90
2.00 91 91 91 90 90 90
3.00 38 39 38 92 91* 92*
5.00 20 20 20 89 89 89
8.00 14 14 13 91 91 90
10.0 12 12 11 92 92 92
r = ratio o f the risk period to the observation period, v = 1, the proportion vaccinated, 
RI = relative incidence to be detected, N l -  sample size using formula (5.1),
N2 = sample size using formula (5.2), N  A = sample size using formula (5.4),
PI = observed power for N l , P2 = observed power for N  2, PA = observed power 
forNA. * Saw-toothed phenomenon.
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5.6 Sample size formula with age effect
All the sample size formulae derived so far apply to a simplified situation in which 
there are no age effects. In practice, strong age effects may be present. Such age 
effects can have a big effect on study power, and must be taken into account in sample 
size calculations. We have seen so far that sample size formulae (5.1), (5.2), and (5.4) 
give accurate sample sizes in the simplified scenario. Expression (5.1) and (5.2) are 
based on binomial proportions, and thus cannot readily be extended to allow for age 
effects, since the likelihood then becomes product multinomial. However, sample size 
formula (5.4) based on the likelihood ratio test can be extended to allow for age 
effects.
In line with the parametric case series models described in chapter 2, in which age 
effects are modelled using a step function, we shall assume that the age-specific 
incidence is piecewise constant. In practical applications, we have found this approach 
for specifying the age effects both convenient and flexible.
5.6.1 Assumptions and notation
We again consider a simplified scenario, but involving age effects. We assume that all 
individuals are followed over the same observation period, which covers J  age groups 
of duration , j  = 0,1,2,..., J  -1 . Suppose that the probability that an individual is
exposed in age group j  is p.. The probability that an individual, randomly selected
j - i
from the population, is exposed during the observation period is v = ^ pj. We
j =o
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suppose furthermore that if an individual is exposed in age group j , the post-exposure 
risk period, of length e*, is entirely contained within age group j. This assumption 
greatly simplifies the calculations, by avoiding any overlaps. It implies thate < e. for 
all age groups j  = 0,1,..., J  - 1. This should not be too restrictive in practice, at least 
when the risk period is short.
Finally, letc^. denote the logarithm of the age-specific relative incidence, relative to
age group 0, so that a0 = 0. We assume that these age effects are known. As before,
let p  = denotes the relative incidence associated with the exposure, and p  its 
logarithm.
5.6.2 Sample size formula allowing for age effects
The full derivation is given in Appendix 2. The sample size formula involves the 
following intermediate quantities. First, let r . denote the weighted ratio of time at risk 
to the overall risk period:
CCj *
5 = 0
Note that if there are no age effects (a. = 0 for all j )  then r] = r,the ratio of the risk 
period to the observation period defined in chapter 4 and section 5.2 of this chapter. 
Second, let/z■ . denote the probability of an individual exposed in age group j  that an
event arising in age group j  occurs during the exposure period:
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Jjp  
r.p +1 - r .
7ij = -----J-  , j  = 0,1,...,J-1.
If there are no age effects, then tTj -  n ,  the binomial probability defined in chapter 4. 
Finally let v. denote the probability that a case is exposed in age group j :
Vj=  -------  > J = 0,1,...,J - l .  (5.6)
/ ,o+ Z a (v + 1- ' ; )
5 = 0
Note that if there is no association between exposure and outcome, so that p  = 1, then 
Vj = pj, the population proportion exposed. If there is an association, however, the
age distribution of exposure in the cases will usually differ from that of the general 
population. If there is no age effect, then vy. = ne / n from expression (4.3) of chapter 4.
Now define the following constants A and B :
a =2Tjv, \”,P -  los {r*ef>+1 -  n)}
5 = 0
(5.7)
A  s=0
Note that when there are no age effects and all individuals are exposed (so v = 1), then 
A reduces to the expression A and B reduces to the expressionB given in section 5.4. 
The total number of events required for 100/% power at the 100a%  significance 
level is
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If there are no age effects, (5.8) reduces to expression (5.4).
5.6.3 Sample size formulae for the number of cases
So far we have presented formulae for «, the number of events. To obtain a sample 
size formula for the number of cases, an estimate of the cumulative incidence over the 
observation period is required. Let A denote this cumulative incidence. Then under the 
Poisson model, the number of cases required (that is, the number of individuals with 
one or more events), n is
n = n
Thus nc <n. Generally, A is not known with any accuracy. In practice, most 
applications of the case series method are to situations where A is very small, in which 
case nc -  n. Furthermore, the independence of repeat events may be open to doubt.
For these reasons, we would generally advise taking nc = n.
5.7 Evaluation of sample size formula with age effects
5.7.1 Simulation study
We evaluated the sample size expression (5.8) as follows. As before, we assumed an 
observation period of 500 time units, but now partitioned into J  = 5 age intervals of
100 units. We fixed the age-specific proportions p} of the population exposed, and
assumed that all individuals in the population are exposed, but varied the age effect: 
increasing, symmetric and decreasing. The parameter values we used are shown in 
Table 5.3 below.
The risk period durations*must be less than the shortest age group, and were set at 5, 
10, and 50 units. For comparability with Tables 5.1 and 5.2, these are reported as 
proportions of the overall observation period and are denoted r . Thus 
r = 0.01,0.05 and 0.1. The values for p  were the same as in the previous simulations, 
but here we only present results from the values of p  = 0.5,1.5,2,3,5,10. We evaluated 
the sample size for powers of 80 and 90 per cent, at 5 per cent significance level. In 
this situation, the combination of three values of r , six values of p , two powers, and 
three age effects required 108 different simulations; each involved 5000 runs.
Table 5.3 Exposure and age effects used in the simulations.
Parameter Age group j
0 1 2 3 4
Proportion exposed, pj 0.35 0.30 0.20 0.10 0.05
Age effect, eaj
Increasing 1 2 3 4 5
Symmetric 1 2 3 2 1
Decreasing 1 1/2 1/3 1/4 1/5
The sample sizes were calculated using expression (5.8) and were rounded up to the 
next integer. For each simulation, we randomly and independently allocated the 
exposure to an age group and the event to an age and exposure group combination. 
Since the simulations are conditional on an event occurring, we used the age-specific 
exposure probabilities defined by expression (5.6) to perform this allocation. We then
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fitted the case series model with five age groups (and thus four age parameters), and 
carried out the likelihood ratio test of the null hypothesis p  = 1. The Monte Carlo 
standard error for the empirical power is about 0.57 per cent at 80 per cent power and
0.42 per cent at 90 per cent power.
5.7.2 Results
The sample sizes and empirical powers are shown in Tables 5.4 and 5.5 for 80% and 
90% power respectively. Note that, since v = 1, n -  ne. The empirical powers
generally correspond closely to the nominal values, across the range of parameter 
values and age settings. There is one exception, namely the rather low (72-73 per 
cent) power obtained for r = 0.01 when p  = 10. This occurred only for nominal power 
of 80 per cent, but not for 90 per cent power, with age effects, but not when there are 
no age effects. We have no definitive explanation for this observation, but we suspect 
it might be due to confounding with age when the expected number of events in the 
risk period is very small, or to the distribution of the data. In practice, it is most 
unlikely that a design value of p  as high as 10 would be used.
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Table 5.4 Sample sizes and empirical powers for 80% nominal power
Age effect
Increasing Symmetric Decreasing
r P n e Power n e Power n e Power
0.01 0.5 3267 81.2 2398 81.5 1825 81.2
1.5 5219 80.8 3842 79.1 2936 77.6
2 1509 78.2 1113 80.8 852 78.0
3 471 79.4 348 79.0 268 79.9
5 161 79.9 119 79.5 92 78.7
10 51 72.2 38 73.1 30 72.5
0.05 0.5 667 80.2 491 81.5 379 80.6
1.5 1103 80.0 825 80.0 649 79.2
2 324 78.9 244 78.9 193 78.8
3 104 81.1 80 78.6 64 78.5
5 38 77.3 29 77.2 24 78.2
10 13 79.5 11 79.5 10 81.1
0.1 0.5 343 78.9 254 79.4 200 78.6
1.5 592 78.9 452 78.2 370 79.6
2 177 80.3 137 79.8 114 80.2
3 59 80.8 47 79.1 40 80.4
5 23 78.8 19 79.4 16 78.8
10 9 77.7 8 79.0 7 77.1
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5.5 Sample sizes and empirical powers for 90 per cent nominal power.
Age effect
Increasing Symmetric Decreasing
r P
n e Power n e Power n e Power
0.01 0.5 4276 90.6 3139 89.0 2390 91.3
1.5 7073 89.7 5207 89.3 3978 89.5
2 2062 91.1 1520 88.8 1163 90.2
3 651 89.6 481 89.5 369 89.7
5 224 89.9 167 91.1 128 90.7
10 72 89.9 54 89.6 42 88.7
0.05 0.5 874 89.7 644 90.4 497 90.4
1.5 1493 90.3 1116 89.5 877 89.2
2 442 90.2 332 88.9 263 89.5
3 143 91.2 109 89.9 87 87.4
5 52 88.2 40 91.7 33 88.0
10 19 88.9 15 90.7 13 89.5
0.1 0.5 450 89.7 334 89.9 263 90.2
1.5 800 89.3 611 89.9 498 89.2
2 241 89.4 186 90.6 154 89.5
3 81 90.8 64 90.5 54 90.2
5 31 90.5 25 90.1 22 89.7
10 12 87.3 11 90.7 10 89.1
5.8 Conclusion
Sample size formulae for the self-controlled case series method have been discussed 
in chapter 4 as well as in chapter 5. In chapter 4, we saw that the sample size formula 
published by Farrington et al [3] was not accurate, neither were the sample size
formulae based on the distribution of ft with both first and second order 
approximations, or the sample size formula based on the binomial proportion without 
continuity correction or variance stabilizing transformation. In this chapter, we have 
shown that sample size formula based on the binomial with continuity correction and 
that with arcsine variance stabilizing transformation are accurate. Equally accurate is 
the sample size formula based on the signed root likelihood ratio statistic which can
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be generalized to take account of age effects. We have seen that the type of age effects 
has a big impact on the sample size required, as shown in Table 5.5. For example (See 
also Musonda et al [44]), suppose the observation period includes the ages 366-730 
days, divided into 4 age groups J  = 3 with periods of lengths e0=el =e2= 91 days,
and e3 = 92 days. Suppose we took the proportions vaccinated in each of the age
intervals to be p Q = 0.6, px = 0.2,p 2 = 0.05,p3 = 0.05. Further take the age effects to
be ea° = l,eai = 0.6, e*2 = eai = 0.4, and the risk period e = 42 days, and
setp  = 3,Zx_ajl =1.96 and Zy = 0.8416 for 80 per cent power to detect a relative
incidence of 3 at the 5 per cent significance level. With these values, we findnc =37,
but if we ignored the age effect, we would obtain nc = 45. Thus it is important to
allow for such age effects in calculating the sample size. In conclusion, we 
recommend the sample size formula based on the signed root likelihood ratio, as 
shown in expressions (5.4) and (5.8).
Our empirical power calculations were based on the likelihood ratio test. In practice, 
statistical significance is sometimes assessed by calculating the 95 per cent confidence 
interval for the relative incidence, and observing whether this confidence interval 
includes l.We also evaluated our recommended sample size formula using this second 
criterion. The empirical powers were generally close to the nominal values, except for 
large relative risks and or very short risk periods when such confidence intervals can 
be markedly non-central as shown in chapter 3.
In calculating the sample size allowing for age effects, we assumed that the age 
effects were known, so as to obtain a one-parameter likelihood. In practice, the age
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effects must be estimated. We had expected this to have some bearing on the results, 
in that some information in the sample is used to estimate the age effects. In the event, 
this effect is small.
A limitation for sample size formula (5.8) is the requirement that the risk period is 
shorter than the age groups involved. Another is that we have assumed that there is a 
single risk period. In practice, it is common to use several, usually rather short, risk 
periods. However, it is often possible to select a single, short risk period of special 
importance, on which to base the sample size calculations. If long risk periods are 
required in situations where age effects must be allowed for, our proposed sample size 
formula may not apply without further modification.
We recommend the sample size formula based on the signed root likelihood ratio 
statistic for use both when there is no age effect and where there is an age effect. In 
particular, the sample size formulae in this chapter help to emphasize the importance 
of taking age into account at the design stage.
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Chapter 6
Application of the self-controlled case series method in surveillance
6.1 Introduction
In this chapter we aim to describe how we can use the self-controlled case series 
method in prospective surveillance. In section 6.2, we briefly describe the use of 
surveillance systems to monitor vaccine safety and relate this to the self-controlled 
case series method. We also identify the possible problems of using the self-controlled 
case series method for prospective surveillance. The background and review of 
various statistical methods used for surveillance are given in section 6.3. Section 6.4 
describes the sequential probability ratio test (SPRT) and the theory behind the SPRT 
is given in section 6.5. Description of the application of the SPRT is given in section 
6.6. Section 6.7 explores using the self-controlled case series adjusting for age. In 
section 6.8, we show results from a simulation study demonstrating possible 
parameter values for a surveillance system, and conclusions are drawn in section 6.9.
6.2 Surveillance systems for adverse events
Two examples of surveillance systems for vaccine-associated adverse events are: the 
Yellow Card system in the UK and the Vaccine Adverse Event Reporting System 
(VAERS) in the US [61]. The Yellow Card Scheme was introduced in 1964 to 
provide a straightforward route for a doctor or dentist and later any member of the
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public to report a suspicion that a medicine could have harmed a patient. The Yellow 
Card Scheme fhttn ://www.vellowcard. gov.uk) is run by the Medicines and Healthcare 
products Regulatory Agency (MHRA).
The Vaccine Adverse Event Reporting System (http://vaers.hhs. gov) is a cooperative 
program for vaccine safety of the Centres for Disease Control and Prevention (CDC) 
and the Food and Drug Administration (FDA) in the US. Like the Yellow Card 
system in the UK, VAERS collects information about adverse events that occur after 
the administration of US licensed vaccines. A similar scheme on the international 
level is conducted by the World Health Organisation (WHO) at the Uppsala 
Monitoring Centre [62].
The data collected in these systems are not independent of the exposure since only 
events occurring after exposure to the drug are collected. Data are usually collected 
from a mixture of populations, and there is no denominator data. There may be no 
confirmation of the reported adverse events. Such data sets may suffer from 
underreporting and differential reporting [63, 64]. There is no control group for 
comparison of adverse event rates [65, 66]. Over reporting may also occur because 
some reported conditions might not meet standard diagnostic criteria [64]. There is 
also lack of information on background incidence of adverse events in the general 
population and information concerning the total number of doses of vaccines or 
vaccine combinations actually administered. For these reasons surveillance systems 
such as VAERS and Yellow Card Scheme cannot be readily used to determine 
whether associations between vaccines and reported adverse events are causal.
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Surveillance system such as VAERS and Yellow Card Scheme are nevertheless useful 
for generating hypotheses to be tested in other settings such as the Vaccine Safety 
Datalink (VSD), or through specially designed epidemiological studies [33, 67].
In this chapter and the next we discuss how the self-controlled case series method can 
be applied to the surveillance of adverse events following vaccination. The aim is to 
obtain better evidence of causality than available from systems such as the Yellow 
Card or VAERS, while remaining in a prospective setting.
There are possibly two ways in which the self-controlled case series method can be 
applied for surveillance. These are:
1. Prospective surveillance of a new vaccine.
2. Long term surveillance to identify changes in the performance of one or 
several existing vaccines.
In the first situation, there is a specific hypothesis to be tested, for example relating to 
intussusception following the introduction of a new rotavirus vaccine [68, 69]. In the 
second situation, one might be interested in monitoring a range of possible exposures, 
not a single one, to check that none of the vaccines in current use are associated with 
some adverse outcome. In this situation, monitoring may concern several outcomes 
with no specific hypotheses. For the second scenario, one needs to protect against 
false positive alarms more than for the first scenario.
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Both the above scenarios can use data that are centrally collected in one or several 
databases, for example the Hospital Episode Statistics (HES) data, UK General 
Practice Research Database (GPRD), immunisation data which is independent from 
clinical records such as the Vaccine Safety Datalink (VSD) database, data from 
Patient Administration System (PAS), and Coded Clinical Records (CCR). Data 
collected routinely as in these databases are the best to use because ascertainment is 
likely to be independent from the exposure. The main difficulty is how to use the self­
controlled case series method, which is a retrospective design, in a prospective 
surveillance context.
6.3 Background and review of some surveillance methods
Statistical methods can play an important role in detecting changes in many processes, 
including mortality and adverse event rates. Some surveillance methods have an 
established history of use with health care, while there is growing interest in others 
such as statistical process control (SPC) methods. The retrospective use of SPC by 
Spiegelhalter et al [70] provides an excellent example of the potential role that risk- 
adjusted control charts could have played in earlier detection of higher mortality rates 
in the Bristol Royal Infirmary and in the general practice of Harold Shipman.
Statistical control charts were first developed in the 1920s by Walter Shewhart at Bell 
Laboratories [71] and have been widely used by Deming [72]. Shewhart and Deming 
independently recognised the value of these methods for detecting statistical changes 
in many applications, though they were initially intended for use in industrial and 
chemical processes. As early as 1942, Deming [73] recognised their potential value
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for disease surveillance and rare events. Important health care concerns in which 
control charts have been shown to be effective include surgical site infections, adverse 
drug events, needle stick injuries, and ventilator-associated pneumonia [74].
Some studies have attributed the growing use of SPC in the medical context to the 
staggering incidence and cost of medical mistakes [75], care induced injury, and 
hospital acquired infections. For example it is reported [75] that in the US alone, 
between 770 000 to 2 million patients are injured per year, 44 000 to 180 000 deaths, 
and the cost of all these accidents/incidents is estimated to be about $8.8 billion 
annually [76-78].
Surveillance systems such as the Yellow Card and VAERS all make use of suitable 
statistical methods to identify possible signals. For example measures of 
disproportionality including Proportional Reporting Ratio (PRR), Reporting Odds 
Ratio (ROR), and Yule’s Q, along with more complex Bayesian methods are 
currently applied in various national spontaneous reporting centres [79-82].
Another approach for continuous systematic review of all combinations of drugs and 
suspected adverse reactions (ADRs) reported to a spontaneous reporting system to 
optimize signal detection makes use of Bayesian methods. This works by relating the 
prior and posterior probabilities before and after linking databases. It is currently 
being used by the Uppsala Monitoring Centre (Bayesian Confidence Propagation 
Neural Network analysis BCPNN) [83-85].
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Cumulative monitoring approaches based on control charts of different kinds are 
widely used. For example it is well known [75] that the simplest types of statistical 
control charts, called Shewhart charts, perform fairly well for detecting moderate-to- 
large rate changes in the parameter of interest. In some industrial applications, more 
advanced tools such as sequential probability ratio test (SPRT), cumulative sum 
(CUSUM) charts are used to detect smaller changes, to monitor low rates, or in 
situations where sufficiently large sample sizes are not available. Examples of health 
care CUSUM applications include surveillance of seasonal influenza [86, 87], 
community Salmonella [88], and fever curves in neutropenic patients. Various new 
SPC methods have been developed for non-standard applications dealing with rare 
events, infectious diseases and other event that naturally occur in clusters, 
overdispersion, naturally cyclic behaviour, and risk adjustment [70]. Related SPC 
methods have also been developed to handle non-homogenous event in 
manufacturing, such as for different production lines.
Another motivation for cumulative monitoring approaches is to accommodate rare 
events that otherwise would require large samples to yield adequate statistical 
sensitivity. SPRTs and CUSUMs are excellent for this purpose, and several other SPC 
methods also have been developed for rare events. Many of these are based on some 
variation of the idea of monitoring the number of cases or time between adverse 
events rather than the more traditional approach of monitoring the number of events 
or deaths within a fixed time period or accumulating sample size [89, 90].
The SPRTs and CUSUMs are the most adaptable cumulative monitoring methods to 
use with the self-controlled case series method. This is because they are based on the
132
likelihood ratio. We adapt them by using the likelihood of the self-controlled case 
series method. In this chapter, we shall concentrate on the SPRTs and in chapter 
seven, we will describe how to use the CUSUMs.
Charts derived from the sequential probability ratio test have been widely used in 
industry to monitor process performance. The SPRT is used both when the monitoring 
is continuous and items can be inspected one by one, and when items are inspected in 
a group after a fixed time interval. Studies have shown that charts based on the SPRT 
will signal an out-of-control process earlier than either the Shewhart p-chart or the 
CUSUM chart [91]. Recently there has been increased attention paid to the use of the 
CUSUM and SPRT charts in a medical context [74, 88, 92]. The SPRT is the most 
powerful method for discriminating between two hypotheses [70, 93], and was 
recommended well over 40 years ago in a medical context for clinical trial and 
clinical experiments [94, 95]. In the next section, we describe charts derived from the 
SPRT by first looking at the theory behind SPRT.
6.4 The sequential probability ratio test (SPRT)
Formal statistical methods for sequential analysis were developed in 1943 
independently by Barnard in the UK and Wald in the US [93, 96]. Suppose we are in a 
situation where we have two hypotheses, the null hypothesis H0 and the alternative
hypothesis/^. Interest is on deciding whether to accept the null hypothesis or reject 
the null hypothesis (hence accepting the alternative). The idea behind sequential 
testing is that we collect observations one at a time; when observation X. = xt has 
been made, we choose between the following options:
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• Accept the null hypothesis # 0 and stop observation.
• Accept the alternative hypothesis H1 and stop observation.
• Defer decision until we have collected another piece of information X i+V
The challenge of course is to find out when to choose the above options. To do that, 
one has to control for two types of error:
a  = P{ Accepting #jWhen # 0 is true} (Type I  error), and 
P = P {Accepting # 0 when Hx is true} (Type II  error).
Note that it is common in this context to treat Hl and # 0 symmetrically. More 
formally, suppose we consider a simple hypothesis HO:0 = 0O against a simple 
alternative#! \ 0 - 0 x. The standard likelihood ratio test has critical region of the form
for some constant K  and X x,...,Xn aren independent observations on the random 
variable X . The expression L(0l;Xl,...,Xn) represents the likelihood when Hx is true 
and the expression L(0o;Xx,...,Xn) represents the likelihood when # 0is true. Note 
that assuming independence the log likelihood ratio Zn is the cumulative sum
Zn = log W ; x , ) + ... + log
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Now consider X l9X 2,...being successive observations obtained sequentially. Wald’s 
[45] sequential probability ratio test has the following form:
• If Zn > log(v4), decide that Hx is true and stop;
• If Zn < log (5 ), decide that H0 is true and stop;
.  Iflo g (5 )< Z „<  log (A) , collect another observation to obtain Zn+l, 
where A and B are two constants such that log (B) < log (A ) . The constants A and 
B are to be determined so that the test will have the prescribed strength (a, p ) .
It can be shown that the SPRT is optimal [45, 75, 91, 92] in the sense that it 
minimizes the average sample size before a decision is made among all sequential test 
which do not have larger error probabilities than the SPRT. An essential feature of the 
sequential test is that the number of observations required by the sequential test 
depends on the outcome of the observations and is, therefore, not predetermined, but a 
random variable [45]. This is because at any stage, the decision to terminate the 
process depends on the observations made so far.
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6.5 Theoretical properties of the SPRT
6.5.1 The relations between the quantities in an SPRT
Following Wald’s [45] derivation, suppose we let / ( X , 6) denote the density of the 
random variable X  under consideration for some parameter 0. As before let H0 be 
the hypothesis that 0 -G 0, and Hx the hypothesis that 6 = 6X. We can thus denote 
/ ( X ,60) as the distribution of X  given that H0is true and by / ( X ,6X) is distribution 
when Hx is true. Successive observations on X  shall be denoted by X 1,X 2,...,.
Further suppose for any integer valuem , the probability that a sample X l,X 2,...,Xmis 
obtained is given by
when is true,
and by
Pom=f(.x iA 0) - A x mAo) when H0istrue.
Suppose we say that the sample (X1,X 2,...,Xn) is of type Oif
<A for m = 1,...,«-1 and <B .
Pon
Similarly, we shall say a sample (X,,..., X n) is of type 1 if
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<A form = 1,...,«-1 and ^ - > A .
PonPom f ( X v 0o)...f(Xm,0o)
Hence it follows from that a sample of type 0 leads to the acceptance of H0 and a 
sample of the type 1 leads to the acceptance of Hx. For any given sample 
{XX9...9X n) of type 1, the probability of obtaining such a sample is therefore at least A 
times as large under hypothesis Hx as under H0. As shown by Wald [45], the 
probability measure of the totality of all samples of type lis the same as the 
probability that the sequential process will terminate with acceptance of Hx. But the
latter probability is equal to a  when H0 is true and to 1 -  ft when Hx is true. This is 
by definition of a  and ft and because the probability that the sequential process will 
eventually terminate is one. Hence,
Similarly, a lower limit for B can be derived as follows.
For any given sample (X1?..., X n) of typeO, the probability of obtaining such a 
sample under Hx is at most B times as large as the probability of obtaining such a 
sample when H0 is true. Thus, also the probability of accepting H0 is at most B times
1 - p > A a  .
The inequality above can be written as
(6.1)
a
and so — — is an upper limit for A. 
a
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as large when Hx is true as when H0 is true. Since the probability of accepting H0 is 
1 -  a  when H0 is true and ft when Hx is true, we obtain the inequality 
P < ( \ - a ) B  .
It follows that
B>-@—  (6.2)
l - a  v '
and thus ^  - is a lower limit for B . 
l - a
The inequalities (6. l) and (6.2) have been derived under the assumption that the 
successive observations Xj,X2,..., etc, are independent. It can be shown [45] that the 
validity of the inequalities (6.1) and (6.2) is not restricted to the case of independent 
observations. They are generally valid also for dependent observations.
6.5.2 Calculating the constants A and B
Suppose that we wish to design a test procedure of strength (a, f t ) . Then our problem 
is to determine the constants A and B such that the resulting test will have the desired 
strength (a, f t) .  Let us denote by ^(<2,/?)and B{a,ft)  the values of A and B ,
respectively, for which the test has the required strength (a ,0 ) .  The exact 
determination of the values A (a, ft) and B (a ,ft)  is usually very laborious [45]. 
However, the inequalities (6.1) and (6.2) permit an approximate determination of 
A and B which will suffice for most practical purposes. From(6.1) and (6.2), it 
follows that
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A ( a ,p )< -—— md B (a ,p )> -  . It can be shown [45] that for most practical
a  l - a
purposes, the constants A and B are approximately equal to: 
a A —A  and5=  ^
a  l - a
Using approximate values of A and B instead of exact values results in some error in 
the Type I  and Type// probabilities. Let us denote by a' and p  the resulting 
probabilities of errors of Type /  and Type II respectively for using approximate 
values of A and B. From (6.1) and (6.2) it follows that
a  a  _v < ------ , and (6.3)
1 - P  1 - p
P  <. P
l - a '  l - a
(6.4)
It follows from the above that
a' < a  and (6.5)
l - P  v 1
? * J L .  M
Multiplying (6.3)by ( l - p ) ( l - p )  and (6.4)by (l -  a)  ( l - a') and adding the two 
inequalities, we obtain
a! + p  <a + p. (6-7)
The inequalities (6.5), (6.6), and (6.7) give useful upper limits for a' and p .  Wald 
[45] argued that since in practical applications, the values a  and p  will usually be
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a  Bsmall, probably in the range 0.01 to 0.05, thus and ■ will be very nearly
1 - p  l - a
equal a  and P , respectively. Inequalities (6.5) and (6.6) indicates that the amount 
by which a'm ay exceeds, or p ’ may exceed p is small and can be neglected for 
practical purposes. In fact, inequality (6.7) implies that at least one of the inequalities 
a! < a  and P' < P must hold. In other words, by using the approximate values of 
A (a ,p )  and B (a ,p )  instead of exact values of A (a, P) and B( a, /?), respectively, at 
most one of the probabilities a  and p  may be increased.
Wald [45] concluded that the use of approximate values of A (a ,p )  and B ( a ,p ) , 
instead of exact values of A (a ,p )  and B (a f0 )  respectively, cannot result in large 
increase in the value of either a  or p. This means, for all practical purposes the test
corresponding to A = -—— and B = ^  provides at least the same protection
a  l - a
against wrong decisions as the test corresponding to the use of the exact values of 
A and B .
The other possible consequence of using approximate values of A (a ,p )  and 
B (a ,p )  instead of exact values is that this may result in an appreciable decrease of 
either or both error probabilities. If this were so, it would mean only that the test
based on the approximate values A = -—— and B = ^  would provide a better
a l - a
protection against wrong decisions than the test based on the exact values. The only 
possible disadvantage is an appreciable increase in the number of observations
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required by the test. But this has been theoretically investigated [45] and it has been 
shown that such an increase in the number of observation is only slight and of no
practical consequence. Thus the test based on the approximate values A = -—— and
a
B = ^  serves the purpose just as well, and the determination of exact values is of 
l - a
little practical importance.
The ideas developed above relate to a situation in which a decision has to be made 
with observations taken singly, that is, by item-by-item inspection. An interesting 
question is therefore whether the sequential test works when items are inspected in 
groups, for example when items are inspected at a particular fixed time interval. Some 
researchers [91, 97] argue that the threshold for grouped data should be adjusted to 
take account of the grouping. But Wald [45] showed that taking observations in 
groups and applying the SPRT should lead to the same conclusions as item-by-item 
inspection. Wald’s theoretical argument on using the SPRT with grouped data 
concluded that, for all practical purposes, grouping does not decrease the protection 
against wrong decisions provided by the test. Hence we shall use grouped data with 
A and B calculated as if the test was based on item-by-item inspection and be re­
assured by Wald’s findings, as used by Spiegelhalter et al [70], that we ought to make 
the same decisions as we would if we had singly collected data. Our strategy in any 
case will be to test performance by simulation.
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6.6 Application of the SPRT to the self-controlled case series method.
6.6.1 Surveillance scenario
In this section, we introduce a hypothetical surveillance system which is set up to 
monitor the performance of a new vaccine, for example the introduction of a new 
rotavirus vaccine (see chapter 8). We shall describe how the self-controlled case series 
method can be used with the SPRT. For definiteness, we shall take the adverse event 
of interest to be intussuscetption in children aged under 2 years [68, 69, 98].
Cases of intussusception in children aged less than two years are reported to a central 
database. At regular time intervals (say every 6 months, or every 12 months) the 
vaccination records of the cases notified in the previous 6 or 12 monthly period are 
ascertained using a mechanism that is independent of the occurrence of the event.
Such data might be obtained from databases such as hospital records, the GPRD or 
VSD [99].
The self-controlled case series method is then applied at the end of each successive 6 
or 12-month calendar time interval. We call this interval the monitoring interval. The 
observation period for each case with an event during that time period includes all 
time spent in the defined age groups (in our example, 0-2 years) within the monitoring 
interval. If the adverse event is a contra-indication for subsequent vaccination, the 
observation period is further constrained to begin with vaccination. The risk period (in 
our example, this might be 2 weeks post-vaccination) will have been defined prior to
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the start of surveillance. In what follows we assume for simplicity that there is a 
single risk period and that each child receives a single vaccine dose.
In the self-controlled case series method, fixed covariates are controlled for as was 
shown in chapter two. For simplicity we shall assume that there is no age effect.
We have two hypotheses: a null hypothesis H0 corresponding to no association, hence
the relative incidenceRI0 = 1, and//, corresponding to a relative incidence
(say,RIl =2) that is deemed important to detect. Note that,RI0, a , p  andRIXhave to
be defined in advance. The log-likelihood ratio is then calculated at the end of each 
fixed time interval.
From chapter two, the log-likelihood with no age effect is
r \
expO8k)e,k
£ e x p (£ )e (.s
V 5 J
where i denotes individuals, and the risk period indexed by k with
0 if unexposed and P0 = 0
1 if exposed
The symbols eik, nik respectively denote length of time at risk and number of events 
experienced by an individual / in risk period k.
Under f /0, P0 = 0. Let p x denote the value of P  under Hx. Thus
P0= 0 andPx = logOR/j). Now let eikt, nikt denote, respectively, the time at risk and
i  k
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number of events experienced by case i in risk period k during the rth monitoring 
interval. Also let L0t^ Llt denote the likelihoods under H0 and Hx, respectively, for time 
interval t.
It follows that:
i°g (L < ,,)= 2X ,log
i,k
and so
f  \ f  \
e ikt
. |o g (L„) =  X % , 1°g
i,k
exp (A )e « ,
S  e in
\ r = 0 ^
S eXP (A )e/s<
v s=o y
A, = log ^
i,k
i A
exp(A)—
S '
r=0
S exP (A K .
V s=o
= S  n iu
i,k
A - ]og S exP(A )-re»,
s=0
V v
S  e m
r=o y y
Hence
A, = logCR/,)-£w,., log(ffl,.„, (6.8)
e.where co kt = ---- ——  is the proportion of time spent by case i in exposure category k
e iot e i\t
during the rth monitoring interval.
In the simulations that follow we shall assume com = 1 -  r and cont = r . Then (6.8) 
above reduces to:
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At = n ltP1 - n t log{ l - r  + e '^r'j (6.9)
where n lt is the number of events during the monitoring interval (t) that occurred in 
the risk period, n t is the baseline incidence of the number of cases arising in the 
monitoring interval (t) and r is the ratio of the risk period to the observation period.
The SPRT chart involves plotting the pair (t,Zt)
monitoring interval t .
In the SPRT chart, sampling should continue if the quantity Zt lies between two 
thresholds log(^) and log(R). When Zt exceeds log (^4), stop and reject H0 in favour 
of Hl and vice versa when Zt is less than log (R) . Thus the boundaries take the form 
of horizontal lines.
6.6.2 Specifications in the SPRT chart
One of the most important specifications before carrying out such a surveillance 
exercise concerns values of a  and f t . The sizes of a  and p  should reflect the costs of 
making the two types of error. For example, if we wish to avoid falsely identifying an
(6.10)
at the rth monitoring interval, where Z0 = 0 and
P1 -  n t log (l -  r + ePlr ) is the sample weight assigned to
V^ o t J
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adequate vaccine as being positively associated with an adverse outcome then 
a  should be made very small, whereas if we consider it a serious mistake to miss a 
poor vaccine which is positively associated with an adverse outcome, then p  should 
be made small. Both errors are serious, so we adopt a convention of using 
equal a  and p . Spiegelhalter [70] advocates that instead of choosing a single value 
for a  and p , a set of horizontal lines can be drawn on the chart to indicate different 
degrees of urgency: for example, a monitoring study might use a  = p  = 0.1 as an 
‘alert’ threshold and a more stringent a -  p  = 0.01 for ‘alarm’. Table 6.1 below gives 
some possible thresholds for various values of a  and p .
Table 6.1 Thresholds for the SPRT for different values of a  and p
a P Lower threshold 
log(R)
Upper threshold 
log(^)
0.05 0.05 -2.94 2.94
0.01 0.01 -4.60 4.60
0.01 0.02 -3.90 4.58
0.02 0.01 -4.58 3.90
0.005 0.005 -5.29 5.29
0.001 0.001 -5.91 5.91
It is also possible to set up several SPRT surveillances in different countries or 
institutions (hospitals or GP practices). If that were to be the case, more stringent 
boundaries may be appropriate because of the many comparisons being made. For 
example if we had 10 centres on surveillance, of 10 centres performing normally, we 
would expect one to cross the ‘alert’ boundary by chance alone. Some authors [70] 
propose a Bonferroni-like adjustment, for example when monitoring n institutions,
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using values of a  = f3 = 0.1/n and a = J3 = 0.01 In for ‘alert’ and ‘alarm’ 
respectively.
The original idea of the SPRT as conceived by Wald [45] was designed to carry out a 
test of hypothesis H0 versus the alternative Hx and then decide either to terminate
because the threshold has been crossed or continue observing because the threshold 
has not been crossed. For long term surveillance we could modify the idea so as to 
restart the procedure when, say, we cross the lower boundary and so are confident 
there is no increase in the relative incidence of an adverse outcome. Modifying an 
SPRT in this way has the advantage that it is not possible to build up excessive 
‘credit’ and so gains sensitivity changes in performance [70], but also has the 
disadvantage that the strict interpretation of a  and ft is lost. Such a loss is not too 
serious if the surveillance system as described here is only an aid to monitoring which 
should eventually trigger remedial action such as investigating by conducting a proper 
retrospective study to confirm or reject the ‘signal’ detected. Another variant is to 
introduce a third, vertical, boundary which effectively places a time limit on the 
surveillance. The rationale for using a third vertical boundary relate to the context in 
which we envisage to use the SPRT, namely focussed surveillance of a new vaccine. 
In such a situation it is not appropriate to wait indefinitely for evidence of safety or 
lack of it. Thus it is appropriate to build in a maximum surveillance time, and design 
the system so as to have a high probability of not hitting this vertical boundary. In the 
simulation study whose results and procedure is reported in section 6.8, we used this 
approach.
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6.7 Adjusting for age in the SPRT
Both adverse events and vaccination are often highly age-dependent. Hence it is 
important to adjust for age. One way to control for age in the SCCS method could be 
to use profile likelihood where we profile out the age parameters as nuisance 
parameters [100].
(  I t  . . r  r  \ ~ \
Thus Zt becomes Zt -  log
(Llt xLlt_v ..Ln ) 
(4» x 1)
where L~ = profile likelihood for ft (the logarithm of the relative incidence) having 
profiled out the age parameter.
There are three possible ways in which the age parameter could be profiled out within 
the surveillance system described earlier, and these are as follows:
1) First obtain the age parameter a (ft) values for the first monitoring interval, 
or for a baseline period, and keep these fixed thereafter or,
2) Re-estimate the age parameter a (ft) separately within each monitoring 
interval or,
3) Re-estimate the age parameter a (ft) at each monitoring time interval using 
all previous data.
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We have left the investigation of these ideas about controlling for age for future 
research. In the next section we present results from simulations showing how the 
SPRT would work in a simplified scenario without controlling for age.
6.8 Simulation study: evaluating the performance of the case series SPRT
6.8.1 Description of the surveillance scenario
Let us assume that we have set up a surveillance system as described in section 6.6.1 
to monitor a new vaccine every six months. In the surveillance system, the numbers of 
cases of a particular adverse outcome are collected at a central reporting centre. Note 
here that the monitoring interval can be of any length depending on prior knowledge 
of a particular vaccine being monitored.
We decided on a surveillance period of 10 years. This 10-year period determines the 
third vertical boundary discussed above. It is used primarily for design purposes, as 
we require that there should be good power to detect a problem within this period. In 
practice the surveillance could continue beyond this boundary. The choice of 10 years 
is arbitrary and could be varied according to requirements. In what follows, ‘power’ 
refers more precisely to operational power, namely the probability of detecting a 
genuine problem before the vertical boundary is reached. We carried out simulations 
for various lengths of surveillance periods, but here we only present results from a ten 
year surveillance period.
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Recall that the SPRT chart involves plotting the pair (t, Zt)
Zt =Zt_j + A?, t = 1,2,3,... (6.10)
where Z0 = 0, and t counts the monitoring interval. For the results presented here, we
used a six months monitoring interval (for simplicity, all ‘months’ contain 4 weeks 
and all ‘years’ 48 weeks).
A, =log
(
—  = nAtPx -  n t log (l -  r + e^rj is the sample weight assigned to
vA) t J
monitoring interval t , where nAt is the number of events during the monitoring
interval that occurred in the risk period, n t is the number of events arising in the
monitoring interval and r is the ratio of the risk period to the observation period. The 
risk period was varied: we used 1, 2 and 4 weeks. A range of relative incidences to be 
detected were investigated but here we only present results from relative incidence of 
1.5,2, 3, 3.5, 4, and 5.
It is important to distinguish between two uses of the relative incidence in the 
simulation. We shall denote RI = ePx the design value, that is, the value used in the 
SPRT. In addition, we shall denote RI2 = ePl the actual value used to generate the 
data. The values of RL included 1, 1.5, 2, 3, 3.5, 4, and 5.
We used a random number generator using SAS program version 8.2 [101] to 
generate the total number of cases in each monitoring interval arising from a Poisson 
distribution:
n t ~ Poisson (A)
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where the underlying rate X was fixed at one of the following values:
A = 5,10,20,50.
The numbers of cases arising in the risk period were generated using the binomial 
distribution with the expression:
nAt ~ Binomial(n t,7r) 
ep2rwhere n  -  —B---------- is the probability of a case being in the risk period.
ePlr + \ - r
We simulated a ten year surveillance period with six month monitoring time interval. 
So, if the process did not give any signal, we expect a total of 20 inspections in which 
the value of the SPRT is calculated every six months. For each combination of 
parameters we repeated the procedure 2000 times. We call a set of 2000 simulations a 
run. In each run, we observed the ability of the surveillance system to detect a 
particular relative incidence by finding the proportions of occasions on which the 
upper, lower and vertical thresholds were crossed. To check the speed of response of 
the surveillance system, we calculated the average time at which a particular boundary 
was crossed for those simulations in which the boundary was crossed.
Figure 6.1 below gives an example of the output. The cumulative value of SPRT is 
plotted at each monitoring interval. We see three realisations of the process, one in 
which the observed number of cases arising in each six month monitoring interval 
leads to the acceptance of alternative hypothesis, that the relative incidence is 5; this
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happens in the second year. In such a situation, monitoring would have to be stopped 
and further investigations carried out.
;e,2]
10
ri=5, a lp h a = b e ta = 0 .0 1 ,  r=1 m o n th , p o is s o n  m e a n  = 5  [x, y ]= x (to ta l c a s e s )  y ( c a s e s  in risk  p e r io d )
Figure 6.1. Example of three realizations with relative incidence 5, ratio of the risk
period to the observation period r =—,A = 5,a = /? = 0.01
6
The lower path is an example of realisation in which the process leads to the 
acceptance of the null hypothesis which also happens in the second year. The middle 
path is a realisation which does not lead to any signal all the way up to the end of the 
surveillance period (ten years). The numbers in the square brackets in Figure 6.1 
represent the total number of events arising in the six month time interval and the 
number of events in the risk period. The nominal Type I  and Type II errors were both 
set at 0.01.
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6.8.2 Simulations based on the design values
Tables 6.2, 6.3, 6.4 below show results from the simulation with one week risk period, 
two weeks risk period, and one month risk period, for a range of relative incidences 
and different values of the baseline incidence X , the mean number of cases per 
monitoring interval. We note some patterns in the results. The patterns noted can be 
described with respect to the risk periods whether short (Table 6.2 r=l/24), middling 
(Table 6.3, r=l/12) or long (Table 6.4 r=l/6 ). They can also be described in terms of 
the relative incidence to be detected whether it is low (RI=1.5, 2), middling (RI=3, 
3.5), or large (RI=4, 5). The baseline incidence X for the number of cases arising in 
each monitoring interval is also likely to have an effect as one would expect, for 
example a pattern emerges with respect to few cases (arising from Poisson mean of 5, 
and 10) and another emerges with respect to more cases (arising from Poisson mean 
of 20 and 50). There is a pattern with respect to the proportions out o f2000 ten year 
surveillance periods that crossed either boundaries or those that did not cross any 
boundary. Below, we describe the patterns observed.
6.8.3 Power and Type I I  error probabilities for design values.
The simulations were done with p2= so that in each case the true relative
incidence was the relative incidence we wanted to detect (the design value). 
Throughout we set nominal Type /  and Type II error probabilities at 0.01. The results 
are summarised in Figures 6.2, 6.3, and 6.4.
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We measured the power by calculating the proportions of the 2000 ten year traces that 
gave a signal by crossing the upper boundary (in favour of the alternative hypothesis). 
We also calculated the proportions crossing the lower boundary (in favour of the null 
hypothesis). The proportions of traces crossing the upper and lower boundary are 
analogous to sensitivity and Type //error of the surveillance system.
Figure 6.2 shows that the power increased with the relative incidence, the baseline 
incidence of the number of cases arising in each six month monitoring interval and the 
risk period. For events arising with Poisson mean of 10 or more, the power is greater 
than 80% for relative incidences of 3 or more. For events arising with Poisson mean 
of 50 or more, the power is in excess of 95% for relative incidence of 2 or more. 
Figure 6.3 shows that the Type //error, that is, crossing the lower boundary in this 
case in favour of the null hypothesis given that the data arises from the distribution 
whose true relative incidence is the one we are trying to detect, is very low in all 
situations. In all cases the actual Type //error probability is much less than the design 
value of 0.01.
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Figure 6.2. Power (percent) by relative incidence, risk period (1 week, 2 weeks, 4 
weeks) and baseline incidence (Poisson mean of 5, 10, 20, 50).
Type II error probability
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Figure 6.3. Type II error (percent) by relative incidence, risk period (1 week, 2 
weeks, 4 weeks) and baseline incidence (Poisson mean of 5, 10, 20, 50).
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Figure 6.4 shows a decreasing relationship between the proportions that did not cross 
either the upper or the lower boundary during the ten year surveillance period with 
relative incidence, risk period and baseline incidence. The proportions of the 2000 
simulated values that did not cross the upper or lower boundary during the ten year 
surveillance period was very high (-100%) when trying to detect a small relative 
incidence, with small baseline incidence. For events with baseline incidence of 10 or 
more, relative risk of 3 or more and risk period of 2 weeks or more, the proportion not 
crossing the lower or upper boundary within 10 years is virtually zero.
Proportions crossing the 10-year boundary
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Figure 6.4. Proportions (percent) by relative incidence, risk period (1 week, 2 weeks, 
4 weeks) and baseline incidence (Poisson mean of 5, 10, 20, 50).
So far we can see that the surveillance system is quite sensitive for detecting a relative
incidence equal to the design value. Later, we investigate the performance of the
surveillance system where data arises from a population whose true relative incidence
is different from the design value.
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Figure 6.5. Effects of risk period, relative incidence and baseline incidence of the number of cases on 
the surveillance system from 2000 simulation of 10 year surveillance period with 6 months monitoring 
time interval when either boundaries were crossed.
6.8.4 Time to crossing a boundary
Figure 6.5 (left panel) shows the average time (years) to crossing the upper boundary, 
conditional on crossing it. Figure 6.5 (right panel) shows the corresponding results for 
lower boundary. Note that these graphs should be interpreted in conjunction with 
Figure 6.4.
In brief, figure 6.5 shows that, conditional on crossing, crossing either boundary 
occurs earlier for the following situations:
(a) As the risk period increases.
160
(b) As the relative incidence to be detected increases.
(c) As the baseline incidence increases (Poisson mean of 5, 20, 20, 50).
Most interest relates to Figure 6.5 (left part). For events with baseline incidence of 10 
or more, and a relative incidence of 3 or more, detection occurs within 5 years on 
average in those detected. For events with an incidence of 50 or more, detection 
occurs within 2 years. This means that if there is a problem, then it is detected 
quickly.
6.8.5 Simulations for relative incidences other than the design value.
In the last three subsections, we have seen how the surveillance system performs 
when we simulated data using a relative incidence equal to the design value. We now 
present simulation results when the true relative incidence RI2 associated with the
event of interest differs from the design value of the SPRT (that is, the relative 
incidence RI the system is designed to detect).
We investigated similar situations as in those given in section 6.8.3 but here we 
present results for the 2 weeks risk period only. The design relative incidence RI is 
1.5, 2, or 3 and the true relative incidenceRI2 is 1, 1.2, 1.5, 2, or 3.
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Table 6.5. Results from 2000 simulations of 10 year surveillance period with six 
months monitoring interval and two weeks risk period.
RI
RI2
Poisson 
Mean no. 
cases
Proportions of 2000 
samples
Pa P b Pc
Average 
year crossed 
Ya Yb
RI
RI2
Poisson 
Mean 
no. cases
Proportions of 2000 
samples.
Pa P b Pc
Average 
year crossed 
Ya Yb
1.5 1.5
1.0 1.2
5 0.0005 0.0000 0.9995 9.50 - 5 0.0005 0.0000 0.9995 8.00 -
10 0.0000 0.0210 0.9790 - 9.09 10 0.0050 0.0055 0.9895 7.44 9.39
20 0.0035 0.2635 0.7330 5.72 7.80 20 0.0350 0.0445 0.9205 6.91 8.04
50 0.0035 0.8265 0.1700 5.01 5.65 50 0.1345 0.2435 0.6220 5.99 6.62
1.5 1.5
2.0 3.0
5 0.0640 0.0000 0.9370 8.03 - 5 0.5080 0.0000 0.4920 7.45 -
10 0.4840 0.0000 0.5160 7.25 - 10 0.9730 0.0000 0.0270 5.32 -
20 0.9250 0.0000 0.0750 5.43 - 20 1.0000 0.0000 0.0000 2.89 -
50 1.0000 0.0000 0.0000 2.57 - 50 1.0000 0.0000 0.0000 1.32 -
2.0 2.0
1.0 1.2
5 0.0010 0.1140 0.8850 6.75 8.46 5 0.0075 0.0535 0.9390 7.38 8.63
10 0.0025 0.5670 0.4305 7.44 6.85 10 0.0230 0.2915 0.6855 6.33 7.24
20 0.0035 0.9140 0.0825 3.97 4.96 20 0.0515 0.6295 0.3190 5.40 5.78
50 0.0030 0.9950 0.0020 2.40 2.52 50 0.0550 0.9020 0.0430 3.10 3.74
2.0 2.0
1.5 3.0
5 0.0440 0.0100 0.9460 6.93 8.65 5 0.8015 0.0000 0.1990 6.05 -
10 0.1570 0.0890 0.7540 6.27 7.27 10 0.9905 0.0000 0.0095 3.92 -
20 0.3180 0.1815 0.5005 5.52 5.98 20 1.0000 0.0000 0.0000 2.10 -
50 0.5710 0.2720 0.1570 4.35 4.69 50 1.0000 0.0000 0.0000 1.02 -
3.0 3.0
1.0 1.2
5 0.0040 0.7865 0.2095 3.55 5.97 5 0.0210 0.6045 0.3745 5.19 6.46
10 0.0035 0.9775 0.0190 3.67 4.02 10 0.0190 0.8895 0.0915 3.44 4.70
20 0.0045 0.9955 0.0000 1.84 2.26 20 0.0150 0.9775 0.0075 3.37 2.94
50 0.0020 0.9980 0.0000 0.50 1.05 50 0.0115 0.9885 0.0000 1.31 1.44
3.0 3.0
1.5 2.0
5 0.0705 0.3230 0.6065 5.50 6.76 5 0.3215 0.0955 0.5830 5.65 6.54
10 0.1090 0.6320 0.2590 4.79 5.39 10 0.5075 0.1785 0.3140 3.88 5.17
20 0.1270 0.8110 0.0620 3.33 4.05 20 0.6670 0.2365 0.0965 3.89 4.11
50 0.1070 0.8915 0.0015 4.35 4.69 50 0.7770 0.2160 0.0070 2.28 2.45
Pa, Pb, PC=proportions of 2000 that crossed the upper boundary, lower boundary, vertical boundary, 
Ya, Yb= the average year when the upper, lower boundary was crossed conditional on having crossed 
the boundary. RI=relative incidence to be detected (design value), RI2=true relative incidence in the
population, a  =  /? =  0.01 Type I and Type II errors.
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6.8.6 True relative incidence=l (RI2 = 1)
We first investigated the performance of the surveillance system when the true 
relative incidence is 1. The quantity of interest is the Type /  error, namely the 
probability of crossing the upper boundary (within 10 years) when the true relative 
incidence is 1. We see from the rows of Table 6.5 (rows RI2 = 1, column Pa) that the
empirical Type /  error is smaller than that used to set the boundaries (0.01). This 
means that in most situations when the true relative incidence is 1, the surveillance 
system will not give a false alarm. As the design relative incidence increases and as 
the base line incidence increases, the system becomes more sensitive by signalling 
very quickly in favour of the null hypothesis (high proportions crossing the lower 
boundary ‘Pb’, see table 6.5). Figure 6.6 below shows the probability of correctly 
concluding that the relative incidence is 1, as indicated by the percentages of traces 
crossing the lower boundary. The probability of correctly concluding that the relative 
incidence is 1 was greater than 90% for design values RI in excess of 2, and baseline 
incidence of 20 or more.
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Probability of correctly concluding that 
the relative incidence is 1
Design value
— •-—  Poisson(5) ---- • -----  Poisson(10)
 • ..... Poisson(20) — -------Poisson(50)
T w o  w e e k s  risk  p er io d
Figure 6.6. Probability of crossing lower boundary.
6.8.7 True relative incidence greater than 1, but not equal to the design value
Tables 6.5 also shows the results from the simulation with design value ( R I) of the 
relative incidences of 1.5, 2, and 3 arising from simulations with true relative 
incidence ( RI2) 1.2, 1.5, 2, and 3. As one would expect, when the true relative 
incidence is larger than the design value (for example RI=1.5 and 
RI2 = 2 or 3, RI = 2 and RI2 = 3) the system very quickly signalled in favour of the
alternative hypothesis. This is indicated by the decreasing average year when the 
upper boundary was crossed and by the high probabilities of crossing the upper 
boundary. In contrast, for the following pairs (RI, RI2): (1.5, 1.2), (2, 1.2), (3, 1.2),
(3, 1.5), the system signalled more frequently in favour of the null hypothesis than for 
the alternative. For the pairs (2, 1.5), (3, 2) the reverse was the case.
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6.8.8 Average year to signal for simulations with different design values
In terms of how quickly the process was able to signal by way of either crossing the 
upper threshold or lower threshold, Table 6.5 show that the smaller the design value 
R I, the longer the process took to signal. The detection times (conditional on 
detection occurring) decrease as the true relative incidence RI2 and the baseline 
incidence increase.
6.9 Conclusion
In this chapter, we have illustrated how the SPRT can be adapted for use with the self­
controlled case series method. We have evaluated the performance of the SPRT by a 
simulation study of a possible surveillance system.
Overall we see from the simulation study that the performance of the surveillance 
system using the SPRT works broadly as intended. Ideally, we would like a system to 
be very quick to detect a true relative incidence greater than 1 and also if there is no 
problem we would like the process not to cross the upper boundary or ideally signal in 
favour of the null hypothesis. The simulation study showed that the system was able 
to achieve all these.
Using the SPRT with the self controlled cases series method has all the advantages of 
using the self-controlled case series method (see chapter 1). A further advantage 
compared to other methods [79-82] is the specification of Type /  and Type //error 
probabilities which control against making wrong decisions. These error levels apply 
to the entire SPRT process, not to each specific monitoring time interval, and for this
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reason the analysis takes account of multiple testing. The adjustment for multiple 
testing is not explicit as in the Bonferroni adjustment, but is incorporated into the 
SPRT in the way that the upper and lower boundaries are calculated. These 
boundaries preserve a  and p  until a final decision is reached as to whether the 
hypothesis should be accepted or rejected [92]. However, we note that the actual Type 
/  and Type II  error probabilities are lower than the nominal values a  = p  = 0.01. 
Typically the actual values are less than half the nominal values. Thus the boundaries 
could be made less stringent without adversely affecting the actual error probabilities; 
nominal values a = p -  0.025 might be appropriate to obtain actual values close to 
0.01.
A possible limitation with the surveillance method is its inability to signal in real time 
since it is based on retrospective data. One possible solution to this would be to make 
the monitoring time interval shorter, though we have not investigated the implications 
of this other than through varying the baseline incidence X . Finally, it should be 
stressed that such a surveillance system would rely on routinely collected data for 
signal detection. Such data have varying degrees of accuracy in diagnostic coding; it 
is for this reason that such a surveillance system should not be viewed as the final 
confirmatory epidemiologic investigation into potential vaccine adverse events. Such 
a surveillance system is also limited to conditions that develop relatively soon after 
vaccination, and would not be suitable for investigation of conditions with a longer 
induction period, for example an adverse outcome that manifests itself several years 
after exposure.
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This chapter provides a ‘proof of principle’: the case series method can be used for 
focused surveillance using the SPRT. Further work is required to incorporate age 
effects, select optimal values of a = p  and the best monitoring interval.
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Chapter 7
Long-term surveillance using CUSUM charts with the self-controlled
case series method
7.1 Introduction
In chapter six we explored various methods used in surveillance systems. We 
identified two possible methods that can be adapted for use with the self-controlled 
case series method. These were the sequential probability ratio test (SPRT) and the 
cumulative sum (CUSUM). We showed how the SPRT can be used with the case 
series method. We now show how the CUSUM can be used with this method. In 
chapter 6 the emphasis was on focused surveillance of a single vaccine and adverse 
event, as would be undertaken after licensure of a new vaccine. The situation we 
consider here is the second scenario described in section 6.2 of chapter 6, namely 
long-term surveillance of several vaccines or several adverse events. The presumption 
is that there is no problem, so that RI2 = 1 (where RI2 is as defined in section 6.8.1 of
chapter 6). The main differences with the earlier scenario are that there is no time 
limit (previously we had a vertical boundary at 10 years) and that we need to control 
the overall Type /  error for several vaccines. We begin by a brief background of the 
genesis of the CUSUM charts in section 7.2, followed by some theory behind the 
CUSUM presented in section 7.3; a note on the control limit of the CUSUM is given 
in section 7.4. Section 7.5 describes the two sided tabular CUSUM. The application of 
the CUSUM to surveillance using the case series method is given in section 7.6, and
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in section 7.7 we present results from a simulation study. We conclude the chapter by 
describing the overall findings in section 7.8.
7.2 Background on CUSUM
The CUSUM procedure is one of the most well-known monitoring methods for 
sequential data. There are two types of CUSUMs, the tabular (algorithmic, decision 
interval) CUSUM and the V-mask form. The tabular CUSUM was first introduced by 
Page [46]. It was developed from the Wald sequential test [45]. It was designed to 
detect changes in a process parameter of interest, for example in our case the relative 
incidence RI (where RI is as defined in section 6.8.1 of chapter 6). Later, Barnard 
[102] developed the V-mask form of the CUSUM. The idea behind the V-mask 
CUSUM was to enable combined detection of both an increase or a decrease of the 
parameter of interest. We restrict attention to the tabular CUSUMs which can easily 
be adapted for use with the self-controlled case series method.
The initial development of CUSUM by Page [46] was for use in industrial problems 
where monitoring of a production process is of interest. In these settings, the CUSUM 
charts have been shown to be ideally suited to detecting small persistent process 
changes[103]. Recently [86, 88, 92, 97, 104, 105], CUSUMs have been used in a 
medical context to monitor outbreaks of infectious disease or congenital 
malformations. Application of the CUSUM to monitoring surgical performance was 
first proposed by Williams et al [106]. The first application of a CUSUM chart to 
monitoring surgical performance is documented in De Leval et al [107] and Steiner et 
al [108] who considered the problem of monitoring outcomes in paediatrics cardiac
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surgery. Rossi et al [109] used CUSUM charts to monitor respiratory and mortality in 
males in North Tuscany. Marshall et al [110] propose a CUSUM dealing with 
simultaneous surveillance of health outcomes over multiple units as well as time 
points.
7.3 The CUSUM
The CUSUM procedure involves plotting
Zt = max(0,Z,_1 + A,), t = 1,2,3,... (7.1)
at the rth observation, where, as for the SPRT, Z0 = 0 and A, is the sample weight
assigned to the rth subgroup as defined in an SPRT. For use with the self-controlled 
case series method, subgroups are a collection of cases taken from the surveillance 
system at fixed monitoring intervals. The CUSUM procedure differs from the SPRT 
because it has a holding barrier at zero rather than a lower absorbing barrier. The 
CUSUM sequentially tests the hypothesis Ho:0 = 60 versus Hx : 0 - 6 x. The process is
assumed to be in state H0 as long as Zt < h , and is deemed to have shifted to state Hx
if Zt > h at some time / . The constant h is called the control limit of the CUSUM. A
CUSUM that exceeds the control limit is said to have ‘signalled’. A signal means that 
the chart has accumulated enough evidence to conclude that the process (surveillance) 
parameter has changed. At this point, it is expected that monitoring will stop and 
remedial action will be taken. Notice that although individual scores ( A t) may be
negative, the tabular CUSUM based on Zt is restricted to values greater or equal to 
zero. This is mainly because the expression (7.1) is designed to detect an increase in
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parameter^. Later we will show how (7.1) can be rewritten to monitor decrease in
parameter#!.
The hypothesis H0 in the CUSUM can never be accepted, while Hx will eventually be 
accepted with probability 1, thus a  = 1 and {3 = 0. Theoretically the CUSUM will 
always eventually signal, although the signal may be a false alarm. The run length of 
the CUSUM is defined as the time (or number of observations) required before the 
CUSUM first exceeds the control limit (i.e. signals). Good choices for the control 
limit// are based on the expected or average run length (ARL) of the CUSUM 
under H0 and Hx. The ideal situation is to have a long ARL when the process is in
state H0 but a short ARL when the process has shifted to state Hx.
Whereas the performance of an SPRT is determined by its nominal error 
rates a  and /?, the efficiency of a CUSUM chart is quantified in terms of length of 
time before an alarm, false or true, is raised. The CUSUM’s performance is assessed 
by the average run length to detection of an alarm. A useful review of some 
alternative measures that can be used to summarise the performance of Statistical 
Process Control (SPC) charts of which the CUSUM is one is provided by Frisen 
[111]. The most commonly used measure as reviewed by Frisen is the average run 
length. When the process is in state H0, the average run length to detection is called
the in-control ARL0 and this is analogous to the Type /  error of an SPRT, whereas the 
out-of-control ARLj is the average run length to detection when the process is in state 
H1 which is analogous to 1 minus the Type//error (power) of an SPRT.
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Brook et al [112] and also Grigg et al [92] showed that the distribution of in-control 
run lengths for a CUSUM scheme is approximately geometric, hence it possesses the 
memoryless property and because it is also discrete, it will usually remain close to 
zero. On the other hand, the out-of-control run length distribution is not geometric 
because the chart in this case will tend to move towards the out-of-control region 
rather than remaining at zero.
The CUSUM may be defined for weights A t other than the log-likelihood ratio in
contrast to the SPRT which is only defined with log-likelihood ratio weights. The log- 
likelihood ratio weights are the best to use in a CUSUM. Moustakides [113] showed 
that the log-likelihood ratio weights are optimal in the sense that, of all CUSUMs with 
the same ARL under the null hypothesis, the CUSUM with log-likelihood ratio 
weights has the shortest ARL under the alternative.
7.4 Determination of the limit h in  a CUSUM
Choosing the control limit h should be based on the expected or average run length of 
the CUSUM under H0 andiTj. Determining the average run length of a CUSUM is
computationally intensive since it is based on all possible outcomes for a long series 
of observations of a monitoring process.
There are various ways of determining the ARL for a CUSUM. Some people use 
simulation, which is straight-forward but can be time consuming. Others have 
calculated the ARL using an integral equation approach [114]. In this approach, 
solutions are only possible via numerical methods. The method is only applicable to
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charts with outcomes that follow a normal distribution. In fact, in some instances in 
this approach, the solution may not even be possible.
Steiner et al [74] have proposed an approach based on Markov chain methodology. In 
this method, properties of the run lengths distribution are used to determine the set of 
probabilities of moving from one point on a chart to another and then manipulating 
the resulting transition matrix [74]. Calculating the ARL using Markov chain 
methodology requires the state space to be discretised so that it is finite. Steiner et al 
do this by enlarging the weights and control limits by a factor (the multiplier) and 
rounding off to the nearest integer. Grigg et al [92] have argued that as the result of 
discretisation, the Markov chain methodology of calculating the ARL may induce 
some error, but the error settles very quickly as the process continues. In our case, we 
shall determine the average run length by simulation. We use this approach because it 
will allow us to explore the behaviour of the self-controlled case series CUSUM and it 
will enable us to explore ARLs for several CUSUMs.
7.5 Two-sided tabular CUSUM
The CUSUM described in the last few sections concentrated on observing a shift of 
one particular parameter of interest, say the relative incidence RI denoting an 
increase from the null value 1. In other circumstances one might also be interested in 
knowing whether a particular vaccine has developed some protective effect with 
respect to the adverse event resulting in a decrease of the relative incidence below 1.
In such situations one could use a two-sided CUSUM. That is, one with the upper 
limit, denoting an increase (which in the case of the relative incidence represents a
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deterioration) of the parameter from the expected, and the other, with the lower limit 
denoting a decrease (which represents protection) of the parameter from expected. 
Page [46] was the first to suggest a two sided CUSUM, that is, the combined use of 
two one-sided tabular CUSUMs, one to detect improvement and the other to detect 
deterioration. Two sided CUSUMs are now widely used [74, 92, 115] and calculations 
of the ARL are needed for both sides.
The CUSUM designed to detect the decrease in the parameter will accumulate 
negative values, hence the updating formula (7.1) can be modified as shown below:
Zt =min(0,Z,_1 -  A,), t = 1,2,3,... (7-2)
where Z0 = 0 as before and A t is still as defined in expression (6.9) of chapter 6. To
enable plotting the CUSUM chart for the two sided on the same plot, the limit to 
detect a decrease in the parameter is usually assigned a negative value. We shall not 
explore the CUSUM based on a decrease in the parameter of interest since this is 
seldom of interest in a surveillance framework.
7.6 Use of the CUSUM for surveillance of adverse events
As outlined above, the CUSUM never results in ‘acceptance’ of the null hypothesis, 
and in this sense is well suited for long-term monitoring of established vaccines, the 
presumption being that such vaccines are safe. The aim of such monitoring could be 
to identify problems resulting from changes in vaccine production or delivery over 
time. Typically, one might expect several adverse events and several vaccines to be
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monitored, thus increasing the chance of a false detection. For this reason, there is a 
danger that such a monitoring scheme will produce too many false warnings. Rather 
than ascribe precise detection limits, it is probably more sensible to use CUSUMs in a 
more informal manner, by plotting the updated values for the several conditions to be 
monitored, and inspecting them informally. In addition to a CUSUM signalling, two 
features might also be of interest:
a. Persistent increasing trends above baseline.
b. Persistent ranking in ‘top’ position of one CUSUM.
Either of these might suggest further, more formal, investigation, perhaps in the first 
instance using the SPRT, or by setting up a suitable epidemiological study. We shall 
concentrate on issues relating to a CUSUM signalling. In the next section, we 
investigate the performance of the self-controlled case series adapted CUSUM by 
determining the average run lengths in a simulation study.
7.7 Simulation study to evaluate the self-controlled case series CUSUM.
7.7.1 Simulation scenario
We considered two settings: surveillance of a single vaccine, and surveillance of 
several vaccines. The simulation study was carried out in a similar way as described 
in sections 6.6.1 and 6.8.1 of chapter 6. The main difference is that the lower and 
vertical boundaries were removed. We computed the average run length of the 
CUSUM for both in control and out of control processes. The other difference was 
that we looked at two approaches when simulating several vaccines. In the first
175
approach, when one vaccine signals we stop the whole process, and start again after 
resetting the CUSUM value of every vaccine to zero. In the second approach, when a 
signal is triggered, the CUSUM value for the signalling vaccine only is reset to zero. 
So as not to make the simulations too unwieldy, we used five vaccines to represent a 
situation corresponding to monitoring several vaccines. This represents a realistic 
choice in the light of childhood immunisation programmes. To determine the average 
run lengths, we simulated for long enough to be sure that the upper limit is eventually 
crossed. In practice we simulated for 100 years.
7.7.2 Average run length in control and out of control for one vaccine.
We begin by looking at the average run length for systems in control and out of 
control when monitoring a single vaccine. Finding the average run length in control is 
similar to investigating the Type /  error in an SPRT (see section 6.8.6 of chapter 6). 
The parameters used in the simulation for the CUSUM were as follows.
Similar to the simulation in the SPRT, we used a monitoring interval of six months. 
We investigated various risk periods, but here we report only results for two weeks 
risk periods. Since in the present context the presumption is that the vaccine is safe, 
we are primarily interested in investigating relatively small changes in the relative 
incidence of adverse events. Accordingly we used design values for the relative 
incidence of 1.5, 2 and 3. We present values of 1, 2, 3, 4, for the control limits h 
because they gave ARLs that were realistic. The baseline incidences we investigated 
were same as in the SPRT, that is, Poisson mean of 5, 10, 20, and 50 per monitoring 
interval. So for one vaccine under investigation, we had a combination of 3 design
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values, 4 control limits, 4 baseline incidences giving a total of 48 different 
simulations. The out-of-control data were simulated using design values, so RI2 = R I .
In the case of a single vaccine, we simulated each scenario 2000 times and for each 
run of 2000 we found the average run length by calculating the average time at which 
the control limit was crossed. We also looked at the median time when the control 
limit was crossed, but only report the average because the distribution of crossing 
times was generally quite symmetric and the results based on means and medians 
were very similar.
Table 7.1 and Figure 7.1 below shows the average run lengths in years of a process in 
control and out of control for one vaccine. We can see from Figure 7.1 that the 
average run length in both situations decreases with decreasing control limit, 
increasing baseline incidence, and increasing design value. The decrease of the 
average run length with increasing design values may be explained as follows. The
sample weight (6.9) in the CUSUM is A, = n ltj3x -  n t log (l -  r + ep'r). In this
expression, for values of the relative incidence close to 1, for example relative
2
incidences less than 5, and low values of r (here r = — ) the values of n xtp x dominate
the values of n t log (l -  r + ePlr^ j hence as the relative incidence increases, the values
of the CUSUM increases quickly such that it crosses the control limit sooner with 
larger design values (Figures 7.1). The average run length is shorter out of control 
than in control at each set of parameter values. The out of control ARL is at least 3 
times the in control ARL at each control limit (see ratio = ARL0 / ARLj in Table 7.1).
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Table 7.1 Average run length for one vaccine in and out of control.
h is the contro 
50.
h X ARL0 for one 
vaccine in control, 
(years)
ARLj for one
vaccine out of control, 
(years)
ratio _ ARL0 
ARLj
Design value Design value Design value
1.5 2 3 1.5 2 3 1.5 2 3
1 5 11.9 8.32 5.54 3.28 1.66 1.08 3.63 5.01 5.13
10 7.48 6.05 4.27 2.05 1.20 0.83 3.65 5.04 5.15
20 5.32 4.55 3.74 1.45 0.90 0.72 3.67 5.06 5.19
50 4.63 3.66 3.13 0.98 0.72 0.60 4.72 5.08 5.22
2 5 31.4 21.9 13.0 8.58 4.35 1.98 3.66 5.03 6.57
10 21.9 15.7 10.9 5.93 2.39 1.40 3.69 6.57 7.79
20 17.0 10.8 7.65 3.60 1.62 0.98 4.72 6.67 7.81
50 10.9 7.53 5.25 1.98 1.00 0.67 5.51 7.53 7.84
3 5 41.7 31.3 22.7 9.26 6.20 3.34 4.51 5.05 6.80
10 35.3 28.4 19.7 7.21 4.63 2.51 4.90 6.14 7.85
20 25.1 17.1 10.1 5.10 2.64 1.28 4.93 6.48 7.89
50 18.6 11.4 9.67 3.35 1.43 0.75 5.55 7.97 12.9
4 5 45.8 36.1 28.9 9.99 7.10 4.24 4.58 5.09 6.82
10 38.8 31.8 22.1 7.88 5.10 2.77 4.92 6.24 7.98
20 29.5 21.8 15.7 5.92 3.35 1.46 4.98 6.51 10.8
50 21.0 15.7 13.8 3.77 1.76 0.88 5.57 8.92 15.7
limit, X is the baseline incidence with Poisson mean of 5, 10, 20 and
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Figure 7.1 Average run lengths in and out of control for one vaccine
7.7.3 Average run length of a CUSUM in control and out of control for five 
vaccines: If one signals, correct it and reset all.
In the case of a surveillance system with several vaccines in which all CUSUMs are 
reset when one signal is triggered, we were interested in the average run length of the 
system as a whole. We investigated a system with 5 parallel CUSUMs. The overall in­
control ARL is the average time to signal for any of the component CUSUMs. Thus it 
is the minimum of the five individual ARL0s . We based each component CUSUM on 
the same parameters, and obtained 10 000 simulations. Then we calculated the 
minimum ARL0s in groups of five. The overall ARL0s is the average of the 2000 
minima.
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When monitoring five vaccines, it is unrealistic to expect all five vaccines to be out of 
control, hence we looked at a situation in which five vaccines are under surveillance 
and only one vaccine is out of control. The ARL, is the time to detection of the out of 
control vaccine, starting from 0. A possible realisation is given in Figure 7.2 below.
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Figure 7.2 CUSUM chart monitoring possible 5 vaccines with one vaccine out of 
control.
Figure 7.2 shows a situation in which five vaccines are under surveillance and all but 
one are in control. The design value of the relative incidence is 2 and the expected 
baseline frequency of cases is 10 cases every six months. The control limit is 2. We 
can see that the system first signalled at about 4.5 years with the fourth vaccine 
(which was in control). The values of the CUSUM for all five vaccines were reset to 
zero and the process continued. After 8 years, the second vaccine signalled (again in 
control). Again all CUSUMs were reset to zero. After 10.5 years the fifth vaccine 
signalled; again all CUSUMs were reset. Finally in 14th year of observation the
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vaccine out of control signalled and again all the vaccines were reset and the year of 
first signalling of the out-of-of control vaccine would have been recorded as 14. Note 
that this is somewhat unusual scenario: in most situations, it is the vaccine out of 
control that would signal first as can be seen by the closeness of its trace to the control 
limit when the in control vaccines signalled. This process was simulated 2000 times 
and the average time to signal was calculated. Table 7.2 below shows the results 
obtained from the simulation.
Overall Table 7.2 shows that the average run length for the system with one vaccine 
out of control was shorter than for the system with five vaccines in control. Figure 7.3 
below illustrates that the average run length in either situation increased with 
increasing control limit, decreased with increasing baseline incidence and decreased 
with increasing design value. However, the values of the ratios ARL0 / ARLj for five
vaccines were consistently less than the corresponding values for a single vaccine (see 
Table 7.1 and Table 7.2).
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Figure 7.3 Average run length of a CUSUM in and out of control with 5 vaccines 
under surveillance.
Ta t>le 7.2 Average run length for in and out of control for 5 vaccines.
h /I ARL0 for five 
vaccine in control 
(years)
ARLj for five vaccines
and one out of control 
(years)
ratio ARL0
ARL,
(Design value) (Design value) (Design value)
1.5 2 3 1.5 2 3 1.5 2 3
1 5 5.23 4.67 2.97 5.11 3.86 1.75 1.02 1.21 1.70
10 3.95 2.96 2.66 3.85 2.26 1.23 1.03 1.31 2.16
20 3.32 2.23 1.99 3.19 1.67 0.89 1.04 1.34 2.23
50 1.62 1.54 1.31 1.27 1.12 0.58 1.28 1.37 2.25
2 5 14.2 9.09 5.61 13.6 7.42 3.12 1.04 1.23 1.80
10 11.4 6.57 4.59 10.6 4.33 1.84 1.08 1.52 2.49
20 9.79 4.93 4.22 6.44 2.46 1.16 1.52 2.00 3.64
50 5.30 4.11 3.25 3.11 1.30 0.72 1.70 3.16 4.51
3 5 16.9 14.7 11.5 15.3 11.1 4.12 1.10 1.32 2.79
10 15.3 13.6 9.76 13.4 5.84 2.38 1.14 2.33 4.10
20 14.2 10.3 9.10 9.18 3.34 1.38 1.55 3.08 6.59
50 11.4 9.05 8.51 4.19 1.59 0.78 2.72 5.69 10.9
4 5 17.7 16.3 15.1 16.9 14.6 5.30 1.05 1.12 2.85
10 16.5 15.2 14.5 14.7 7.57 2.87 1.12 2.01 5.05
20 15.7 14.7 13.4 12.0 4.16 1.68 1.31 3.53 7.98
50 14.8 14.0 12.1 5.35 1.95 0.87 2.77 7.18 13.9
h is the control limit, A is the baseline incidence with Poisson mean 
50. If one signals, correct it and reset all.
of 5. 0, 20 and
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7.7.4 Average run length of a CUSUM in control and out of control for five 
vaccines: If one signals, correct and reset only the signalling vaccine.
We now present results from simulations in which when one vaccine of the five 
vaccines under surveillance signals, only the signalling vaccine is reset to zero. For 
this situation, we defined the system ARL0 as the average time between signals in the
long run when all vaccines are in control. So we left the process running until we had 
2000 signals and calculated the average time interval between successive signals. 
Figure 7.4 below shows a possible realisation of such a surveillance system.
Control limit h=2
i  i i i i i r
0 2 4 6 8 1012141618202224262830323436384042444648505254
Time to signal (Years)
— • 1st Vaccine in control •
 • ..... 3rd Vaccine in control ---- • —
—  -• 5th Vaccine in control
2nd Vaccine in control 
4th Vaccine in control
ri=3, 2  m o n th s  risk  p er io d  p o is s o n  m e a n  = 5 0
Figure 7.4 CUSUM chart monitoring possible 5 vaccines resetting only the vaccine 
out of control.
In the realisation shown in Figure 7.4, all five vaccines under surveillance are in 
control and the system is under surveillance for 54 years. The design value in this case 
was a relative incidence of 3, the baseline incidence was 50 cases in each monitoring
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interval and the control limit was set at 2. We see that the fifth vaccine signalled first 
in the 5 year. This vaccine alone would then have been looked at, its CUSUM reset 
to zero and the surveillance would have continued. The second signal, by the fourth 
vaccine, was in the sixth year of observation and a similar action would have been 
taken for this vaccine alone, and so on. The ARL0 of the system is therefore the
average interval between signals when all vaccines are in control. The ARLj is the
average time to detect an out-of-control vaccine starting from zero. Table 7.3 below 
shows the results from the simulations.
Table 7.3 Average run length for in and out of control for 5 vaccines.
h X ARL0 5 Vaccines in
control. Average time 
interval between false 
signals (years)
ARLj 5 vaccines
with one out of control. 
Average time interval 
between signals (years)
ratio = ARL0
ARLj
(Design value) (Design value) (Design value)
1.5 2 3 1.5 2 3 1.5 2 3
1 5 4.35 2.36 1.78 3.26 1.67 1.10 1.33 1.41 1.62
10 2.76 1.74 1.59 2.05 1.18 0.85 1.35 1.47 1.87
20 2.03 1.51 1.49 1.46 0.92 0.70 1.39 1.64 2.13
50 1.49 1.40 1.32 0.99 0.73 0.58 1.51 1.92 2.28
2 5 12.9 8.71 4.13 8.60 4.35 1.96 1.50 2.00 2.11
10 10.9 5.92 4.39 6.00 2.38 1.38 1.82 2.49 3.18
20 7.74 4.61 4.08 3.55 1.64 0.98 2.18 2.81 4.16
50 4.62 3.84 2.92 1.98 1.04 0.65 2.33 3.69 4.49
3 5 15.1 13.4 9.60 9.20 6.20 3.37 1.64 2.16 2.85
10 13.8 12.2 8.11 7.20 4.69 2.51 1.92 2.60 3.23
20 11.8 9.10 7.90 5.12 2.66 1.27 2.30 3.42 6.22
50 10.0 8.50 7.23 3.35 1.42 0.75 2.99 5.99 9.64
4 5 16.8 15.6 13.9 9.97 7.12 4.24 1.69 2.19 3.28
10 15.4 14.3 10.3 7.90 5.14 2.76 1.95 2.78 3.73
20 13.9 12.2 9.60 5.90 3.35 1.49 2.36 3.64 6.44
50 11.9 10.7 8.26 3.77 1.72 0.85 3.16 6.22 9.72
h is the control limit, X is the baseline incidence with Poisson mean of 5, 10, 20 and 
50. If one signals, correct and reset only the signalling vaccine.
The average time intervals in control and out of control shows a similar trend as 
before, except that just resetting the problem vaccine means that the average
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frequency of signals is greater. In particular, the ARL values are shorter than those
ARLfound in Table 7.2. The other notable difference is that th e    ratios are generally
ARL,
larger when only the signalling vaccine is reset compared to the situation when all
ARLvaccines are reset (see Table 7.2, Tale 7.3 and the corresponding ratios  ). ThereARL,
are exceptions, corresponding to high values of h and high design values, in which the 
ARLratios are smaller when only the signalling vaccine is reset. These values are
indicated in bold in Tables 7.2 and 7.3.
7.8 Conclusion
In this chapter, we explored how the self-controlled case series sample weight 
A t = nAtpx -  n t log (l -  r + ePxr }may be used in CUSUM charts. We have shown in
different situations how such CUSUMs may be useful in long term surveillance of 
new vaccines. Unlike Marshall et al [110] who concentrated on false discovery rates 
(FDR) and successful discovery rates (SDR) in assessing the performance of the 
CUSUM, we assessed the performance of the case series CUSUM using average run 
lengths, suitably redefined for the surveillance of several vaccines. The method of 
Marshall et al [110] based on the false detection rate applies perhaps more 
appropriately to the surveillance of large number of units. However, it lacks the focus 
on detection times which is provided by the system ARL0 and ARL, formulation.
Our ‘system’ ARL0 and ARL, are practically relevant parameters. The
system ARL0 measures the time interval between false signals when the system is in
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control. A large value of ARL0 is desirable. Surveillance of several vaccines 
drastically reduces the ARL0 obtained for a single vaccine. In an effort to increase the 
ARL0 we investigated a resetting scheme where all vaccines are reset, not just the 
signalling vaccine. This does indeed increase the ARL0, but also affects the ARLj.
The ARLj is an upper limit on the time interval between a problem occurring and
when it is detected (it is an upper limit because the CUSUM will generally be greater 
than zero when the problem occurs). This time interval must be kept small; detection 
within 2 years might be a reasonable requirement. Thus using the ARLj may 
underestimate the speed at which problem vaccines are identified.
Choosing the control limit h should be based on the expected or average run length of 
the CUSUM under/f0 an d # ,. Based on our simulations, if one vaccine is under
observation, with a two week risk period, a six months observation period, and we are 
interested to detect a relative incidence of 3 based on the assumption that there are 
likely to be few cases arising in each six month monitoring interval (baseline 
incidence with mean of five), the simulation study (Table 7.1) shows that setting the 
control limit at 2 will have an average run length of 13.0 years when the system is in 
control and average run length of 1.98 years when it is out of control. These values 
appear reasonable.
However, the choice h = 2 with design value 3 is no longer adequate when 5 vaccines 
are involved. If all vaccines are reset upon signalling, then ARL0 = 5.6 land
ARL, = 3.12 (Table 7.2), whereas if just signalling vaccines are reset, then
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ARL0 =4.14 and ARLj =1.96 (Table 7.3). In both cases the ARL0 values are rather too 
short. In this case, using h = 3 may be advisable.
In general when monitoring several vaccines, we note that the system ARL0 is much
shorter than the ARL0 for a single vaccine. Also the ratios ARL0 / ARLj were much
close to 1 especially when trying to detect a smaller relative incidence (design value = 
1.5) as apparent in Table 7.2. It is generally advisable to use large design values( 2 
and 3) and higher control limits. For most of the values we considered, it seems best 
to reset the signalling vaccine only rather than resetting all vaccines. However, this 
may not be the case for more frequent events (higher X ), in which case it could be best 
to reset all vaccines upon signalling.
It is not possible to suggest a single control limit to use when using the CUSUM 
based on the self-controlled case series method. This will depend on the risk period, 
the baseline incidences for the number of cases, the monitoring interval, the number 
of vaccines under observation, the way the surveillance is to be carried out especially 
when several vaccines are under observation, and the relative incidence to be 
detected. Our results show that a practical system may be possible, but requires 
careful choice of the parameters h and the design value, if we are to avoid swamping 
the system with false positive signals.
Note that even though the ARL is standard practice for evaluating the performance of 
a CUSUM [110], others [111, 116] have argued that the ARL is not ideal because the 
distribution of the run length may be skewed (though for the case series CUSUM, we 
found that median run lengths yielded similar results). Hence one has to be careful as
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to what inferences can be drawn from an alarm signalled. Certainly an alarm signalled 
by a CUSUM does not constitute proof of causal association. However, among 
various methods for surveillance, it is argued [111, 113] that the ARL for a CUSUM 
is optimal to detect a change that occurs at the specific time.
Overall, a monitoring system using a combination of the SPRT and CUSUM based on 
the self-controlled case series method appears to be feasible, and could prove a very 
useful tool.
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Chapter 8
Oral vaccines and intussusception
8.1 Introduction:
In this chapter, we describe a study conducted by GlaxoSmithKline (GSK) 
Biologicals to assess the incidence of intussusception in children less than 2 years of 
age in Latin America. We concentrate on an a-posteriori analysis of the data using the 
self-controlled case series method to assess whether intussusception is causally 
associated with oral polio vaccine (OPV). In section 8.2, we describe the background 
and rationale of the study. The objectives and study design are given in section 8.3, 
the study cohort and conduct of the study are described in section 8.4, the descriptive 
analysis is given in section 8.5, further statistical analysis is described in section 8.6, 
and conclusions are given in section 8.7.
8.2 Background and rationale
In August 1998, the first rotavirus vaccine, a tetravalent rhesus human reassortant 
rotavirus vaccine (RRV-TV) manufactured by Wyeth-Lederle (marketed as 
RotaShield™) was licensed in the United States of America (USA) and was 
recommended for routine immunisation of infants [68, 117]. The recommendations 
were suspended in July 1999 after the US Centres for Disease Control and Prevention 
(CDC) Adverse Events Reporting System identified 15 children who developed
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intussusception after administration of the vaccine [69]. Additional epidemiological 
data lending support to a causal link was evident by October, 1999. Wyeth Lederle 
Vaccines and Pediatrics voluntarily withdrew RotaShield™ from the market, and 
CDC withdrew its recommendation for routine immunisation [118, 119]. Subsequent 
studies showed that RRV-TV is associated with increased risk of intussusception and 
the risk was shown to be highest between 3 to 7 days after the first vaccination dose 
[38, 120].
For most parents and paediatricians in the USA, the withdrawal of RotaShield™ was 
disappointing because it meant that the winter burden of severe rotavirus diarrhoea, 
which leads to an estimated 600 000 clinic visits, 50 000-60 000 hospital admissions, 
and 20-40 deaths, might continue for several years before another vaccine became 
available [119, 121]. The international medical community was disappointed because 
a vaccine that might have prevented 440 000 childhood deaths each year, or one in 20 
deaths among children younger than 5 years, would remain a distant hope rather than 
an anticipated reality [122]. The rate of intussusception is not well known world wide, 
but a Cuban study [37] estimated a rate of about 45 per 100,000 live births which was 
similar to that found in the United States over a comparable period [123]. In some 
countries rates lower than those found in the United States have been observed [124].
Intussusception is a fairly uncommon type of acute intestinal obstruction. It occurs 
primarily in young children and is the most frequent cause of an acute abdominal 
emergency in the first 2 years of life. It rarely occurs in adults [125]. Most cases of 
intussusception are considered idiopathic. Children suffering from intussusception 
have problems, for example it is reported that about 5% to 10% of cases of
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intussusception include an inverted appendiceal stump, Meckel’s diverticulum 
(remnant of the embryonic yolk sac), intestinal polyps, lymphoid hyperplasia, 
hemangioma or lymphosarcoma. Twenty percent of the cases are noted to have upper 
respiratory tract infections [126]. Several other reports have indicated the presence of 
infectious agents in cases of intussusception, but the implications of these findings are 
unclear since most studies do not include a comparison group [127-133].
There is no clear evidence of association between natural rotavirus infection and 
intussusception [132, 134, 135]. Seasonality of rotavirus infection is well documented 
in the USA, and no seasonal variation in the occurrence of intussusception has been 
observed in most studies. Most studies have found that hospitalisation for 
intussusception was evenly distributed throughout the year while rotavirus disease 
peaked during the known season [136, 137]. However, in the Cuban study [37], cases 
showed a marked seasonality with cases peaking in December-May and low in June to 
May. The authors [37] argued that some of the observed seasonality was attributable 
to the seasonality of births in Cuba. In Nigeria, seasonality of intussusception has also 
been reported where most cases occur between October and April [138]. Generally, 
human rotavirus is not considered as a major etiological agent of intussusception in 
infants, though some studies have suggested that rotavirus and other viral epidemics 
may play a role in the aetiology of intussusception [139-141].
Following the withdrawal of the RotaShield™ vaccine, there remained an urgent need 
for an effective vaccine because of the dramatic disease burden associated with 
rotavirus. The background incidence of intussusception in many countries is not 
known. The World Health Organisation (WHO) ethics workgroup [142]
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recommended that such data be collected to help assess the risk/benefit ratio for use of 
rotavirus vaccines. Following the rotavirus vaccine experience, concerns arose as to 
whether oral polio vaccines might also be associated with intussusception. Two 
previous studies, both exploratory, had reported a significant increased risk of 
intussusception in the third or fourth weeks after doses of oral polio vaccine (OPV) 
administered at 4 months of age. Other studies have not confirmed these findings [36, 
37,143] albeit an increased risk after the third dose in the 14-27 days risk period was 
found in one case series study by Andrews et al [36] but this finding was thought to 
have been just a chance finding due to the number of risk periods examined. The 
authors [36] warned of the need for caution when looking at many risk periods 
without an a priori hypothesis . The Food and Drug Administration (FDA) and CDC 
had to tackle uncomfortable questions about how to detect such rare events before 
licensing future vaccines for rotavirus.
GlaxoSmithKline (GSK) Biologicals [144] have developed a new rotavirus vaccine 
based on human rotavirus strain and are currently performing clinical studies world­
wide to evaluate this vaccine. Several studies are currently ongoing in Latin America 
(Argentina, Brazil, Chile, Costa Rica, Honduras, Mexico, Nicaragua, Panama, Peru, 
Dominican Republic, Columbia) to test GSK Biologicals’ rotavirus vaccine in infants. 
In view of the recommendations to obtain intussusception data in different geographic 
settings, GSK Biologicals performed the GSK204 surveillance study described here. 
This was a hospital based multicentre study to assess the incidence of intussusception 
in children less than 2 years of age in Latin America.
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8.3 Objectives and design of the study
The primary objective in the study was:
To estimate the incidence of intussusception in children less than 24 months of age in 
hospitals in Latin America.
For the purposes of the thesis, we undertook a-posteriori analyses following 
discussions with GSK as part of our collaboration. These analyses were not part of the 
initial objectives when the study was set up. But it was agreed that the data set 
collected may be suitable for the use of the self-controlled case series method to 
investigate the following question:
Is oral polio vaccine associated with an increase in intussusception in children less 
than 24 months of age?
This can be investigated using the self-controlled case series method taking OPV 
vaccination as the exposure. OPV has already been investigated in the UK for 
evidence of causal association with intussusception (Andrews et al [36]) and in Cuba 
[37]. The purpose of these a-posteriori analyses was to identify if there were any 
causal agents of intussusception other than rotavirus vaccine as found in the US [69].
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8.4 The study
The study was designed as a hospital-based, multi-centre study. It was designed to 
enrol all cases of intussusception (definite, probable, possible or suspected) from 
children who received care at participating hospitals and listed on a Screening Sheet. 
Subjects were enrolled during a period of at least one year beginning at study start.
For the enrolled subjects, the participation in the study consisted of an interview of the 
subjects’ parents. The study was designed to be a self-contained study and the 
duration of the study was at least one year. Collection of data was by using hard copy 
Case Report Form (CRF).
8.4.1 Study cohort and conduct
The target population for enrolment was all subjects seen on an in or out-patient basis 
with confirmed diagnosis of intussusception during a one year period beginning at 
study start. All intussusception cases (definite, probable, possible, and suspected) seen 
at the participating hospitals were included in the study if they fulfilled the eligibility 
criteria. Only subjects whom the investigator believed had met the requirements of the 
protocol [144] were enrolled in the study. It was decided that for the purposes of the 
present analysis, only definite cases were to be analysed.
The inclusion criterion for the cases was as follows:
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• A male or female infant aged less than twenty four months at the time of 
diagnosis of intussusception (patients became ineligible on the day of their 
second birthday).
• Subject was diagnosed with definite (radiographically, surgically or by post­
mortem examination), probable, possible or suspected intussusception during 
the period of one year beginning at study start.
• He or she did not have a radiographically or surgically confirmed case of 
intussusception prior to the current episode.
• Written informed consent was obtained from the parent or guardian of the 
subject.
The study was conducted according to Good Clinical Practice, the Declaration of 
Helsinki (Protocol [144] Appendix Al) and the International Guidelines for Ethical 
Review of Epidemiological Studies (Protocol [144] Appendix All) and logical rules 
and regulations of each participant country. The study was conducted in eleven Latin 
and Central American countries (Argentina, Brazil, Chile, Costa Rica, Honduras, 
Mexico, Nicaragua, Panama, Peru, Dominican Republic, and Columbia) between 
December 2002 and May 2005.
8.4.2 Case finding
Children admitted to or cared for at participating sites for definite, probable, possible, 
suspected intussusceptions were identified by daily reviews of admission logs, 
computerised hospital admission records, emergency department records, surgical 
records and radiology logs. Patients complaining of symptoms of intussusception
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usually arrived at the admission and entry (A&E) department or outpatient paediatric 
clinics in the participating hospital. On preliminary query diagnosis by the 
paediatricians or A&E medical officers, the patients were admitted into the hospital 
and sent to Diagnostic Imaging for an ultrasound scan. On confirmation of 
intussusception by ultrasound, air enema (usually performed compared to barium) was 
carried out to confirm the diagnosis and reduce the intussusception. If attempts at 
reduction failed, the patient was sent for surgical reduction. If there were perforations 
or necrosis, then resections were carried out. Patients were then sent to the ward to 
recover. Data from each case were then keyed into the hospital computer under the 
ICD code for intussusception. Written informed consent was sought from child’s 
parent or guardian if the child met the eligibility criteria.
8.4.3 Data collection
Data regarding the episode of intussusception including vaccination history, clinical 
symptoms noted on admission, diagnostic procedures, surgical and radiographic 
procedures performed, microbiology results and methods and outcome of admission 
were collected from hospital records, physician records, and vaccination booklets of 
all eligible subjects as well as interviews with parents or guardian.
8.5 Descriptive analyses of the GSK204 data
Overall, there were 531 cases in the GSK204 data set. Of these, 495 received polio 
vaccine, of which 492 had oral polio vaccine and 3 received injected vaccine. As
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mentioned above, only definite cases that had oral polio vaccine were considered for 
analysis and these were 456. The following analyses are based on these 456 cases.
8.5.1 Distribution of cases by country
Table 8.1 below shows the number of cases per country and when the study started in 
each country.
Table 8.1 Distribution of cases by country
Country Study Start Study End Number of cases
Argentina 02-Mar-03 02-Mar-05 40
Brazil 21-Mar-03 21-Dec-05 16
Chile 27-Jan-03 31-Jan-05 55
Costa Rica 17-Jan-02 31-Dec-03 24
Honduras 27-Jan-03 27-Jan-05 36
Mexico 06-Jan-03 20-Jan-05 120
Nicaragua 03-Mar-03 03-Mar-05 9
Panama 10-Jan-03 10-Jan-05 54
Peru 30-Sep-03 30-Sep-04 39
Dominican Republic 20-Jan-03 20-Jan-05 26
Columbia 02-May-03 02-May-05 37
There is much variation in the number of cases across the different countries. Mexico, 
Chile, and Panama seem to have had more cases than the other countries and 
Nicaragua had the fewest number of cases. The numbers of cases vary enormously, 
perhaps in part due to differences in case ascertainment.
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8.5.2 Sex and age at diagnosis
Overall there were more boys (61%) than girls. A similar finding was made in the UK 
by Andrews et al [36]. Table 8.2 below summarises age at diagnosis in days by 
gender. The mean age at diagnosis did not vary substantially by gender, other than 
some indication that girls on average (mean=231.1 days) were slightly older at 
diagnosis compared to boys (mean=224 days). Age at diagnosis ranged from a 
minimum of 65 days to a maximum of 660 days for girls and from 66 days to 704 
days for boys. Overall the distribution of age at diagnosis was positively skewed 
ranging from 65 days to 704 days with a mean age at diagnosis of 226.8 days and a 
median age of 196.5 days. Figure 8.1 below shows the distribution of age at diagnosis. 
The graph shows that most diagnoses were made between 100 days and 275 days.
Table 8.2 Distribution of age at diagnosis by gender
Age at diagnosis 
days
Median Mean Std Dev Minimum Maximum
Female
(176) 202.5 231.1 115.1 65.0 660.0
Male
(280) 196.0 224.0 105.5 66.0 704.0
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Figure 8.1. Distribution of age at diagnosis
8.5.3 Number of doses of OPV received
Children received a maximum of 5 doses of OPV. There was substantial variation in 
the number of doses of OPV received by different individuals. Most children received 
the first dose, the second dose and the third dose. A few children received a fourth, 
and only 12 had a fifth dose. Table 8.3 below shows the number of doses received by 
the children in the data set.
Table 8.3 Distribution of number of individuals who received OPV doses in 
the 204 data set
Dosel Dose2 Dose3 Dose4 Dose5 Dosel2 Dosel23 Dosel234 Dosel2345
Yes 426 358 261 86 12 357 257 86 12
No 30 98 195 370 444 99 199 370 444
Total 456 456 456 456 456 456 456 456 456
Dosel means number o f individuals who received first dose, Dose2 means those who 
received second dose etc, and Dosel 2 means those who received dosel and dose 2, 
Dosel23 those who received dosel, dose2 and dose3 etc.
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As one would expect, age at vaccination increases with the dose given. Table 8.4 
below shows this relationship. Further, Figures 8.2 and 8.3 show the distribution of 
age at vaccination for each dose.
Table 8.4 Distribution of age at vaccination
Age at vaccination 
days
Dose of OPV Mean Std Dev Minimum Maximum
(Numbers) days days days days
First Dose 
(426) 41.1 36.9 0.0 236.0
Second Dose 
(358) 102.4 35.1 31.0 206.0
Third Dose 
(261) 161.0 42.8 57.0 387.0
Fourth Dose 
(86) 215.3 90.7 118.0 585.0
Fifth Dose 
(12) 314.4 153.0 179.0 619.0
The age distribution for doses 1, 2 and 3 are markedly bimodal, possibly reflecting 
different vaccination practices in different countries. Table 8.5 below shows the 
distribution of the interval between vaccination and diagnosis of intussusception at 
each dose. The interval between receipt of OPV and diagnosis of intussusception 
ranged from 3 days to 667 days for the first dose, for the second dose, the interval 
ranged from the day of vaccination to 602 days, for the third dose, six cases were 
diagnosed before receiving the third dose, and three cases were diagnosed before 
receiving the fourth dose, and the interval between diagnosis and receipt of 5th dose 
ranged from 8 days to 193 days. This distribution reflects the way vaccination 
histories were collected, namely retrospectively from date of event (other than in the 9 
cases with information on post-event vaccination).
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Figure 8.2 Distribution of age at vaccination
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Figure 8.3 Distribution of age at vaccination continued
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Table 8.5 Distribution of interval between vaccination and diagnosis
of intussusception.
Interval between vaccination and diagnosis at each dose
Dose of OPV Mean Std Dev Minimum Maximum
(Numbers) days days days days
First Dose 
(426) 184.7 115.1 3.0 667.0
Second Dose 
(358) 139.4 111.6 0.0 602.0
Third Dose 
(261) 109.7 109.1 -48.0 545.0
Fourth Dose 
(86) 105.3 103.8 -54.0 482.0
Fifth Dose 
(12) 93.4 66.7 8.0 193.0
8.6 Statistical analysis
To assess the association between OPV and intussusception, the self-controlled case 
series method was used. We used risk periods of 31 days (0-30) after vaccination. We 
also split this into two risk periods, 0-15 and 16-30 days. These risk periods were 
chosen so as to compare with other studies[36, 37,143]. For each analysis, we 
adjusted for age which was grouped into 24 different age categories of about 30 days 
each, except for the analysis of dose 5. Age was grouped in this way so as to take 
account of age in each month over the 2 years of the maximum possible observation 
period of each individual. For the analysis of dose 5, it was not sensible to have 24 
different age groups as there were only 12 cases. To avoid unbounded estimates due 
to not having cases in some age groups, we grouped age in 5 longer age-groups as 
follows: 0-150 days, 150-300 days, 300-450 days, 450-600 days and 600-750 days.
One requirement of the self-controlled case series method is that the probability of 
exposure should not be affected by the occurrence of an outcome event [7]. In the
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GSK204 study, the histories of the exposure was recorded when or soon after the 
cases were entered in the study. There was no follow-up after the outcome event and 
hence no information was collected on exposure after entering the study. In such 
situations when using the self-controlled case series method for single exposures, it is 
recommended to define the observation period starting from the exposure up to the 
end of the study (Farrington [2]). However, this study involved five different doses of 
vaccines, giving exposures at five different time points. The self-controlled case series 
method for censoring events has so far been used with one exposure. When there are 
several doses, one has to analyse the data starting with the latest dose first. If there is 
no significant association for this dose then one can analyse the previous dose and 
proceed iteratively in this way. The approach is necessary to avoid bias from 
unobserved exposures after the outcome events. Only if such later doses are not 
associated with the outcome can the current dose be evaluated in an unbiased way. 
Thus, we started by analysing data at dose 5, and only if we got a non significant 
result did we analyse dose 4, moving down the doses in this way. Thus, for the 
analysis of dose k , the observation period isfv^fr) where = age at dose k and 
b = age at end of study, and we assume no effect for doses A: +1, A: + 2,..., 5. Hence the 
fact that later doses may be unobserved is immaterial.
Table 8.6 below shows the relative incidences obtained in each analysis for each dose 
and for each risk period. Included in the table is the number of events in each risk 
period at each dose. In all situations the relative incidence is not significantly different 
from 1, indicating no association between vaccination and OPV given at any dose, 
though the effect of dose 5 is very poorly estimated as there are so few cases.
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Table 8.6 Relative incidence and number of events in risk periods after vaccination
for each dose and 95% confidence intervals
Dose 0-15 days No. of 16-30 days No. of 0-30 days No. of
RI (95% Cl) events RI (95% Cl) events RI (95% Cl) events
Opv5 2.79 (0.25, 30.9) 1 5.22 (0.73, 37.4) 1 4.04 (0.67, 24.4) 2
Opv4 1.01 (0.38, 2.72) 11 0.78 (0.30, 2.06) 7 0.88 (0.38, 2.04) 18
Opv3 0.71 (0.41, 1.24) 22 0.92 (0.58, 1.46) 28 0.84 (0.55, 1.28) 50
Opv2 0.86 (0.45, 1.61) 14 1.39 (0.89, 2.17) 28 1.19(0.79, 1.80) 42
Opvl 1.34 (0.55,3.24) 8 0.74 (0.30, 1.85) 7 0.97 (0.48, 1.95) 15
Opvl, Opv2, etc =Oral polio vaccine given at first dose, second dose etc, RI=relative 
incidence.
8.7 Conclusions
The aim of the analysis was to investigate whether incidence of intussusception in 
children less than 24 months of age in hospitals involved in the GSK204 study was 
associated with oral polio vaccine (OPV). The results shown in Table 8.6 do not 
support the hypothesis that OPV is causally related to intussusception. There is no 
evidence of causal relationship at any dose. With the exception of dose 5 the point 
estimates are generally close to unity, with narrow confidence intervals, indicating 
that the analyses have good power. For the dose 5 analysis, there were 12 cases, with 
two cases in the 30 day risk period. In this case, the confidence intervals are very wide 
as one would expect due to lack of power.
One of the advantages of the self-controlled case series method is that it implicitly 
controls for fixed factors, hence in these analyses, fixed factors such as social and 
economic factors, country, sex, and any bias due to individual level confounding, for 
example confounding due to vaccination and unmeasured risk factors for 
intussusception have been taken into account.
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The rigour in the way the study was conducted and the way the cases were ascertained 
gives us confidence in these findings. Further our analyses were restricted to definite 
cases only. In addition, the cases of intussusception were ascertained independently of 
any perceived link of OPV with intussusception since the primary objective of the 
study was to assess the incidence of intussusception in children less than 24 months of 
age in hospitals involved in the study. The vaccination history of various vaccines in 
each case was then recorded without any focus on a particular vaccine, using data 
from vaccination booklets.
Our earlier findings relating to the properties of the self-controlled case series method 
in chapters 2 and 3, suggest that the self-controlled case series method gives 
effectively unbiased results when the number of cases is at least 20 for a relative 
incidence greater than one. It is only seriously biased for number of cases of about 10 
if the ratio of the risk period to observation period takes extreme values. In this study, 
the ratio of risk period to observation period was approximately 0.04.The number of 
cases for each dose was all above 50 except for dose 5. Hence we expect estimates at 
each of these doses other than dose 5 not to be substantially biased.
In chapters 4 and 5 we saw that for a ratio of the risk period of about 0.05, with 100 or 
more cases (Table 5.2) one has power of 80% or more to detect a relative incidence of 
at least 3. In this data set, we had well over 100 cases for doses 1 to 3 hence the power 
appears adequate. The power for dose 5, however, is inadequate.
A limitation of the study was the censoring of post-event vaccination histories. This 
would have resulted in some difficulties completing the analysis of all doses had a
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significant result been obtained at some point. But this was not an issue in these data 
as there was no significant result at any dose. A further problem we would have had to 
consider is the issue of multiple testing. Again here as there was no significant result, 
we did not need to worry unduly about this. Another limitation is the fact that there 
were only 12 cases with dose 5. This resulted in low power and imprecise confidence 
intervals for this dose. A possible solution to this is to obtain bootstrap confidence 
intervals and possibly using multiple imputations for the missing data so as to 
reanalyse the data with similar number of cases as those at first dose.
The study was undertaken with the primary objective of providing baseline 
information for the surveillance of a new rotavirus vaccine. Such surveillance could 
be undertaken using the methods described in chapters 6 and 7. Specifically, as 
surveillance would be focussed on a single new vaccine, the SPRT approach 
described in chapter 6 would be most appropriate.
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Chapter 9
Conclusions
The first issue we considered in this thesis was to explore some further statistical 
properties of the self-controlled case series method, these were explored in chapter 
two. To this end we derived expressions to second order for the asymptotic bias and 
variance of the estimator of log relative incidence in a simplified setting. These 
enabled us to understand in qualitative terms the impact of quantities such as the 
length of the risk period and the relative incidence on the accuracy and precision of 
the estimates. We studied these effects graphically to examine how the bias, variance, 
and asymptotic mean square error vary with the ratio of the risk period to the 
observation period, and how they vary with the relative incidence at fixed sample 
sizes.
The main finding is that asymptotic bias and variance (and hence AMSE) are smallest 
when the expected number of events within the risk period and outside the risk period 
are equal. The greater the difference between these two expected frequencies, the 
greater the bias and variance. The asymptotic second order expression suggest that 
there is little bias with sample sizes in excess of 20 for the types of scenarios we 
might expect to encounter in practice.
All in all, the self-controlled case series model seems to perform very well. 
Asymptotically, the estimates obtained are not biased. The relative incidence
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estimator is biased when trying to detect a relative incidence less than one (a situation 
which seldom arises in practice), when the risk period is short, for example 1 day risk 
period and when there are very few cases (for example n=10).
The main limitations of the findings from the expressions of the asymptotic bias, 
variance and AMSE is that they make no allowance for age effects. We did not take 
age into account because the calculations for the bias, variance and AMSE become 
unwieldy. Instead we explored the effect of age in the simulation study reported in 
chapter three.
The results from the simulations were presented starting with what we called the 
‘standard scenario’ which is representative of many studies of paediatric vaccines. In 
the standard scenario we found that the estimates were substantially biased for sample 
sizes of 20 or less, when the true relative incidence was < 1. However for relative 
incidence >1.5 the biases were moderate even with sample sizes of 10 cases, and 
very small when the number of cases was > 50. Risk periods as short as 1 day and up 
to a maximum of 200 days (for a total observation period of 500 days) were 
investigated. In these situations, the estimates were biased for short risk periods. For 
example when the risk period was 1 day, the bias was large when the relative 
incidence was 0.5 even with 500 cases. Generally speaking, the longer the risk period 
in the range considered (up to 200 days), the less biased the estimates were.
Different age effects classified as weak symmetric, strong symmetric, weak monotone 
increasing, strong monotone increasing were explored as was the effect of different
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distributions of age at exposure. There was little evidence that these affected the 
performance of the self-controlled case series model.
Indefinite risk periods were looked at. This was done to answer questions by some 
researchers [51, 52] who have argued that the self-controlled case series model may 
not be effective if one is looking at a situation were adverse events may manifest 
themselves a long time after exposure. We explored this issue by extending the risk 
periods to indefinite length. Results showed that overall there was little bias except 
for large relative incidences and distributions of age at event and age at exposure that 
induce confounding between exposure and age effects. This confounding and the bias 
it generates can be controlled by including unvaccinated cases.
In most situations explored in the simulation study, the coverage probabilities from 
ten thousand samples of different number of cases were in excess of their nominal 
values, even in the presence of substantial bias (see Tables 3.1 to 3.20 inclusive). This 
was not surprising, since when the expected number of event in the risk period is very
small, the variance of ft = log(/3) (where p  = ep is the estimate of the relative
incidence) is very large, as may be seen from the asymptotic calculations of chapter 2. 
Hence the confidence intervals will themselves be very wide. Confidence intervals 
based on profile likelihood methods may be preferable, but were not investigated.
In chapter 2 we found that when there are no age effects, the magnitude of the 
asymptotic bias depended largely on the imbalance of events in the risk and control 
periods, that is when the expected number of events in the risk period was less than 
that in the control period, the bias was negative, and vice versa. When the two
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expectations were equal, the bias was zero. The simulation study explored more 
complex situations and finite samples. Qualitatively similar results emerged for a 
given sample size: the bias was greatest in magnitude when the expected number of 
events in the risk period was much smaller than the expected number in the control 
period. In practice, bias is only a real problem when the risk period is very short or 
relative incidence is low. In other circumstances, sample sizes in excess of 20 appear 
to give reliable results.
The overall conclusion from the analytical calculations of Chapter 2 and the 
simulation study of Chapter 3 is that estimates and confidence intervals based on 
asymptotic theory are reliable except in extreme scenarios (namely very small sample 
sizes, very small risk period, low relative incidence).
The next issue to be investigated was to improve the design of self-controlled case 
series studies by obtaining and validating sample size formulae. These were presented 
in chapters 4 and 5. We started off by investigating the first published sample size 
formula by Farrington et al [3] and found that this formula was not accurate. We then 
investigated other approaches. This led us to derive six other sample size formulae, 
one based on the distribution of the logarithm of the relative incidence, three based on 
the binomial distribution and two based on the signed root likelihood ratio statistic. Of 
the six sample size formulae derived, four were found to be accurate. Of the accurate 
sample size formulae, two were based on the binomial distribution namely that using 
a continuity correction and that using the arcsine variance stabilising transformation. 
The other two good formulae were based on the signed root likelihood ratio statistic 
with and without age adjustment. Our overall recommendation in designing a study
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using the self-controlled case series method without age effects is to use either the 
formula based on the binomial distribution with arcsine variance stabilising 
transformation, or the formula based on the signed root likelihood ratio statistic. If age 
is to be taken into consideration, then there is only one sample size formula to use and 
this is the formula based on the signed root likelihood ratio statistic.
The third topic that we explored was to extend the self-controlled case series method 
to prospective surveillance. We had to find a way of incorporating the retrospective 
self-controlled case series method within a prospective surveillance system. We used 
the ideas of Wald [45] and Page [46] to derive a self-controlled case series based 
sequential probability ratio test (SPRT) and cumulative sum (CUSUM) for use in 
surveillance. Detailed findings are presented in chapters 6 and 7. We envisage using 
the SPRT for focused surveillance of a new vaccine, whereas the CUSUM can be 
used for routine surveillance of several established vaccines. A detailed simulation 
study showing how the SPRT and CUSUM can be applied was illustrated and results 
presented.
A possible limitation of an SPRT and CUSUM surveillance system using the case 
series method is the inability to produce a signal in real time since it is necessarily 
based on retrospective data. One possible solution to this is to make the monitoring 
time interval as short as possible. We used a 6-month monitoring interval. The 
monitoring time interval could be of any length depending on prior knowledge of the 
vaccine being investigated. The surveillance system would rely on routinely collected 
case data for signal detection. Such data have varying degrees of accuracy in 
diagnostic coding. It is for this reason that such a surveillance system should not be
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viewed as the final confirmatory epidemiologic investigation into potential vaccine- 
associated adverse events. However, a system based on the case series method does 
provide stronger evidence of association than signal based solely on spontaneous 
reporting.
Overall, simulation studies showed that the performance of a focused surveillance 
system using the SPRT is as desired. Ideally, we would like a system to be very quick 
to detect a true relative incidence greater than 1 and also if there is no problem we 
would like the process not to cross the upper boundary or possibly signal in favour of 
the null hypothesis. The simulation study showed that the system was able to achieve 
both requirements as indicated both by the probability of crossing the upper boundary 
and also by the average time to detection of a signal.
Using the SPRT with the self-controlled cases series log-likelihood has all the 
advantages of using the self-controlled case series method (in particular control of 
confounders). The other advantage of using the self-controlled case series SPRT 
compared to other methods [79-82] that are frequently used in surveillance systems is 
the prior specification of the Type I  and Type II  errors. The Type /  and Type II errors 
control against making wrong decisions. These error levels apply to the entire SPRT 
process, not to each specific monitoring time interval, and thus the analyses take 
account of multiple testing. The adjustment for multiple testing is not explicit as in the 
Bonferroni adjustment, but rather the adjustment is incorporated into the SPRT in the 
way that the upper and lower boundaries are calculated. These boundaries preserve 
the specific alpha and beta until a final decision is reached as to whether the 
hypothesis should be accepted or rejected. However, for the self-controlled case series
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based SPRT, we found that the actual Type I  and Type II error probabilities were 
lower than the nominal values.
Chapter seven explored how we can use the self-controlled case series method to 
construct CUSUM charts for the long term surveillance of several vaccines in routine 
use. We assessed the performance of the self-controlled case series CUSUM using the 
standard practice of using the average run length (ARL) to select chart thresholds and 
to summarise performance after adapting the definitions of ARL to the surveillance of 
several vaccines. We used this method in preference to the false discovery rate (FDR) 
and successful discovery rate of Marshall et al [110]. We found that our ‘system 
average run length in control’ denoted ARL0 and ‘system average run length out-of-
control’ denoted ARLj are practically relevant and interpretable parameters.
The system average run length in control of a self-controlled case series CUSUM 
measures the time interval between false signals when the system is in control. A 
large value of ARL0 is desirable. We found that surveillance of several vaccines
drastically reduces the ARL0 obtained for a single vaccine. In an effort to increase the
ARL0 we investigated a resetting scheme where all vaccines are reset, not just the
signalling vaccine. This does indeed increase the system average run length in­
control, but also affects the system average run length out-of-control.
The system average run length out-of-control ( ARLj) is an upper limit on the time
between a problem occurring and when it is detected (it is an upper limit because the 
CUSUM will generally be greater than zero when the problem occurs). Ideally this
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must be kept small; for example detection within 2 years might be a reasonable 
requirement.
The method of Marshall et al [110] based on the false detection rate of a CUSUM 
applies perhaps more appropriately to the surveillance of large number of units. 
However, it lacks the focus on detection times which is provided by the system 
average run length in control and the system average run length out-of-control 
formulation. In general our findings showed that when monitoring several vaccines, 
the system ARL0 of the self-controlled based CUSUM is much shorter than the
ARL0 when we are monitoring a single vaccine.
It was not possible to suggest a single control limit to use when using the CUSUM 
based on the self-controlled case series method. This depends on the risk period, the 
baseline incidence for the number of cases, the observation period (monitoring 
interval), the number of vaccines under observation, the way the surveillance will be 
carried out especially when several vaccines are under observation, and the relative 
incidence to be detected. Our results showed that a practical system is possible, but 
require careful choice of the parameters h and the design value, bearing in mind the 
need to avoid swamping the system with false positive signals.
Overall chapter six and seven showed that a monitoring system for a single new 
vaccine based on the self-controlled case series method with the SPRT is feasible, and 
could prove to be a very useful tool. Further work is required to incorporate age 
effects, select optimal values of a  and p  in the case of the SPRT and the best
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monitoring interval. It is perhaps less clear that a CUSUM-based system for 
monitoring several vaccines would produce reliable results.
In chapter 8 we undertook an analysis of data on intussusception and oral polio 
vaccine. In line with other studies, we did not find strong evidence of association. One 
specific difficulty with these data was how to take account of censoring of exposure 
histories at different doses. We proposed a stepwise estimation procedure, starting at 
the last dose. In the latter part of the chapter we brought to bear the new insights 
obtained in this thesis on the issues of bias and surveillance of new rotavirus vaccines.
The work undertaken in this thesis suggests some avenues for further research. It 
would be interesting to obtain analytic expressions for the asymptotic bias and 
variance of the log relative incidence estimator, allowing for age effects. The sample 
size expression we obtained, taking into account age effects, works for short risk 
periods, but different methods are required for long risk periods. Perhaps most 
importantly, more work is required to design a practical surveillance system using 
SPRT or CUSUM, based on the case series method, taking account of age effects.
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APPENDIX 2
The case series likelihood for the parameters p  and a . , j  =  0 , J -1  is
n  7 -1
L(/3,a0,...,aj_x) = Y [ Y [ Y \
i=\  y = 0  £ = 0 ,1
exp (aj+ f]k)eljt
7-1
X E eXP {as +Pt) eis.
V 5 = 0  ?=o,i
where eijk is the observation time for event / in age group j  and risk period
k (k = 0, unexposed; k = l, exposed), and nijk is the number of events (0 or 1)
occurring in this period. Note that in the formulation, independent multiple events 
within the same individual are represented as separate terms in the likelihood. 
Suppose now that the ccj are regarded as known. The log likelihood ratio for P  is
D(/3) = 2
  n
i, j ,k i=l
^  exp (as + fit) eh
s,t
E exP (a ,)e,s
V sp
If the event / occurs in an unexposed individual, its contribution to £>(/?) is zero. 
Otherwise, under the assumptions set out in section 5.6.1,
7-1
£ e x p  («SK ,  = 2 > “' e*
S,t 5 = 0
J - \
S exp(«s+Pt)eiS, = E e“' e, + exp(a S(o )(^  ~ l )e'
5 = 0
where  ^(z) is the age group exposure. Thus
D {p ) = 2
7-1
xP ~ Y ,n ij log(r}ep + l - r y)
j = o
where x is the total number of events occurring in a risk period, m . is the total
number of events occurring in individuals exposed at age j , and r . is defined in
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section 5.6.2. The log likelihood ratio reaches its minimum at the maximum 
likelihood estimator p , which is the solution of
j -i
x = V  m .---J-
L -k  J B>0 r.-
r;eh
;ep +1-7}
Substituting this expression for xin T )^ jw e  obtain The test statistic upon
which the sample size calculation is based is
The asymptotic variance of p  is
V (* )= j - i
2 > / r , ( l - ; r , )
j = 0
where the are defined in section 5.6.2. Expanding 7^/?jin a Taylor series around 
p , and substituting V^pj we  obtain, to first order in n ,
j -i
T = sgn (p)  ^ | 2 g  rrij \j3rCj -  log [ r /  + 1-  ry.) 
P 2
e  j"/ /? j=°9)
Finally, replace mpoynvj, with Vj as defined in section 5.6.2. Thus
sgn.(p)yfnA,B^ where A and B are given in equation (5.7). Note that by 
expanding A and B to second order in p , it can be shown that
A —> 0 and B —»1 as p  0, as expected.
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List of acronyms
ADRs Adverse Drug Reactions
A&E Admission and Entry
AMSE Asymptotic Mean Square Error
ARL Average Run Length
ARL0 system Average Run Length in-control
ARL{ system Average Run Length out-control
BCPNN Bayesian Confidence Propagation Neural Network
CCR Coded Clinical Records
CDC Centres for Disease Control and prevention
Cl Confidence Interval
CRF Case Report Form
CUSUM Cumulative Sum
DTP Diphteria Tetanus Pertussis
FDA Food and Drug Administration
FDR False Discovery Rate
GSK GlasxoSmithKline
GPRD General Practice Research Database
HES Hospital Episode Statistics
H 0 Null hypothesis
H l Alternative Hypothesis
ICD International Classification of Diseases 
ITP Idiopathic Thrombocytpenic Purpura 
MCSE Monte Carlo Standard Error
MHRA Medicines and Healthcare products Regulatory Agency
MMR Measles Mumps and Rubella 
OPV Oral Polio Vaccine 
PAS Patient Administration System 
PRR Proportional Reporting Ratios 
RI Relative Incidence
R I0 Relative Incidence under the null hypothesis
RL1 The design Relative Incidence value used in the SPRT
RL2 The actual Relative Incidence value used to generate data
RRV-TV Tetravalent Rhesus Human Reassortant Rotavirux Vaccine
ROR Reporting Odds Ratios
SCCS Self-Controlled Case Series
SCCSM Self-Controlled Case Series Method
SDR Successful Discovery Rate
SPC Statistical Process Control
SPRT Sequential Probability Ratio Test
UK United Kingdom
USA United States America
US United States
VAERS Vaccine Adverse Event Reporting System 
VSD Vaccine Safety Datalink 
WHO World Health Organisation
APPENDIX 3 
Papers published or submitted from the thesis
Sample sizes for self-controlled case series studies [44] (Covering chapter 4 and 
5).
Self-controlled case series analyses: small sample performance[145] (Covering 
chapter 2 and 3).
Tutorial in Biostatistics: The self-controlled case series method [7] (Covering part 
of chapter 4).
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